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Population nonlinear mixed-effects modelling of pharmacokinetics and 
pharmacodynamics of tuberculosis treatment 
Maxwell Tawanda Chirehwa - 2018 
 
The pharmacokinetics of rifampicin, isoniazid, pyrazinamide and ethambutol in TB/HIV 
coinfected patients recruited in two phase III clinical trials (61 patients in TB-HAART and 222 
patients in RAFA study) were described using nonlinear mixed-effects modelling. 
Concentration-time data for rifampicin (TB-HAART study) was used to develop a 
semimechanistic pharmacokinetic model incorporating autoinduction and saturable 
pharmacokinetics. A model describing the pharmacokinetics of pyrazinamide (TB-HAART 
study) was developed and used to evaluate the 24-hour area under the concentration-time 
curve (AUC0–24), and maximum concentrations (Cmax) achieved with the currently 
recommended weight-adjusted doses for drug-susceptible and -resistant tuberculosis. 
Concentration-time data from the RAFA study were used to characterise the pharmacokinetics 
of the four drugs of the fixed dose combination (FDC) therapy including desacetyl-rifampicin, 
and acetyl-isoniazid. Binary recursive techniques were applied in the conditional inference 
framework to determine predictors including drug exposure of time-to-stable culture 
conversion and poor long-term treatment outcomes.  
 
The model describing the pharmacokinetics of rifampicin predicted that increasing the dose 
results in a more than proportional increase in exposure. Clearance of rifampicin increased by 
90% from baseline to steady-state due to autoinduction and the process takes up to 21 days. 
Monte Carlo simulations showed that rifampicin doses of at least 25 mg/kg would be required 
to achieve an AUC0–24/MIC ratio of at least 271. Based on the model describing the 
pharmacokinetics of isoniazid, co-administration of isoniazid and efavirenz-based 
antiretroviral therapy results in a 54% reduction in isoniazid exposure only in fast acetylators. 
There were disparities in exposure across weight bands for all the four drugs: patients with 
lower weight had reduced exposure. To match drug exposure across the weight bands, we 
recommend the addition of one FDC tablet to patients with weight less than 55 kg. There is 
need to explore the use of fat-free mass-adjusted dosing since cumulative evidence shows its 
superiority over total body weight in driving exposure via allometric scaling for all first-line 
antituberculosis drugs. Individual drug exposures were not predictive of either time-to-stable 
culture conversion or long-term tuberculosis treatment outcomes. Baseline X-ray grading, HIV 
stage as TB diagnosis, and treatment arm were predictive of time-to-stable culture conversion 
while the presence of cavities, patient’s level of physical activity and CD4 count were the 




Contributions to the field ........................................................................................................ i 
Declaration of work ............................................................................................................... iii 
Acknowledgements ............................................................................................................... v 
Abstract................................................................................................................................ vii 
List of tables .......................................................................................................................... xi 
List of figures ....................................................................................................................... xii 
Abbreviations and acronyms ............................................................................................... xiv 
Chapter 1: Introduction and literature review ......................................................................... 1 
1.1 Global disease burden of tuberculosis ......................................................................... 1 
1.2 Tuberculosis disease ................................................................................................... 2 
1.3 Tuberculosis treatment ................................................................................................ 3 
1.4 Pharmacology of antituberculosis drugs ...................................................................... 5 
1.4.1 Pharmacology of rifampicin ................................................................................... 5 
1.4.2 Pharmacology of isoniazid .................................................................................. 11 
1.4.3 Pharmacology of pyrazinamide ........................................................................... 17 
1.4.4 Pharmacology of ethambutol ............................................................................... 21 
1.5 Multidrug nature of tuberculosis treatment ................................................................. 25 
1.6 Tuberculosis treatment outcomes .............................................................................. 27 
1.7 Pharmacometrics ....................................................................................................... 29 
1.8 Study justification ....................................................................................................... 34 
1.9 Objectives .................................................................................................................. 38 
Chapter 2: Methodology ...................................................................................................... 39 
2.1 Study designs and data description ........................................................................... 39 
2.1.1 TB-HAART Study ................................................................................................ 39 
2.1.2 RAFA Study ........................................................................................................ 41 
2.2 Software .................................................................................................................... 43 
2.3 Pharmacokinetic modelling approach ........................................................................ 43 
2.4 PK-PD analysis approach .......................................................................................... 44 
Chapter 3: Model-based evaluation of higher doses of rifampicin using a semimechanistic 
model incorporating autoinduction and saturation of hepatic extraction ............................... 46 
3.1 Abstract ..................................................................................................................... 46 
3.2 Introduction ................................................................................................................ 47 
3.3 Methodology .............................................................................................................. 49 
3.4 Results ...................................................................................................................... 53 
3.5 Discussion ................................................................................................................. 63 
3.6 Appendix ................................................................................................................... 69 
ix 
 
Chapter 4: Pharmacokinetics of pyrazinamide and optimal dosing regimens for drug-
sensitive and -resistant tuberculosis .................................................................................... 70 
4.1 Abstract ..................................................................................................................... 70 
4.2 Introduction ................................................................................................................ 71 
4.3 Methodology .............................................................................................................. 73 
4.4 Results ...................................................................................................................... 77 
4.5 Discussion ................................................................................................................. 85 
Chapter 5: Effect of efavirenz-based antiretroviral therapy on pharmacokinetics of isoniazid 
and acetyl-isoniazid ............................................................................................................ 90 
5.1 Abstract ..................................................................................................................... 90 
5.2 Introduction ................................................................................................................ 92 
5.3 Methods .................................................................................................................... 94 
5.4 Results ...................................................................................................................... 99 
5.5 Discussion ............................................................................................................... 108 
Chapter 6: Pharmacokinetics of rifampicin, pyrazinamide, and ethambutol in patients 
recruited in the RAFA study .............................................................................................. 113 
6.1 Introduction .............................................................................................................. 113 
6.2 Methods .................................................................................................................. 115 
6.3 Results .................................................................................................................... 117 
6.3.1 Pharmacokinetics of rifampicin and desacetyl-rifampicin ................................... 117 
6.3.2 Pharmacokinetics of pyrazinamide .................................................................... 123 
6.3.3 Pharmacokinetics of ethambutol ....................................................................... 127 
6.3.4 Model-based steady-state individual exposure to rifampicin, pyrazinamide, and 
ethambutol ................................................................................................................. 130 
6.4 Discussion ............................................................................................................... 134 
6.3 Appendix ................................................................................................................. 141 
Chapter 7: Correlates of tuberculosis treatment outcomes in a cohort of TB/HIV co-infected 
patients ............................................................................................................................. 142 
7.1 Introduction .............................................................................................................. 142 
7.2 Methods .................................................................................................................. 143 
7.3 Results .................................................................................................................... 144 
7.3.1 Time-to-stable culture conversion ..................................................................... 144 
7.3.2 Long-term treatment outcome ........................................................................... 149 
7.4 Discussion ............................................................................................................... 153 
Chapter 8: Conclusions ..................................................................................................... 156 
8.1 Pharmacokinetics of rifampicin and desacetyl-rifampicin: increased dose, 
autoinduction and saturable pharmacokinetics .............................................................. 157 
8.2 Pharmacokinetics of pyrazinamide and optimal doses for drug-susceptible and -
resistant tuberculosis ..................................................................................................... 160 
x 
 
8.3 The effect of increased dose of rifampicin and efavirenz-based ART on 
pharmacokinetics of co-administered drugs ................................................................... 162 
8.4 Drivers of time-to-stable culture conversion and long-term tuberculosis treatment 
outcomes ....................................................................................................................... 163 
8.5 Implications of findings on tuberculosis treatment and research .............................. 164 
8.6 Overall summary ..................................................................................................... 165 
References ....................................................................................................................... 166 
Appendix 1: NONMEM scripts ........................................................................................... 190 
Appendix 2: Approval to include publications in the thesis ................................................ 220 





List of tables 
Table 2.1 Study design for TB-HAART study ...................................................................... 40 
Table 3.1 Baseline characteristics of patients in TB-HAART (rifampicin model) .................. 53 
Table 3.2 Values estimated by the final model .................................................................... 58 
Table 3.3 Simulated exposures at first dose and steady state by dosea .............................. 59 
Table 4.1 Baseline characteristics of patients in TB-HAART (pyrazinamide model) ............ 77 
Table 4.2 Estimated parameter values from the final model for pyrazinamide (TB-HAART 
study) .................................................................................................................................. 79 
Table 4.3 Proportion of simulated patients with drug-susceptible TB achieving a target 
AUC0- 24 of 363 mg·h/liter .................................................................................................... 82 
Table 5.1 Baseline characteristics of patients with isoniazid concentrations (RAFA study) 100 
Table 5.2 Parameter estimates of the final model for isoniazid and acetyl-isoniazid .......... 104 
Table 6.1 Baseline characteristics of patients with rifampicin concentrations (RAFA study)
 ......................................................................................................................................... 118 
Table 6.2 Parameter estimates of the final model for rifampicin and desacetyl-rifampicin 
(RAFA study) .................................................................................................................... 121 
Table 6.3 Baseline characteristics of patients recruited in the pharmacokinetic sub-study 
(RAFA study) .................................................................................................................... 123 
Table 6.4 Parameter estimates of the final model for pyrazinamide (RAFA study) ............ 124 
Table 6.5 Parameter estimates of the final model for ethambutol (RAFA study) ................ 127 
Table 7.1 Parameter estimates of the base and final model for time-to-stable culture 
conversion ........................................................................................................................ 147 
Table 7.2 Characteristics of patients with drug concentration for all four drugs stratified by 
long-term treatment outcome ............................................................................................ 150 
Table 7.3 Associations between derived cut-offs of predictors and poor long-term treatment 




List of figures 
Figure 1.1 Estimated tuberculosis incidence rates, 2016 ....................................................... 2 
Figure 1.2 A schematic representation of isoniazid (INH) metabolism and the enzymes 
involved in the metabolic pathways of isoniazid .................................................................. 13 
Figure 2.1 Treatment schedule for the RAFA study  ............................................................ 42 
Figure 3.1 Schematic diagram of the final model for rifampicin (TB-HAART study) ............. 54 
Figure 3.2 Prediction-corrected VPC for rifampicin model (TB-HAART study) stratified by day 
after treatment initiation ....................................................................................................... 56 
Figure 3.3 Change in AUC0–24 over time and simulated day 29 concentrations for doses of 10 
mg/kg to 35 mg/kg .............................................................................................................. 60 
Figure 3.4 Distribution of exposures (AUC0–24) at steady state (day 29) based on the 
currently recommended doses ............................................................................................ 61 
Figure 3.5 Probabilities of target (steady-state AUC0–24/MIC ratio of 271) attainment over a 
range of MICs (plotted on a log2 scale) ............................................................................... 62 
Figure 3.6 Comparison of simulated exposure (Cmax and AUC0–24, median and 90% range) 
on day 14 after TB treatment initiation ................................................................................. 65 
Figure 4.1 Visual predictive check for pyrazinamide model (TB-HAART study) stratified by 
treatment day ...................................................................................................................... 80 
Figure 4.2 Box plots of simulated AUC0–24 for currently recommended doses for 
drug-susceptible TB and 3 alternative dosing strategies, stratified by weight band ............. 81 
Figure 4.3 Predicted concentrations for typical male patients weighing 34 kg and 46 kg ..... 83 
Figure 4.4 Box plots of simulated AUC0–24 achieved during treatment of MDR-TB .............. 84 
Figure 5.1 Schematic diagram of the model describing the pharmacokinetics of isoniazid and 
acetyl-isoniazid ................................................................................................................. 101 
Figure 5.2 Visual predictive checks for isoniazid and acetyl-isoniazid stratified by metabolic 
status ................................................................................................................................ 105 
Figure 5.3 Boxplot of AUC0–24 for isoniazid and acetyl-isoniazid stratified by treatment arm
 ......................................................................................................................................... 106 
Figure 5.4 Boxplot of Cmax for isoniazid stratified by treatment arm ................................... 107 
Figure 6.1 Schematic diagram of the semi-mechanistic model of rifampicin and desacetyl 
rifampicin in TB/HIV co-infected patients ........................................................................... 119 
Figure 6.2 Prediction-corrected visual predictive check for a model describing the 
pharmacokinetics of rifampicin and desacetyl-rifampicin. .................................................. 122 
Figure 6.3 Prediction-corrected visual predictive check for a model describing the 
pharmacokinetics of pyrazinamide .................................................................................... 126 
xiii 
 
Figure 6.4 Prediction-corrected visual predictive check for a model describing the 
pharmacokinetics of ethambutol. ....................................................................................... 129 
Figure 6.5 Steady-state AUC024 (left) and Cmax (right) for rifampicin stratified by the treatment 
arm. .................................................................................................................................. 131 
Figure 6.6 Steady-state AUC0–24 (left) and Cmax (right) for pyrazinamide stratified by the 
treatment arm.................................................................................................................... 132 
Figure 6.7 Steady-state AUC0–24 (left) and Cmax (right) for ethambutol stratified by the 
treatment arm ................................................................................................................... 133 
Figure 6.8 Goodness of fit plots for the model describing pharmacokinetics of rifampicin (left) 
and desacetyl-rifampicin (right) ......................................................................................... 141 
Figure 6.9 Goodness of fit plots for the model describing pharmacokinetics of pyrazinamide 
(left) and ethambutol (right) ............................................................................................... 141 
Figure 7.1 Steady-state AUC0–24 and Cmax for rifampicin, isoniazid, pyrazinamide and 
ethambutol used for the PK-PD analysis ........................................................................... 144 
Figure 7.2 Visual predictive check of the time-to-stable culture conversion. ...................... 145 
Figure 7.3 Variables predictive of time-to-stable culture conversion .................................. 146 
Figure 7.4 Visual predictive check of the time-to-stable culture stratified by patient 
characteristics. .................................................................................................................. 148 




Abbreviations and acronyms 
AcINH Acetyl-isoniazid 
AIC Akaike Information Criterion 
ALT Alanine Aminotransferase 
ART Antiretroviral Therapy 
AST Aspartate transaminase 
ATT Antituberculosis Treatment 
AUC0–24 24-hour area under the concentration-time curve 
BLQ Below the Limit of Quantification 
BOV Between-Occasion Variability 
BSV Between-Subject Variability 
CAR Constitutive Androstane Receptor 
CART Classification and Regression Trees 
CFR Cumulative Fraction of Response 
CFU Colony Forming Units 
CI Confidence Interval 
CL Clearance 
CLH Hepatic clearance 
CLint Intrinsic clearance 
CLint,max Maximum Intrinsic clearance 
Cmax Maximum plasma concentration 
Cmin Minimum plasma concentration 
DNA Deoxyribonucleic acid 
EBA Early Bactericidal Activity 
EFV Efavirenz 
EH Hepatic extraction 
F Oral bioavailability 
xv 
 
FDC Fixed Dose Combination  
FFM Fat-Free Mass 
FOCE-I First-Order Conditional Estimation with eta-epsilon Interaction 
Fprehep Prehepatic oral bioavailability 
fu Unbound fraction 
GOF Goodness of Fit 
HAART Highly Active Antiretroviral Therapy 
HIV Human Immunodeficiency Virus  
INA Isonicotinic acid 
INH Isoniazid 
Ka Absorption rate constant 
Km Michaelis-menten constant 
Ktransit Absorption intercompartment transfer rate 
LLOQ Lower Limit of Quantification 
M. tuberculosis Mycobacterium tuberculosis 
MARS Multivariate Adaptive Regression Splines 
MDR-TB Multidrug Resistant-tuberculosis 
MIC Minimum Inhibitory Concentration 
mRNA Messenger Ribonucleic acid 
MTT Mean Transit Time 
NAT2 N-acetyltransferase 2 
NCA Noncompartmental Analysis 
NN  Number of absorption transit compartments 
OFV Objective Function Value 






P-pg P-glycoprotein  
PsN Perl-speaks-NONMEM 
PTA Probability of Target Attainment 
PXR Pregnane X receptor 
Q Intercompartmental clearance 
QH Hepatic plasma flow 
SIR Sampling Importance Resampling 
TB Tuberculosis 
TBW Total Body Weight 
Tmax Time to maximum plasma concentration 
TTE Time-to-event 
V Volume of distribution 
VC Volume of distribution of the central compartment 
VH Volume of distribution of the liver 
VP Volume of distribution of the peripheral compartment 
VPC Visual Predictive Check 




Chapter 1: Introduction and literature review 
1.1 Global disease burden of tuberculosis 
In 2015, new cases of tuberculosis were estimated to be around 10.4 million worldwide (World 
Health Organization, 2016). The incidence of tuberculosis continues to grow because of the 
high prevalence of Human Immunodeficiency Virus (HIV), bacterial resistance to medications, 
migration from regions of high prevalence, and living conditions (Knechel, 2009). New 
tuberculosis cases are unevenly distributed by geographical region, sex, and age. Slightly 
more than half (56%) of the new tuberculosis cases are men, and the remaining proportion is 
shared between women (34%) and children (10%). A quarter of the new infections in 2015 
occurred in the World Health Organization (WHO) African region. In the same year, the 
incidence rate for three countries in the Southern Africa region (Lesotho, Mozambique and 
South Africa) was estimated to be above 500 per 100 000 people. Figure 1 shows the 
incidence rates of tuberculosis in 2016 at country level. Above a tenth of all new tuberculosis 
cases were people living with HIV (World Health Organization, 2016). Among new and relapse 
cases of tuberculosis, HIV prevalence was highest in the African region with most countries in 
Southern Africa recording prevalence above 50%. Tuberculosis remained one of the top 10 
causes of mortality, and around 1.4 million and 0.39 million TB deaths were estimated in 2015 
among HIV-negative and HIV-positive people, respectively. In the African region, the 
proportion of deaths due to TB among HIV-positive people is more than double that of HIV-





Figure 1.1 Estimated tuberculosis incidence rates, 20160F1 
 
1.2 Tuberculosis disease 
Mycobacterium tuberculosis (M. tuberculosis) is the causative agent for tuberculosis. It is a 
rod-shaped, non-spore forming, and aerobic bacterium that grows slowly compared to other 
bacteria (Grange, 2009). It has a complex and well-developed cell wall that is responsible for 
acid-fastness, slow growth rate, host defence mechanism, and resistance (Brennan & Nikaido, 
1995; Knechel, 2009). The cell wall is also a barrier to penetration of antituberculosis drugs: 
the hydrophilic nature of the peptidoglycan and arabinogalactan layer reduces penetration of 
hydrophobic compounds (Brennan & Nikaido, 1995) and the combination of mycolic acids and 
long chain fatty acids hinders the penetration of hydrophobic and hydrophilic drugs (Liu, 
Rosenberg, & Nikaido, 1995). Molecules that escape these barriers are exposed to the 
multidrug efflux pumps in the cell membrane which pump them out before reaching 
intracellular targets (Nikaido, 2001). Essential to M. tuberculosis survival within macrophages 
is the lipoarabinomannan, an immunogenic carbohydrate structural antigen component of the 
cell wall that down-regulates macrophage effector functions (Chan, Fan, Hunter, et al., 1991; 
Lee, Li, Chatterjee, et al., 2004). M. tuberculosis can survive and grow within macrophages 
thus presenting an additional layer of complexity for drugs to penetrate and this layer also 
                                               
1 Reprinted from Global tuberculosis report 2017. Geneva: World Health Organization; 2017. Licence: 
CC BY-NCSA 3.0 IGO with permission from the World Health Organization. 
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exposes the drug molecules to host cell efflux transporters (Hartkoorn et al., 2007). Thus 
antituberculosis drug concentrations inside macrophages become inadequate to eradicate the 
subpopulation of bacilli in macrophages (Dartois, 2014). Macrophages together with other 
immune cells form granulomas in an attempt to contain the infection (Ramakrishnan, 2012). 
The presence of granulomas creates a barrier for antituberculosis drugs reaching the target 
as it also protects the bacilli within lesions (Dartois & Barry, 2010). The bacilli in the 
granulomas could then be activated during or after treatment resulting in relapse. 
 
Populations of M. tuberculosis can be described as consisting of subpopulations. These can 
be broadly classified as: (1) actively growing, (2) slow/non-replicating M. tuberculosis bacteria 
that undergo spurts of metabolism, (3) intracellular bacilli present in the acidic compartments 
of macrophages or lung lesions, and (4) M. tuberculosis persisters found in hypoxic 
microenvironments (Mitchison, 1979). As will be described in the next section, the activity of 
antituberculosis drugs is preferential to these subpopulations: the drug activity either increases 
or decreases depending on growth rate of the bacilli , and/or pH at the site of infection 
(Mitchison, 1979; Vernon, 2011). 
 
1.3 Tuberculosis treatment 
The World Health Organisation currently recommends a six-month regimen for the treatment 
of drug-susceptible tuberculosis. Patients are administered rifampicin, isoniazid, 
pyrazinamide, and ethambutol daily as Fixed Dose Combination (FDC). Treatment of drug-
susceptible tuberculosis consists of an intensive (first two months) and a continuation phase. 
All four drugs are administered in the intensive phase and only rifampicin and isoniazid in the 
continuation phase. Adult tuberculosis patients administer weight-adjusted daily doses of the 
FDC, with each tablet containing 150 mg of rifampicin, 75 mg of isoniazid, 400 mg of 
pyrazinamide, and 375 mg of ethambutol. Patients with a weight between 30–37 kg receive 
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two tablets and those with weighing 38–54 kg, 55–70 kg, and above 70 kg receive three, four, 





1.4 Pharmacology of antituberculosis drugs 
 
1.4.1 Pharmacology of rifampicin 
Rifampicin is the cornerstone of the current drug regimen for the treatment of drug-susceptible 
tuberculosis. It prevents DNA-directed mRNA synthesis by binding to the β subunit of DNA 
dependent RNA polymerase (rpoB) (Donald & McIlleron, 2009; Gumbo, 2010). Mutations to 
the rpoB gene cause resistance to rifampicin and close to 90% happen at codons 526 and 
531. Rifampicin-resistant strains occur in approximately 1 in 107 to 1 in 108 bacilli (Mitchison, 
2000; Somoskovi, Parsons, & Salfinger, 2001). The Minimum Inhibitory Concentrations (MICs) 
of rifampicin in drug-susceptible M. tuberculosis clinical isolates ranged from 0.016 to 0.5 mg/L 
and the distribution is similar in different geographic regions (Chigutsa et al., 2015; Lee & 
Heifets, 1987; Schon et al., 2009). 
 
Rifampicin is administered orally, and its absorption is highly variable (Burman, Gallicano, & 
Peloquin, 2001; Wilkins et al., 2008). Following a 600 mg oral dose, rifampicin concentrations 
reach a peak (Cmax) of 6–14 mg/L within 1.5–4 hours post-dose (Donald & McIlleron, 2009; 
Sirgel et al., 2005). Pharmacokinetic parameters of rifampicin are affected by food intake: Cmax 
is reduced by a third and time to Cmax (Tmax) is doubled (Acocella, 1978; Lin, Yu, Liu, et al., 
2014; Peloquin, Namdar, Singleton, & Nix, 1999; Zent & Smith, 1995). Intake of rifampicin on 
an empty stomach also reduces the variability in exposure (Peloquin, Namdar, Singleton, & 
Nix, 1999). In a cross-over study, the absolute bioavailability of rifampicin was found to be 
71% in the fed state compared to the 87% observed in the fasted state (Saktiawati et al., 
2016). The absorption process of rifampicin has been described with population modelling as 
a first-order process with or without delay using a lag time or transit compartments (Rockwood 




Rifampicin undergoes extensive first-pass metabolism before reaching the systemic 
circulation, and it is approximately 80% bound to plasma protein especially albumin (Acocella, 
1983; Boman & Ringberger, 1974). It is metabolised by liver esterase which deacetylates it 
within the hepatocytes to form desacetyl-rifampicin (Acocella, 1978). Both rifampicin and 
desacetyl-rifampicin are largely excreted in bile with a minor proportion excreted renally. At 
doses of around 450 mg, the capacity of the liver to extract rifampicin is saturated hence 
increasing the dose results in a more than linear increase in exposure. A 50% increase in the 
dose (600 mg to 900 mg) resulted in nearly double the concentrations and tripling of exposure 
was observed after doubling the dose from 10 mg/kg to 20 mg/kg (Acocella, 1978; Decroix et 
al., 1969). The saturation may be due to the achievement of a transport maximum in bile at 
doses of around 450 mg. 
 
Rifampicin induces a number of drug metabolising enzymes via the nuclear pregnane X 
receptor (PXR) and constitutive androstane receptor (CAR) (Chen & Raymond, 2006). This 
induction also affects rifampicin’s own metabolism, such that the exposure on the first day of 
treatment is greater than at steady state as a result of a change in clearance (Acocella, 1978). 
It is also a substrate of the P-glycoprotein (P-gp), a drug efflux pump encoded by the ABCB1 
gene (Schuetz, Schinkel, Relling, et al., 1996). Reports show widely varying time to full 
induction: one week to one month (Niemi et al., 2003; Smythe et al., 2012). Recent research 
results reported after the publication of results in this thesis were in keeping with the previously 
estimated values (Svensson, Aarnoutse, et al., 2017). A dose-dependent effect of 
autoinduction, which tends to decrease the elimination half-life of rifampicin over the first two 
weeks of treatment, has also been observed: the change in half-life was higher for the 900 mg 
dose compared to the 600 mg dose (Acocella, Pagani, Marchetti, et al., 1971). Population 
pharmacokinetic modelling was applied to quantify the extent of autoinduction and Svensson 
et al. reported that the induction process takes around 24 days to complete and Smythe et al. 
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reported a longer duration of 40 days, assuming 5 half-lives of the induction process. (Smythe 
et al., 2012; Svensson, Aarnoutse, et al., 2017) 
 
The population pharmacokinetics of rifampicin has been described using a one-compartment 
disposition model after a single dose or at steady state. At steady state, the apparent 
clearance (CL/F) reported in African patients ranges between 11 L/h and 25 L/h (Chigutsa et 
al., 2011; Denti, Martinson, et al., 2015; Rockwood et al., 2016; Smythe et al., 2012; Wilkins 
et al., 2008). In TB/HIV co-infected patients from South Africa, HIV-infected and ART naïve 
patients had 21% reduced clearance, and a 46% reduction in clearance was reported among 
HIV-infected patients on double dose lopinavir/ritonavir (Rockwood et al., 2016). Pregnant 
women from South Africa were shown to have 14% reduced clearance of rifampicin compared 
to non-pregnant counterparts (Denti, Martinson, et al., 2015). Comparing single-drug to FDC 
formulation, Wilkins et al. reported a 23% increase in oral clearance among patients who 
received single-drug formulation. However, this relationship could be a result of the effect of 
formulation on bioavailability, rather than clearance itself, as there was a near 100% 
correlation between CL/F and apparent volume of distribution (V/F) (Wilkins et al., 2008). 
Genetic polymorphism in SLCO1B1 rs41490932 has been reported to reduced exposure to 
rifampicin. Patients with the heterozygous mutation have 18% reduced bioavailability while 
those with the homozygous mutation have 28% lower bioavailability compared to the wild-type 
(Chigutsa et al., 2011). A 30% reduced volume of distribution in females reported by Chigutsa 
et al. could reflect the effect of body size and composition on disposition parameters. The 
model by Chigutsa et al. and that of Wilkins et al. applied allometric scaling using total body 
weight whereas the models by Denti et al. and Rockwood et al. used fat-free mass. The effect 
of sex on V/F was not significant in the models by Denti et al. and Rockwood et al., possibly 
because of the difference in body composition between males and females had been 
accounted for by allometric scaling. Related to these findings are pharmacokinetic results from 
Malawi, where males were reported to have 20% increased clearance after adjustment for 
body size using total body weight (Sloan et al., 2017). Females have higher fat compared to 
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males, hence receive higher doses per kg of fat-free mass than males when dosed using the 
currently recommended weight-adjusted dosing. This results in a disparity in exposure, as 
presented by McIlleron et al. who showed that males with lower weight have significantly 
reduced exposure than the rest of the patients (McIlleron et al., 2012). Clearance of rifampicin 
is modified in patients with liver damage, who show increased elimination half-life (Jeanes, 
Jessamine, & Eidus, 1972). The reduction in rifampicin clearance as a result of renal 
impairment does not warrant dose modification, but renally impaired patients should be 
monitored for acute interstitial nephritis or further deterioration of renal function (Acocella, 
1978; Malhotra, 2003; Neugarten, Gallo, & Baldwin, 1983).  
 
Besides variability due to patient characteristics, some formulations of rifampicin have been 
shown to have reduced bioavailability and others are unstable ex vivo. In a pooled analysis of 
drug formulations from tuberculosis programmes and pharmacies in six countries, rifampicin 
content was reduced to less than 85% in 13% of analysed samples. More FDCs than single-
drug tablets had reduced rifampicin content (Laserson, Kenyon, Kenyon, et al., 2001). Under 
accelerated storage conditions of temperature and humidity, decomposition of rifampicin was 
observed (Bhutani, Mariappan, & Singh, 2004; Singh & Mohan, 2003). A 98% degradation of 
rifampicin in the presence of isoniazid compared to rifampicin alone or with pyrazinamide 
reported by Seifart et al. suggest that the two drugs could have interacted in the formulation 
environment during storage (Seifart, Parkin, & Donald, 1991). 
 
An integrated pharmacokinetic model for rifampicin and desacetyl-rifampicin has been 
developed for healthy Asian adults and African children with tuberculosis (Denti et al., 2017; 
Seng et al., 2015b). In the model by Seng et al., pharmacokinetics of desacetyl-rifampicin was 
described using a two-compartment model with input from the central plasma compartment of 
rifampicin. In their model, the clearance of desacetyl-rifampicin was estimated to be 95.8 L/h. 
Concurrently with the work presented in this, Denti et al. developed a elegant semimechanistic 
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well-stirred liver model with jointly saturable hepatic extraction for both rifampicin and 
desacetyl-rifampicin. The authors defined two pathways associated with the clearance of 
rifampicin: formation of desacetyl-rifampicin and other metabolites or excretion. Disposition of 
desacetyl-rifampicin was characterised by a one-compartment model (Denti et al., 2017). 
 
The currently recommended rifampicin dose of 10 mg/kg (approximately 600 mg daily) was 
selected based on (1) concentrations above the Minimum Inhibitory Concentration (MIC), (2) 
the fact that adverse events were thought to be likely to be dose-related, and (3) cost (van 
Ingen et al., 2011). The relationship between the dose and toxicity is of less importance as 
recent evidence shows that daily doses of up to 35 mg/kg of body weight are well tolerated 
(Boeree et al., 2015). In this study, the adverse events observed were not related to any 
specific dose of rifampicin. Increased doses of rifampicin had been evaluated in the early 
studies by comparing doses from 10 mg/kg to 12.5 mg/kg of body weight. The rate of sputum 
conversion was similar in the two treatment groups, but the 25% increase in dose might have 
been too conservative (Long, Snider, & Farer, 1979). The recent study by Boeree et al. also 
showed that doses of 30 mg/kg and 35 mg/kg resulted in greater estimated fall in bacterial 
load than 10 mg/kg during the first 14 days of treatment (Boeree et al., 2015). Prior to the 
publication of the results by Boeree et al., several pharmacodynamic indices for rifamycins 
had been proposed using data from in vitro and in vivo experiments. Nuermberger and Grosset 
suggested that rifamycins, have concentration-dependent killing hence the ratio of Cmax/MIC 
and area under the concentration-time curve (AUC) over MIC (AUC/MIC) will correlate best 
with the rate of bacterial killing (Nuermberger & Grosset, 2004). Some researchers argue that 
of the two indices, AUC0–24/MIC is the best index associated with bacterial killing (Gumbo, 
Louie, Deziel, et al., 2007; Jayaram et al., 2003). Using an aerosol infection model, Jayaram 
et al. identified that AUC0–24/MIC ratio ≥ 271 was important to achieve a 1-log10 CFU decline 
in vivo. For the prevention of resistance to rifampicin, Gumbo et al. reported that a Cmax/ MIC 
ratio of ≥ 175 is required (Gumbo, Louie, Deziel, et al., 2007). In order to achieve the required 
pharmacodynamic targets (AUC0–24/MIC and Cmax/MIC), Goutelle et al. suggested the use of 
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a 1 200 mg dose which is approximately 20 mg/kg (Goutelle et al., 2009). However, the 
bacteriological response in the 10 mg/kg, 15 mg/kg, and 20 mg/kg treatment groups was 
compared during eight weeks of treatment, and no evidence of superiority of the >10 mg/kg 
doses was observed, supporting the idea that higher doses of rifampicin need to be evaluated 
over longer treatment durations (Aarnoutse et al., 2017). The need for higher doses of 
rifampicin is further strengthened by the results reported by Boeree et al.: the decline in 
bacterial load as measured by time-to-positivity in liquid media was significantly longer for only 
the 30 mg/kg and 35 mg/kg dose compared to the 10 mg/kg dose (Boeree et al., 2015). In a 
separate study (the main study of the results presented in this thesis), 12-month mortality was 
not significantly reduced in the 15 mg/kg dose treatment arm, however, the PK-PD relationship 
could have been modified by severe immune suppression as the effect of the higher dose of 
rifampicin was observed only in patients with CD4+ count of <100 cells/µL (Merle et al., 2016). 
In support of the argument for the need for higher doses, doses of at least 30 mg/kg were 
reported to eradicate persistent M. tuberculosis, allowing relapse free, and shorter treatment 
duration in a Cornell mouse model (Liu et al., 2017). A possible reason is that the higher 
doses will also result in a more than linear increase in the concentrations of rifampicin inside 
the bacteria due to saturation of bacterial efflux pumps (Gumbo, Louie, Deziel, et al., 2007).  
Induction of the expression of several proteins that alter the metabolism of other drugs is a 
major side-effect of rifampicin. Enzyme induction by rifampicin could potentially reduce the 
efficacy of the co-administered drugs and increase the formation of toxic metabolite(s). 
(Donald & McIlleron, 2009). Other untoward effects that occur in less than 4% of patients 
taking rifampicin include rash, fever, nausea, and vomiting. Patients who receive another 




1.4.2 Pharmacology of isoniazid 
Isoniazid was introduced for the treatment of tuberculosis in 1952 and has remained as one 
of the backbone drugs of tuberculosis chemotherapy. It has excellent bactericidal activity 
against M. tuberculosis, a wide therapeutic margin (around 16 for a 300 mg dose1F2), it is cheap 
and prevents resistance to companion drugs (Donald & Schaaf, 2011; Mitchison, 2000). 
Isoniazid is a prodrug that enters the mycobacterial cell by passive diffusion and is then 
activated by M. tuberculosis katG-encoded catalase-peroxidase (Timmins & Deretic, 2006). 
The activated isoniazid targets the NADH-dependent enoyl-acyl carrier protein reductase 
coded for by the inhA gene, which is responsible for the synthesis of long fatty acyl chains of 
mycolic acids (Zhang, Heym, Allen, et al., 1992). The MIC of isoniazid in drug-susceptible M. 
tuberculosis ranges from 0.02 to 0.125 mg/L in broth and from 0.1 to 0.2 mg/L on solid media 
(Chigutsa et al., 2015; Lee & Heifets, 1987; Suo, Chang, Lin, et al., 1988). Mutation of the 
katG gene results in resistance due to inactivation of isoniazid. Resistance to isoniazid, and 
lack of its protective effect results in poor treatment outcomes. 
 
Isoniazid is water-soluble and readily absorbed in the gastrointestinal tract with a short delay 
(approximately 20 minutes) before reaching the systemic circulation. However, this delay is 
characterised by large variability (Wilkins et al., 2011). The speed and extent of absorption of 
isoniazid is not affected by intake of antacids, but it is greatly influenced by concomitant food 
intake. The maximum concentration is reduced by 51% while the time to reach the maximum 
concentration is increased by 89% (Peloquin, Namdar, Dodge, et al., 1999), and comparable 
results have been reported by other researchers (Melander et al., 1976; Saktiawati et al., 
2016). Zent and Smith also reported that the pharmacokinetics of isoniazid are affected by 
concomitant food intake, however with modest effects: Cmax reduced by 20%, AUC0–8 reduced 
by 19% and Tmax prolonged by 21% (Zent & Smith, 1995). Isoniazid is primarily metabolised 
                                               
2 “The therapeutic margin is the ratio between the usual dose size and the dose that yields detectable 
EBA” (Mitchison, 2000) 
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by N-acetyltransferase-2 enzyme (NAT2) isoforms to its principal metabolite acetyl-isoniazid 
and other metabolites (Ellard & Gammon, 1976; Gumbo, 2010). NAT2 is predominantly found 
in the liver and intestines and is coded by a polymorphic gene. Mutations of NAT2 result in 
different rates of acetylation of isoniazid and individuals can be classified as fast, intermediate 
and slow acetylators (Deguchi, Mashimo, & Suzuki, 1990; Parkin et al., 1997). Because of this 
genetic variability, NAT2 contributes to around 88% of the variability in isoniazid clearance 
(Kinzig-Schippers et al., 2005; Sim, Abuhammad, & Ryan, 2014). Seng et al. showed that 
inclusion of NAT2 in a population pharmacokinetic model reduces the between-subject 
variability from 86% to 14% (Seng et al., 2015a). The difference in acetylation could potentially 
influence therapeutic response and toxicity. Pre-systemic elimination including hepatic first-
pass extraction is affected by NAT2 phenotype, with significant extraction in fast and to a 
lesser extent in intermediate and slow acetylators. As a result, peak concentrations of 
isoniazid, usually observed between 1 to 2 hours post a 300 mg dose depends on the 
acetylator status. On average, Cmax for fast acetylators is around 1.8 mg/L while that for 
intermediate and slow acetylators is 3 mg/L and 6 mg/L, respectively (Parkin et al., 1997; 
Peloquin et al., 1997; Requena-Méndez et al., 2014). In fast acetylators, the rate of elimination 
via the acetylation pathway is around four times that of other routes while in slow acetylators 
the rate of elimination via acetylation is comparable to other routes (Ellard, 1976). Figure 2 





Figure 1.2 A schematic representation of isoniazid (INH) metabolism and the enzymes 
involved in the metabolic pathways of isoniazid  AcHz: acetylhydrazine; AcINH, 
acetyl-isoniazid; DiAcHz: diacetylhydrazine; GST: glutathione S-transferases; Hz: 
Hydrazine; INA: isonicotinic acid; MPO: myeloperoxidase; NAT2: N-acetyltransferase 2; 
P450: cytochrome P450; R.M.: reactive metabolite. (from Wang et al., 2016) 2F3 
 
The proportion of fast acetylators varies between 13% and 74% in studies conducted in South 
Africa, and around 50% in West Africa (Donald et al., 2004; Schaaf et al., 2005; Smythe, 2016; 
Wilkins et al., 2011). In a cohort of South African patients, CL/F among fast acetylators was 
estimated to be more than double that of slow acetylators (21.6 vs 9.7 L/h) (Wilkins et al., 
2011). In keeping with these results, Smythe also reported a 2-fold increase in CL/F among 
fast compared to slow acetylators in a cohort of TB/HIV co-infected patients from West Africa 
(23 vs 10.3 L/h). A smaller difference of 68% higher CL/F in fast acetylators was reported 
among Tanzanian tuberculosis patients (Denti, Jeremiah, et al., 2015). Mixture modelling was 
applied to assign patients to the most probable acetylator status in the study by Wilkins et al. 
and Symthe, while in the study by Denti et al. genotyping results were available. Regardless 
                                               
3 Reprinted from Acta Pharm Sin B, 6(5): 384-392, Wang P et al., Isoniazid metabolism and 
hepatotoxicity, Figure 1, Page 386, Copyright 2016. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/) 
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of acetylator status, allometric scaling was included on CL/F using fat-free mass, which was 
superior to total body weight as body size descriptor, except for the model presented by 
Wilkins et al., where fat-free mass was not evaluated. Besides acetylator status, and body 
size, clearance of isoniazid is influenced by HIV infection, ART intake, and age. Isoniazid 
clearance in TB/HIV co-infected patients was 23% lower than HIV negative tuberculosis 
patients (Rockwood et al., 2016). In a similar setting, Wilkins et al. showed that HIV positive 
patients have 17% reduced clearance compared to HIV negative patients (Wilkins et al., 
2011). In a cohort of TB/HIV patients from Mozambique, nevirapine did not affect the 
pharmacokinetics of isoniazid. However, efavirenz, a widely used antiretroviral therapy drug, 
reduced isoniazid AUC0–24 by 29% (Bhatt et al., 2014). The influence of age on isoniazid 
clearance reported by Kergueris et al. reflects reduced renal function associated with older 
age, and the effect would be more pronounced in slow acetylators whose renal clearance 
accounts for around 25% of the total clearance. (Kergueris, Bourin, & Larousse, 1986; Weber 
& Hein, 1979).  
 
Isoniazid is responsible for the initial kill of around 95% of the bacteria in the first two days of 
treatment (Mitchison, 2000). An early bactericidal activity (EBA) of 0.72 log10 CFU/day was 
achieved with a dose of 300 mg (Jindani, Aber, Edwards, et al., 1980; Jindani, Doré, & 
Mitchison, 2003). Donald et al. presented corroborating results and also showed that the EBA 
of isoniazid remains unchanged with or without co-administered drugs (Donald et al., 1997). 
A decline of at least 0.55 log10 CFU/mL of sputum per day is associated with reduced infectivity 
and risk of resistance to isoniazid (Donald & McIlleron, 2009). Isoniazid sterilising activity is 
limited in the presence of rifampicin and pyrazinamide, and its activity is hypothesized as 
diminishing with a decrease in metabolic activity and depletion of the bacilli (Dickinson & 
Mitchison, 1981; Donald & McIlleron, 2009). Contrary to this hypothesis, Gumbo et al. showed 
that the decline in isoniazid activity is related to the development of drug resistance and 
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postulated that the resistance could be a result of mutation of the katG or the isoniazid-related 
induction of multidrug resistance pumps (Gumbo, Louie, Liu, Ambrose, et al., 2007).  
 
Acetyl-isoniazid in the product of acetylation of isoniazid by NAT2. Concentrations of 
acetyl-isoniazid are usually higher in fast acetylators vs slow acetylators, and peak 
concentrations occur earlier in fast acetylators (Hutchings, Monie, Spragg, et al., 1988). The 
apparent half-life of acetyl-isoniazid is double that of isoniazid (4.57 hours vs 2 hours). 
Population pharmacokinetics of acetyl-isoniazid have been reported in healthy Asian 
volunteers. A two-compartment model adequately described the pharmacokinetics of 
acetyl-isoniazid formed from acetylation of isoniazid (Seng et al., 2015a). The model estimated 
fraction of isoniazid converted to acetyl-isoniazid of 97.3% was same regardless of acetylator 
phenotype. Two pathways for the clearance of acetyl-isoniazid were identified: formation of 
isonicotinic acid and other metabolites. The same authors also observed a marginal but 
significant change in clearance of isoniazid for every 10% change in creatinine clearance from 
a reference value of 113 mL/min. 
 
Based on mouse models, an AUC0–24/MIC ratio of approximately 500 was identified as the 
best explanatory PK-PD index associated with bactericidal activity of isoniazid after 4 to 6 days 
of exposure followed by Cmax/MIC ratio (Jayaram et al., 2004). In an in vitro experiment, 
Gumbo et al. also showed that the ratio of the AUC0–24/MIC is the PK-PD index associated 
with microbial kill (Gumbo, Louie, Liu, Brown, et al., 2007). By using classification and 
regression trees, AUC0–24 of isoniazid was reportedly  associated with long-term tuberculosis 
treatment outcomes with a cut-off value of 53 mg·h/L separating poor and favourable 
outcomes in patients with pyrazinamide AUC0–24 > 363 mg·h/L and rifampicin AUC0–24 < 13 
mg·h/L. At two months, peak concentrations were identified as best predictors of culture 
conversion, and again isoniazid was included in the decision tree after pyrazinamide and 
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rifampicin (Pasipanodya et al., 2013). AUC and 2-hour post-dose concentrations were 
identified as PK-PD indices associated with optimal EBA defined as 90% of the maximum 
EBA. Achieving AUC0–∞ of at least 10.52 mg·h/L or 2-hour concentrations > 2.19 mg/L was 
associated with achieving the optimal EBA (Donald et al., 2007).  
 
The two main metabolic pathways (acetylation and hydrolysis) of isoniazid contribute to 
hepatotoxicity via hydrazine metabolites. In slow acetylators, direct hydrolysis of isoniazid 
forms hydrazines that could cause liver damage (Scales & Timbrell, 1982). In a meta-analysis 
of 14 studies, the odds of developing INH-induced hepatotoxicity in slow acetylators was 4.6 
times higher compared to fast acetylators (Wang, Xie, Hao, et al., 2012). The risk of 
hepatotoxicity was 7-fold higher in slow acetylators with CYP2E1 C1/C1 genotype (Huang et 
al., 2003). Results from a study of 218 Indian patients also showed that slow acetylator status 
and CYP2E1 C/D or C/C genotype together were associated with a high frequency of drug-
induced liver injury (Bose et al., 2011). In fast acetylators, hydrolysis of acetylhydrazine, a 
product of metabolism of acetyl-isoniazid, results in the formation of the toxic isoniazid 
hydrazine (Scales & Timbrell, 1982). Overall, hepatotoxicity is fatal in less than 1% of patients 
receiving isoniazid. Neurotoxicity is another side effect of isoniazid intake and is closely related 
to the dose. Patients who are slow acetylators and malnourished have higher chances of 





1.4.3 Pharmacology of pyrazinamide 
Pyrazinamide is a pro-drug that was first used for the treatment of pulmonary tuberculosis in 
1952 (Yeager, Munroe, & Dessau, 1952). Its use was limited, due to hepatic toxicity associated 
with high doses, until the early 80’s, when its ability to shorten treatment duration was 
discovered (British Thoracic Association, 1982; Fox, 1981). The British Thoracic association 
reported a higher proportion of two-months culture negative results in patients receiving 
pyrazinamide-containing regimens compared to control regimen (77% vs 64%, p-value<0.01).  
 
There are relatively few population pharmacokinetics models for pyrazinamide, and the 
disposition of pyrazinamide is presented as a one-compartment model (Alsultan et al., 2017; 
Chigutsa, McIlleron, & Holford, 2010; Denti, Jeremiah, et al., 2015; Peloquin et al., 1997, 1998; 
Rockwood et al., 2016; Smythe, 2016; Wilkins et al., 2006; Zhu et al., 2002). However, some 
components of the models differ significantly. Pyrazinamide absorption is known to be rapid, 
reaching a maximum concentration of around 53 mg/L in a fasted state, between 1-2 hours 
post-dose (Peloquin et al., 1998). To describe the absorption of pyrazinamide, Wilkins et al. 
applied a sequential zero-order and first-order absorption process with the former 
characterising the release of the drug from its oral formulation into the absorption 
compartment. Their model could also identify two sub-populations with different rates of 
absorption (Wilkins et al., 2006). Denti et al. and Rockwood et al. accounted for a delay in 
absorption of pyrazinamide using a chain of transit compartments (Denti, Jeremiah, et al., 
2015; Rockwood et al., 2016), whereas data from other studies did not support a delay in 
absorption (Alsultan et al., 2017; Wilkins et al., 2006) or a delay was not reported. Concomitant 
food intake has little to no impact on both absorption and bioavailability of pyrazinamide 




Pyrazinamide is rapidly distributed and has a longer non-dose dependent elimination half-life 
(~9.5 hours) compared to the co-administered drugs in the FDC (Ellard, 1969; Lacroix et al., 
1989; Peloquin et al., 1997). Pyrazinamide is first hydrolyzed to its active form pyrazinoic acid 
by microsomal deamidase in the liver and then oxidised to 5-hydroxypyrazinoic acid by 
xanthine oxidase (Weiner & Tinker, 1972). Only 4% of the dose is excreted unchanged in bile 
and approximately a third of the dose as pyrazinoic acid (Ellard, 1969). Xanthine oxidase is 
also involved in the conversion of pyrazinamide to 5-hydroxypyrazinamide. Clearance of 
pyrazinamide ranges between 2.8–5.06 L/h in African patients (Alsultan et al., 2017; Denti, 
Jeremiah, et al., 2015; Rockwood et al., 2016; Smythe, 2016; Vinnard et al., 2017; Wilkins et 
al., 2006). Clearance of pyrazinamide was reported to change with time on treatment with the 
other first-line anti-TB agents. In patients from Tanzania, pyrazinamide clearance increased 
by 16% in the first two months of treatment (Denti, Jeremiah, et al., 2015). A higher increase 
of 30% was reported in a cohort of patients from West Africa (Smythe, 2016). In a study by 
Chigutsa et al. pyrazinamide clearance was described using a parallel first-order and mixed-
order elimination model which was superior to the first-order elimination (Chigutsa, McIlleron, 
& Holford, 2010). Results of a recent study conducted in Botswana showed a 22% reduced 
clearance in patients who had activation of %CD38+DR+CD8+ (Vinnard et al., 2017). Allometric 
scaling has been applied in the population pharmacokinetics models using either total body 
weight or fat-free mass. In models where allometric scaling was applied based on total body 
weight, authors identified the effect of sex on bioavailability, volume of distribution, or 
clearance consistently. Chigutsa et al. reported a 26% increased bioavailability in females 
(Chigutsa, McIlleron, & Holford, 2010). Wilkins et al. and Alsultan et al. showed that males had 
4.55 L and 7.5 L higher volume of distribution respectively (Alsultan et al., 2017; Wilkins et al., 
2006). Females had 40% lower clearance in a cohort of tuberculosis patients from Botswana 




Pyrazinamide is more effective against slowly- or non-replicating bacteria that are 
characterised by reduced metabolism, lower energy reserves and decreased membrane 
potential (Zhang, Wade, Scorpio, et al., 2003). The activity of pyrazinamide is highly 
dependent on its conversion to pyrazinoic acid (Konno, Feldmann, & McDermott, 1967). 
Pyrazinamide enters the tuberculosis bacilli by passive diffusion (Zhang et al., 1999) and 
possibly active transport (Raynaud et al., 1999), and then is converted by bacterial 
pyrazinamidase into pyrazinoic acid. In an acidic environment (low pH), a small proportion of 
uncharged protonated pyrazinoic acid, which permeates through the cell membrane, facilitates 
the accumulation of pyrazinoic acid anions and protons, and kills the bacteria (Zhang et al., 
1999; Zhang & Mitchison, 2003). Pyrazinoic acid kills the bacteria by inhibiting both protein 
and RNA synthesis, serine uptake, and disruption of membrane potential (Zhang, Wade, 
Scorpio, Zhang, & Sun, 2003). Pyrazinoic acid leaves the cell via passive diffusion and 
excreted by weak efflux pump (Zhang et al., 1999). The mechanism associated with 
pyrazinamide resistance involves mutation of the pncA gene that encodes pyrazinamidase 
and results in reduced or loss of enzyme activity (Hirano, Takahashi, Kazumi, et al., 1997; 
Juréen, Werngren, Toro, et al., 2008).  
 
The effect of exposure to pyrazinamide on tuberculosis treatment outcome has been explored 
using a number of metrics: AUC0–24, Cmax, AUC0–24/MIC, Cmax/MIC and time above the MIC 
(Gumbo, Dona, Meek, et al., 2009). In a cohort of predominantly TB/HIV co-infected patients 
from Botswana, Chideya et al. reported that patients with low pyrazinamide Cmax (<35 mg/L) 
had poor treatment outcome compared to those with Cmax of at least 35 mg/L (50% vs 16%; 
p-value<0.01). Poor treatment outcome was defined as treatment failure or death during 
tuberculosis treatment (Chideya et al., 2009). The results of CART analyses on the data from 
two separate studies also showed that pyrazinamide Cmax is a significant predictor of treatment 
outcome. The proportion of patients who were culture positive at two months after treatment 
initiation was higher among patients with pyrazinamide Cmax < 58.3 mg/L compared to those 
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with a Cmax of at least 58.3 mg/L (14% vs 2%; P value= 0.035) (Pasipanodya et al., 2013). 
Pyrazinamide AUC0–24 was reported to be correlated with long-term treatment outcomes 
(treatment failure, death, or relapse) and AUC0–24 of 363 mg·h/L separated poor from 
favourable treatment outcomes (Pasipanodya et al., 2013). Using Multivariate Adaptive 
Regression Splines (MARS), Chigutsa et al. reported that pyrazinamide AUC0–24/MIC > 11.3 
is correlated with culture conversion among patients with rifampicin Cmax ≥ 8.3 mg/L. An in 
vitro study using hollow-fiber systems also identified pyrazinamide AUC0–24/MIC as the PK-PD 
index linked to microbial killing, and time above MIC as the index associated with suppression 
of resistance (Gumbo, Dona, Meek, & Leff, 2009). In some studies, MICs are rarely 
determined hence the use of indices computed using MIC is reduced. In such cases, 
researchers will have to use either AUC and Cmax to evaluate the probability of treatment 
success. Between these two, AUC is expected to be more robust than Cmax because the latter 
is dependent on blood sampling time, precision of drug intake time, and drug absorption, which 
is highly variable (Urso, Blardi, & Giorgi, 2002). 
 
Hepatoxicity is the most serious adverse effect associated with pyrazinamide (Girling, 1977). 
Signs and symptoms of hepatic disease appear if high daily oral doses of around 40–50 mg/kg 
are administered for extended periods (Donald & McIlleron, 2009; Gumbo, 2010). 
Pyrazinamide may also result in elevated plasma uric acid concentrations that could cause 
acute episodes of gout. Other side effects of pyrazinamide include arthralgias, anorexia, 





1.4.4 Pharmacology of ethambutol 
Ethambutol is the “fourth drug” in the FDC for the treatment of drug-susceptible tuberculosis 
(Bass et al., 1994). In comparison to Para-Aminosalicylic Acid (PAS), ethambutol was found 
to be more effective and well tolerated as a companion drug to isoniazid (Bobrowitz & Robins, 
1967). At doses of 15 mg/kg of body weight, ethambutol exerts a bacteriostatic effect 
(Hopewell, 2010). Ethambutol MICs ranges from 0.6–2 mg/L in clinical isolates of M. 
tuberculosis from South Africa (Chigutsa et al., 2015). The primary reason for including 
ethambutol as part of the FDC therapy is to reduce the risk of resistance to rifampicin in 
patients with known strains that have primary resistance to isoniazid (Bass et al., 1994). Its 
mechanism of action involves alteration of the mycobacterium cell wall structure by inhibiting 
biosynthesis of the arabinan component of the mycobacterial cell wall core (Deng et al., 1995; 
Rastogi, Labrousse, & Goh, 1996; Takayama & Kilburn, 1989).  
 
Approximately 80% of the oral dose of ethambutol reaches the systemic circulation, and 
plasma protein binding is around 10–40% (Gumbo, 2010; Lee, Brater, Gambertoglio, et al., 
1980; Lee, Gambertoglio, Brater, et al., 1977). Peak plasma concentrations of ethambutol are 
dose proportional and occur between 2–4 hours after a dose. With the currently recommended 
doses of 15 mg/kg, the peak concentrations are expected to be around 4 mg/L (Bass et al., 
1994). Ethambutol is mostly excreted unchanged in urine, in a proportion that was reported to 
vary widely (40–80%) in early studies of ethambutol pharmacokinetics (Lee, Brater, 
Gambertoglio, & Benet, 1980). However, recent reports are in agreement that around 80% of 
the drug is renally eliminated unchanged (Donald & McIlleron, 2009; Gumbo, 2010) and less 
than 15% of the dose is recovered in urine as metabolites. Metabolism of ethambutol involves 
oxidation by alcohol dehydrogenase to an aldehyde intermediate. The metabolite is further 





Ethambutol is widely distributed in body tissues, and more recently, it has been shown to 
accumulate in diseased tissues and penetrates lesions with a lesion-to-plasma ratio between 
9 and 12 (Zimmerman et al., 2017). The decline in plasma concentration of ethambutol after 
Cmax is biphasic, and if a one-compartment model is applied, a disappearance half-life of 
between 3 and 4 hours is expected. The slower terminal phase may be observed from 10–12 
hours post-dose and has a half-life of 10–15 hours (Peloquin et al., 1999). Population 
pharmacokinetics of ethambutol have been reported among healthy volunteers and patients 
from the United States and Africa (Peloquin et al. 1999; Zhu et al. 2004; Denti et al. 2015; 
Smythe 2016; Jönsson et al. 2011; Hall et al. 2012). 
 
Plasma concentrations of ethambutol have been described using a two-compartment 
disposition model with different absorption models and first-order elimination. In three of the 
models, a first-order absorption was implemented with a delay characterised by using a chain 
of transit compartments with a mean absorption time of 2–3 hours (Denti, Jeremiah, et al., 
2015; Jönsson et al., 2011; Smythe, 2016). Hall et al. also described the absorption as a first-
order process, but without a delay. Peloquin et al. and Zhu et al. described the absorption of 
ethambutol as a zero-order process, which they found superior to the first-order absorption 
process. All these models identified first-order elimination of ethambutol. In three studies 
conducted in African tuberculosis patients, the clearance of ethambutol was comparable and 
ranging from 39 to 46 L/h (Denti, Jeremiah, et al., 2015; Jönsson et al., 2011; Smythe, 2016). 
Allometric scaling was applied to account for the effect of body size and composition on 
disposition parameters. Jönsson et al. and Denti et al. accounted for this effect by using total 
body weight on all clearance and volume of distribution parameters whereas Smythe applied 
allometric scaling using fat-free mass on clearance and total body weight on volume of 
distribution. 
 
 Concomitant intake of antacids reduces exposure to ethambutol, and Peloquin et al. reported 
a 29% and 10% reduction in Cmax and AUC0–∞ respectively (Peloquin et al., 1999). Another 
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study also reached a similar conclusion and recommendations were made to avoid taking 
antacids concomitantly or just before ethambutol (Mattila, Linnoila, Seppälä, et al., 1978). 
Intake of food before or concomitantly reduces the rate of absorption minimally, but does not 
affect the extent of absorption (Ameer, Polk, Kline, et al., 1982; Peloquin et al., 1999). HIV has 
been reported to reduce plasma concentrations of ethambutol: Zhu et al. observed a 20% 
reduction in Cmax, and McIlleron et al. reported a 27% reduction in AUC in HIV positive patients 
(McIlleron et al., 2006; Zhu et al., 2004). In separate studies, Jönsson et al. and Smythe 
reported a 15% reduction in bioavailability in HIV positive patients (Jönsson et al., 2011; 
Smythe, 2016). Smythe also reported a 11.4% increase in bioavailability of ethambutol from 
the first dose to steady-state (Smythe, 2016). The effect of age on clearance of ethambutol in 
Tanzanian patients reported by Denti et al. is consistent with its elimination via the kidneys, 
since drug clearance in the older patients is expected to be lower as a result of reduced renal 
function (Denti, Jeremiah, et al., 2015). The effect of age was also reported in a cohort of 
tuberculosis patients from South Africa (McIlleron et al., 2006). 
 
Optimal antimicrobial kill of M. tuberculosis by ethambutol is associated with the AUC0–24/MIC 
index, and the time above MIC was found to be significant in suppressing efflux pump related 
drug resistance (Srivastava et al., 2010). Chigutsa et al. applied MARS techniques and 
discovered that the sterilising effect of ethambutol was evident in patients with ethambutol 
Cmax/MIC > 0.46 and rifampicin AUC0–24 < 35.4 mg·h/L (Chigutsa et al., 2015). EBA of 
ethambutol is dose-dependent, and a daily dose of 15 mg/kg has an EBA of 0.05 log10 CFU/mL 
sputum/day.  
 
The most common adverse effect associated with ethambutol intake is optic neuritis, and 
routine visual acuity testing is recommended for patients with pre-existing ocular problems 
(Forget & Menzies, 2006; Girling, 1977). Upon termination of ethambutol intake, gradual 
improvement in vision is possible (Alsultan & Peloquin, 2014a). Doses of at least 30 mg/kg 
24 
 
are most likely associated with toxicity, but patients with impaired renal function may also be 
affected at the currently recommended dose (Girling, 1977). Elevated plasma uric acid has 
also been reported, and other less common side effects include cholestatic jaundice, interstitial 





1.5 Multidrug nature of tuberculosis treatment 
The four drugs described above do not work in isolation but function together with potential 
synergism and antagonism while targeting different M. tuberculosis subpopulations. With the 
current combination therapy of both antituberculosis drugs and antiretroviral therapy, there is 
paucity of information on synergism and antagonism of drugs driving treatment response. In 
an in vitro experiment, the combination of rifampicin, isoniazid and ethambutol was reported 
to show synergism in isoniazid-resistant isolates (Rey-Jurado, Tudó, Martínez, et al., 2012). 
Monotherapy with pyrazinamide only showed minimum sterilising activity, but its synergism 
with rifampicin was crucial to shortening tuberculosis treatment duration to six months (British 
Medical Research Council, 1981). MARS analysis methodology was applied to PK-PD data 
from a study conducted in South Africa and the authors reported that the sterilising activity 
was driven mainly by isoniazid and ethambutol in patients who had low rifampicin exposure 
(Chigutsa et al., 2015). The same authors also reported that in patients with rifampicin Cmax > 
8.2 mg/L, the sterilising activity was determined by the synergistic interaction of rifampicin and 
pyrazinamide (AUC0–24/MIC ratio of 11.3). Concentration-dependent antagonism of isoniazid 
vs rifampicin and pyrazinamide was reported in Indian children with pulmonary tuberculosis. 
The proportion of poor treatment outcomes was higher in children who had isoniazid AUC0–24 
> 31.8 mg·h/L, pyrazinamide Cmax ≤ 38.1 mg/L, and rifampicin Cmax ≤ 6.2 mg/L. Chigutsa et al. 
also reported the antagonism of isoniazid on sterilising activities of rifampicin and 
pyrazinamide in patients with low (AUC0–24 < 35.4 mg·h/L) rifampicin exposure. Using MARS 
analysis, isoniazid (Cmax < 4.6 mg/L) was reported to have an antagonistic effect on culture 
conversion in patients who had rifampicin Cmax/MIC < 28 (Rockwood et al., 2017). Treatment 
of TB/HIV coinfected patients is complicated by multidrug nature of both tuberculosis and HIV 
therapy, and there could be potential pharmacokinetic drug-drug interactions. The effect of 
antituberculosis drugs especially rifampicin on antiretroviral therapy has been well studied 
(Lalloo, 2009; McIlleron, Meintjes, Burman, et al., 2007; Semvua et al., 2015), but few studies 
have evaluated the impart of ART on pharmacokinetics of first-line antituberculosis drugs 
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(Bhatt et al., 2014; Naidoo et al., 2017). Identifying PK-PD relationships is challenging due to 
variability in drug exposure caused by factors that include drug-drug interaction, genetic 





1.6 Tuberculosis treatment outcomes 
The evaluation of test regimens for the treatment of tuberculosis requires well-defined 
endpoints. The time at which an event occurs, such as time-to-stable culture conversion 
(TSCC), time-to-death on or after treatment, or time-to-relapse all provide rich quantitative 
information compared to the qualitative positive/negative status at a time point e.g. two-month 
culture results. (Chigutsa et al., 2013; García-García et al., 2002; Gillespie et al., 2014; 
Pasipanodya et al., 2013; Smythe, 2016; Svensson & Karlsson, 2017). TSCC is defined by 
two consecutive culture negative results at visits separated by a week, two weeks, or a month. 
The date of culture conversion is then defined as the date of the first negative culture result 
(Gillespie et al., 2014; Wallis et al., 2009). Relapse is defined as the presence of 
microbiologically confirmed tuberculosis in patients who successfully completed treatment 
with negative culture results. In tuberculosis control programmes, any deaths during the 
course of tuberculosis treatment are classified as tuberculosis related (World Health 
Organization, International Union Against Tuberculosis and Lung Disease, & Royal 
Netherlands Tuberculosis Association, 2001). In clinical trials, patients could be monitored for 
longer than the treatment duration and any deaths are also classified as tuberculosis related.  
 
The drug related factors described in sections 1.4 and 1.5 contribute to overall tuberculosis 
treatment outcomes, but disease factors and patient characteristics also influence treatment 
success. Presence of cavitation has been reported to delay time-to-culture conversion 
(Dorman et al., 2009; Güler, Ünsal, Dursun, et al., 2006; Telzak et al., 1997; Visser et al., 
2012) and is also associated with treatment failure or relapse (Benator et al., 2002). Visser et 
al. also reported that shorter baseline time-to-positivity was associated with delayed time-to-
sputum culture conversion (Visser et al., 2012). Time-to-culture or smear conversion is also 
correlated with patient’s sex: male patients generally convert at a later stage than females 
(Banu Rekha et al., 2007; Caetano Mota, Carvalho, Valente, Braga, & Duarte, 2012; Hesseling 
et al., 2010). The results of a pooled analysis reported by Banu Rekha et al. also showed that 
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higher number of chest X-ray zones affected was associated with delayed culture conversion 
(Banu Rekha et al., 2007). In TB/HIV coinfected patients, relapse was reported to be high in 
patients with CD4+ count < 100 cells/µL (Pulido et al., 1997). Patients with low BMI are 
reported to have increased chances of poor long term treatment outcomes including death 
and relapse (Hanrahan et al., 2010; Hesseling et al., 2010; Mupere et al., 2012; Yen et al., 





Pharmacometrics is the science of developing and applying mathematical and statistical 
methods to characterise, understand, and predict pharmacokinetics, pharmacodynamics, and 
disease progression (Williams & Ette, 2007). Pharmacokinetics describes the time course of 
drug concentration in different body spaces such as plasma, blood, urine and tissues 
(Gabrielsson & Weiner, 2007). It covers the process of absorption, distribution, metabolism, 
and excretion. Pharmacodynamics is the study of the time course of biological effects of drugs, 
and the relationship of these effects with drug exposure (Gabrielsson & Weiner, 2007).  
 
The biological processes linked to pharmacokinetics are complex and usually simplified using 
compartmental models: the body is described by a series of compartments in which the drug 
is distributed (Lavielle, 2014). The link between the compartments can be turned into a 
mathematical model by using differential equations and the differential equations are used to 
capture the changes in drug concentrations over time. Population pharmacokinetics is then 
the application of mathematical and statistical models to a cohort of patients in a study, 
considering the different levels of variability (between patient and within patient/between 
occasion). Application of population modelling comes with some advantages over traditional 
noncompartmental analysis: inclusion of sparse data, integrating data from different studies, 
the inclusion of prior knowledge, higher statistical power, and suitability for dose 
individualisation (Bonate, 2011).  
 
Data collected for pharmacokinetic analysis usually involves several measurements such as 
drug concentrations from the same subject following single or multiple doses. These 
measurements are correlated and classical analysis methods that assume independence of 
measurements lead to invalid inferences. Population modelling/mixed-effects modelling allows 
estimation of individual pharmacokinetic parameters via the inclusion of random effects to 
30 
 
account for the correlation between measurements from the same subject. In 
pharmacokinetics, the relationship between drug concentrations and parameters is usually 
nonlinear hence population modelling is also called nonlinear mixed-effects modelling. More 
formally, nonlinear mixed-effects models consist of two components: a structural model and a 
stochastic model. The structural model is a function that describes the average time course of 
measured concentrations and may include covariates. The stochastic model includes 
between/within-subject variability of the model’s parameters and residual unexplained 
variability (Upton & Mould, 2014).  
 
To formalise these concepts mathematically, let us take the response variable Y, which 
consists of measurements, e.g. drug concentrations measured from n subjects with each ith 
subject contributing ni measurements at different time points 𝑡𝑖1, 𝑡𝑖2, ⋯ , 𝑡𝑖𝑛𝑖. The vector of the 
observed measurements becomes 𝑌 =  {𝑌1,1, 𝑌1,2, ⋯ , 𝑌𝑛,1, 𝑌𝑛,2, ⋯ , 𝑌𝑛,𝑛𝑖}
𝑇
. The jth measurement 
of subject i can be described as  
𝑦𝑖𝑗 = 𝑓(𝐱𝒊𝒋;  𝚯𝒊) + 𝑖𝑗 (1.1) 
Where 𝑓(∙) is the individual prediction described by a nonlinear function with parameter vector 
𝚯𝒊 and independent variables (time, dose and covariates). 𝑖𝑗 is the residual unexplained 
variability describing the deviation of the individual prediction from the observed value and is 
assumed to follow a gaussian distribution with mean of zero and estimated variance of 𝜎2. 
The individual parameters (e.g. clearance) are positive and often right skewed hence a log-
normal distribution is assumed as shown in equation 1.2.  
𝑝𝑘𝑖 = 𝜃𝑘 ∙ 𝑒
𝜂𝑘𝑖 (1.2) 
 
Where 𝑝𝑘𝑖 is the individual value for the i
th subject of the kth parameter in 𝜣𝒊 and 𝜃𝑘 is the 
typical/population value of 𝑝𝑘𝑖. The random effect 𝜂𝑘𝑖 describes the random deviation between 
31 
 
the ith individual parameter value and the typical parameter value (population parameter 
value), and it is assumed to follow a gaussian distribution with mean zero and estimated 
variance of 𝜔𝑘
2. A variance-covariance matrix for all the random effects (etas) is then 
estimated. The effect of covariates on the typical parameters can also be estimated as an 
additional fixed effect. Variability in individual parameters over time can be estimated as 
another level of random effects and this level of variability is called within-subject variability or 
between-occasion variability, with an occasion usually defined as a collection of 
measurements following a dose (Ette & Williams, 2004; Karlsson & Sheiner, 1993). 
 
Methods to describe the exposure-response relationship are available, and the choice of the 
method for analysis is guided by the type of the data available. As explained in section 1.6, 
time to a specific event is often used as a response variable for tuberculosis treatment 
outcome. For time-to-event (TTE) data, the time of an event is observed for the subject that 
experience the event during the observation period, while it may never occur during the 
observation period in others, in which case it is considered right-censored, meaning that it is 
unknown if and when the event may have happened after the end of the observation period. 
One could use the Cox proportional hazard regression model or parametric models, such as 
exponential, Weibull, Gompertz, and surge functions (Charles, Touitou, & Selmaoui, 2009; 
Holford, 2013). If the time between outcome measurements is long, it is recommended to 
apply methods that account for the fact that the event occurred between the first positive 
observation and the previous negative one (interval censoring). Assuming the event of interest 
occurred at the time of observation would lead to incorrect conclusions about the estimated 
survival curves and the effects of covariates on time (Radke, 2003). In TTE modelling with 
only a single event, the outcome/event is modelled using the instantaneous hazard ℎ(𝑡) of an 
event occurring at time t:  
ℎ(𝑡) = lim
𝛿𝑡→0






The effect of individual covariates can be included on the hazard of the event occurring. 
Related to the hazard function is the probability of an event occurring to individual after time 
𝑡 > 𝜏, called the survivor function  




With time-to-event data, three scenarios are possible: 
a) The event occurs at time t with probability: 𝑓(𝑡) = 𝑆(𝑡) ∙ ℎ(𝑡) 
b) The event occurs in interval 𝑎 < 𝑇 ≤ 𝑏 with probability: 
𝑓(𝑡) = 𝑆(𝑡0, 𝑡𝑎) ∙ (1 − 𝑆(𝑡𝑎 , 𝑡𝑏)) were 𝑆(𝑡0, 𝑡𝑎) is the survival function from entry to time 
t=a and 𝑆(𝑡𝑎 , 𝑡𝑏) is the survivor function in the interval when the event occurred. 
c) The event is right-censored/ not observed with probability: 𝑓(𝑡) = 𝑆(𝑡0, 𝑡𝑒𝑛𝑑) 
 
The parametric methods described in the previous paragraph are powerful, but have some 
limitations: (1) they force a specific link between the response and covariates and (2)  do not 
allow data driven covariate interactions (Bou-Hamad, Larocque, & Ben-Ameur, 2011). 
Recursive partitioning methods offer an alternative to conventional time-to-event analysis 
methods. The methods involve stratifying and segmenting the covariate space into 
nonoverlapping regions/nodes by applying a binary split to covariates in a stepwise manner 
(James, Witten, Hastie, et al., 2013). The final product of the analysis is presented as a tree 
diagram, and at the top of the tree is the root node which contains all the data. The subsequent 
nodes are either internal nodes (those that are further split) or terminal nodes. Recursive 
methods are flexible, require fewer assumptions and can handle nonstandard and nonlinear 
data structures efficiently (De Rose & Pallara, 1997).  
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The idea behind the stratification and segmentation is to force each node to become more 
homogeneous using a splitting criterion. Ciampi et al. suggested the use of a log-rank statistic 
to determine the best split, and it leads to a split that assures the best separation of the median 
time-to-event in two children nodes (Ciampi, Thiffault, Nakache, et al., 1986). This method and 
many others (Davis & Anderson, 1989; Gordon & Olshen, 1985; Segal, 1988) fail to recognise 
the two steps involved in developing the tree: (1) selection of splitting variable and (2) selection 
of splitting point. These methods then tend to favour covariates that have many possible 
splitting points. Hothorn et al. developed an unbiased conditional inference tree algorithm for 
right censored data to address the problem by separating the selection of splitting variable 
and the splitting point (Hothorn, Hornik, & Zeileis, 2006). The method was further developed 
to account for interval-censored data, and variable selection by the method is unbiased. The 
method was also shown to be able to recover the correct tree structure and has good predictive 
performance (Fu & Simonoff, 2017). A permutation test is applied to select a variable to split 
on using the log-rank score as the test statistic and a predefined level of significance 𝛼. The 
test is applied under the null hypothesis of no relationship between the response and any 
covariate by fixing the covariates and conditioning on all possible permutations of the 
response. If no covariate is significant, the procedure stops, otherwise the next step will be to 
select the splitting point. The permutation test framework is also applied to find the optimal 
binary split for the selected covariate. A description of the methods of handling missing 





1.8 Study justification 
Efforts to reduce mortality in TB/HIV co-infected patients are focussing on early introduction 
of antiretroviral therapy (Abdool Karim et al., 2010). Other recent studies are focussing on 
increasing the doses of rifampicin, but the inclusion criteria exclude HIV-positive patients with 
low CD4+ count (< 350 cells/µL) (Boeree et al., 2015). It is important to characterise 
pharmacokinetic variability of tuberculosis treatment in TB/HIV co-infected patients including 
those that have low CD4+ count. The relationship between drug exposure and treatment 
outcomes in patients with low CD4+ count might differ from those with a CD4+ count of at 
least 350 cells/µL hence the need to describe the PK-PD relationship in this specific 
population.  
 
Rifampicin induces its own metabolism (autoinduction) and doses of at least 450 mg show 
saturable pharmacokinetics. Smythe et al. described the autoinduction process using 
pharmacokinetic data collected only on two occasions, and each patient contributed three 
samples hence these data might not accurately describe the change in exposure to rifampicin 
over time (Smythe et al., 2012). In the current body of work, nonlinear mixed-effects modelling 
was applied to a rich rifampicin pharmacokinetic dataset with repeated intensive sampling over 
four occasions during the first four weeks of treatment. Pharmacokinetic data were obtained 
from 60 patients spanning a range of doses: 300 mg to 750 mg. Through the application of 
semimechanistic modelling techniques, the data could be expected to contribute towards the 
understanding of the duration and extent of autoinduction. The range of doses is also 
important for describing the nonlinear pharmacokinetics of rifampicin: increase in dose results 
in more than proportional increase in exposure to rifampicin as a result of saturable 
pharmacokinetics. Pharmacokinetic data for desacetyl-rifampicin together with increased 
rifampicin doses of up to 15 mg/kg is important for separating metabolic pathways and 
identifying the saturable pathway(s). In addition, joint modelling of rifampicin and desacetyl-
rifampicin helps identify correlations between the parent drug and metabolite. Subsequent to 
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the publication of results from this thesis, Svensson et al. also reported on autoinduction of 
rifampicin and its saturable pharmacokinetics using pharmacokinetic data of rifampicin with 
doses up to 40 mg/kg (Svensson, Aarnoutse, et al., 2017). However, at the time of working on 
chapter 3, this was not known. In their study, pharmacokinetic data was collected in the first 
two week of treatment which is less than the four weeks in our first study (chapter 3) and did 
not quantify metabolite pharmacokinetic data included in our second study (chapter 6). 
 
Pyrazinamide is used for the treatment of drug-susceptible and -resistant tuberculosis. 
Changes in clearance of pyrazinamide during treatment are documented in patients from 
Tanzania and West Africa (Denti, Jeremiah, et al., 2015; Smythe, 2016). The increase has not 
been reported in South African patients or more importantly in TB/HIV co-infected patients, 
and its effect on drug exposure. The currently recommended dose of pyrazinamide achieves 
low exposure in males who have low weight (McIlleron et al., 2012). A proposal was put 
forward for a 1500 mg of pyrazinamide for all patients, but this is unfeasible with the current 
FDC treatment regimen (Sahota & Della Pasqua, 2012). A dosing regimen that fits into the 
current FDC treatment regimen would be much preferable and could be acceptable to the 
community working on tuberculosis treatment. There are currently no reports on the evaluation 
of exposure to pyrazinamide in patients with drug-resistant tuberculosis regarding whether the 
dose administered achieve therapeutic targets and if the patients in different weight bands 
achieve comparable exposure levels.  
 
Co-administration of antituberculosis and antiretroviral drugs results in potential drug-drug 
interaction. Researchers are focussing on the effect of rifampicin on exposure to antiretroviral 
drugs (Semvua et al., 2015). Antiretroviral drugs could also affect the pharmacokinetics of 
antituberculosis drugs. Results of a non-compartmental analysis showed that concomitant 
intake of efavirenz-based antiretroviral therapy was associated with a 29% reduction in 
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isoniazid AUC (Bhatt et al., 2014). However, the cohort in that study was small and the 
difference in metabolism due acetylator phenotype was not considered. In the present study, 
we used nonlinear mixed-effects modelling to describe jointly, the pharmacokinetics pf 
isoniazid and acetyl-isoniazid hence shared information (correlations) between the 
pharmacokinetics of parent and metabolite data can be incorporated. In the absence of 
acetylator status of patients, mixture modelling applied in the analysis is a powerful tool to 
differentiate pharmacokinetic parameters of patients belonging to different acetylator status. 
By including metabolite data and separating metabolic pathways, it is possible to determine 
whether covariates affect one or both pathways and if the effect is similar between fast and 
slow acetylators. In the cohort of TB/HIV co-infected patients receiving efavirenz based ART, 
it is possible to evaluate the effect of reduced exposure on attaining therapeutic targets. 
 
With the current efforts on increasing the dose of rifampicin and early introduction of ART in 
TB/HIV co-infected patients, the relationship between antituberculosis drug exposure and 
treatment outcomes still needs investigation. PK-PD analysis helps determine the effects of 
drug exposure observed under different treatment strategies, and of clinical markers on 
treatment outcomes. It also provides evidence for or against dose adjustment and/or policy 
change. Early results of the RAFA clinical trial showed improved survival in patients who 
received 50% increased dose of rifampicin only in patients with CD4. <100 cells/µL. The 
strengths of the PK-PD analysis in this report are: availability of rich pharmacokinetic data with 
all the four first-line antituberculosis drugs, data were collected from a well characterised 
clinical cohort of patient participating in a randomised clinical trial, data includes serial culture 
results collected during the treatment as opposed to single time point (e.g. two-month) culture, 
a wider range of rifampicin concentrations in one arm, and patients were followed up for 18 
months after the end of treatment. The use of data mining techniques (classification and 
regression trees in particular) to determine the association between drug exposure and 
tuberculosis treatment outcomes is increasing (Pasipanodya et al., 2013; Smythe, 2016). 
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These methods are effective in identifying nonlinear relationships between drug exposure and 
tuberculosis outcomes. However, the methods tend to favour covariates measured on a 
continuous scale, and even with high variability associated with the pharmacokinetics of 
antituberculosis drugs (Devaleenal Daniel, Ramachandran, & Swaminathan, 2017), the 
techniques would identify the effect of continuous covariates. The conditional inference 
framework applied to PK-PD modelling in this thesis eliminates the bias towards selection of 
continuous covariates. In addition, the methods apply nonparametric statistical significance 





The purpose of the research was: 
1. To describe the population pharmacokinetics of rifampicin and pyrazinamide in patients 
from South Africa, quantify the changes in parameters in the first month of treatment and 
determine factors contributing to variability between patients using nonlinear mixed-
effects modelling techniques. The models developed will be used to evaluated exposure 
levels achieved by the patients against known therapeutic targets to provide evidence for 
dose adjustments. 
 
2. To describe the population pharmacokinetics of rifampicin, isoniazid, pyrazinamide, 
ethambutol, desacetyl-rifampicin, and acetyl-isoniazid in West African patients and apply 
nonlinear mixed-effects modelling methods to evaluate the effect of concomitant intake of 
efavirenz-based antiretroviral therapy and a range of rifampicin doses up to 50% higher 
than the standard on pharmacokinetics on pharmacokinetics of companion drugs.  
 
3. To characterise the impact of pharmacokinetics of first-line antituberculosis drugs, and 
tuberculosis and HIV disease markers on tuberculosis treatment outcomes (time-to-stable 






Chapter 2: Methodology 
2.1 Study designs and data description 
2.1.1 TB-HAART Study 
HIV-1 infected and treatment naïve patients aged 18 to 65 years were recruited for the study 
between March 2007 and April 2008. Recruitment was done at primary health care centres in 
and around Durban, South Africa. Patients were included in the study if they had no history of 
previous antituberculosis treatment in the 24 months before the study, were not currently 
enrolled in a drug or treatment trial, and provided informed consent to participate in the trial, 
were willing to undergo HIV testing and provide blood samples for pharmacokinetics. A female 
patient was recruited if she had been post-menopausal for at least 12 months or was surgically 
incapable of bearing children. A female of childbearing potential was recruited provided that 
she had a confirmed negative pregnancy test, and agreed to use an accepted method of 
contraception for the duration of the study. Patients were excluded if there was evidence of 
pre-existing non-tuberculosis disease likely to affect response to or assessment of treatment 
effects. Patients with mental illness, WHO stage IV disease requiring drugs that would 
potentially interact with study drugs, weighing below 30 kg and who had clinical evidence of 
severe illness were also excluded. Having a history of drug abuse in the six months before the 
study, history of high daily alcohol intake (>0.5 L) and history of multi-drug resistant 
tuberculosis would make an individual ineligible for the study. 
 
The main study was a six-arm clinical trial to investigate the bioavailability of rifampicin, 
isoniazid, zidovudine, lamivudine and efavirenz. The results presented in chapter three and 
four are based on data from patients recruited in treatment arms 1 to 5 shown in Table 1. 
Patients in arms 1, 2 and 3 were started on antiretroviral therapy after day 14 of treatment 
initiation. Each patient took a dose of antiretroviral therapy consisting of 600 mg of efavirenz 
daily, 150 mg of lamivudine twice daily and 300 mg of zidovudine twice a day. Patients in 
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treatment arms 4 and 5 received antiretroviral therapy upon completion of antituberculosis 
treatment. 
Table 2.1 Study design for TB-HAART study 






350 – 500 cells/µL Arm 1: HAART + ATT Arm 4: ATT  
220 – 349 cells/µL Arm 2: HAART + ATT Arm 5: ATT  
< 200 cells/µL Arm 3: HAART + ATT  Arm 6: HAART 
HAART: Highly Active Antiretroviral therapy, ATT: Antituberculosis treatment 
 
The National Tuberculosis Control Programme supplied the 4-drug FDC (Rifafour e-275 
[Sanofi-Aventis, South Africa] and Antib-4 [Rusan Pharma, India]) used in the study. Each 
tablet contained rifampicin (150 mg), isoniazid (75 mg), pyrazinamide (400 mg) and 
ethambutol (275 mg). Patients were administered weight-adjusted doses of the FDC 
according to the WHO guidelines at the time of the study (World Health Organization, 2003). 
Patients weighing 30 to 37 kg received two tablets and those weighing 38 to 54 kg, 55 to 70 
kg and >70 kg received 3, 4 and 5 tablets respectively. Antituberculosis treatment was 
administered on weekdays (Monday to Friday) except in 10 patients recruited after a change 
of dosing policy who received daily doses of the treatment.  
 
Patients were admitted on the afternoon before the pharmacokinetic assessment on the 1st, 
8th, 15th and 29th day of treatment. Patients fasted from midnight after an evening meal and a 
22h00 snack. On the pharmacokinetic sampling day, 10 mL of blood was collected prior to 
dose intake which was observed by a study team member and at 1, 2, 3, 4, 6, 8 and 12 hours 
post-dose. Blood specimens were immediately placed on ice and plasma separated by 
centrifugation within 30 minutes before storage at -80oC. The clinical analysis of the plasma 
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sample was conducted by the analytical laboratory at the Division of Clinical Pharmacology, 
University of Cape Town. Plasma drug concentrations for rifampicin and pyrazinamide were 
quantified by tandem HPLC mass spectrometry (Applied Biosystems API 200) as previously 
described (McIlleron et al., 2007). 
 
2.1.2 RAFA Study 
Patients were recruited at tuberculosis centres in three countries in West Africa: Benin, 
Guinea, and Senegal. For the pharmacokinetic sub-study, only patients recruited in Benin and 
Guinea were considered. Patients were included in the study if all the following criteria are 
fulfilled: aged above 18 years, had positive HIV test result, had CD4+ lymphocyte count of at 
least 50 cells/µL, had recent positive acid-fast bacilli on any smear or molecular test, naïve to 
antiretroviral therapy and had voluntarily signed informed consent to participate in the study. 
Patients who met any of the following conditions were excluded from the study: pregnant 
women, lactating women, women who are unwilling to use contraception, HIV-2 infected, use 
of recreational drugs or alcohol that could prejudice the conduct of the study, AST or ALT 
greater than five times the normal value and unable to provide informed consent.  
 
The RAFA study was a three-treatment arm study defined by the timing of introduction of 
antiretroviral therapy and rifampicin dose as shown in Figure 3. Patients in arm A received 
efavirenz-based antiretroviral therapy at two weeks post antituberculosis treatment initiation, 
and in arm B, antiretroviral therapy was delayed by two months. Patients in arm C received a 
higher dose of rifampicin (+50%) in the intensive phase of treatment and started antiretroviral 
therapy in the continuation phase of antituberculosis treatment. Patients received 600 mg of 





Figure 2.1 Treatment schedule for the RAFA study 3F4 
 
The FDC treatment dispensed in the trial was made available by the National Tuberculosis 
and HIV programmes in each country. Extra rifampicin tablets administered to patients in arm 
C were purchased for the trial. Patients took weight-adjusted daily doses of the FDC containing 
rifampicin, isoniazid, pyrazinamide, and ethambutol, and those in arm C took additional tablets 
containing rifampicin only to achieve a dose of approximately 15 mg/kg of body weight.  
 
Patients who were recruited into the pharmacokinetic sub-study had pharmacokinetic 
sampling performed at a visit after one month and before two months of antituberculosis 
treatment. On the pharmacokinetic sampling day, patients took an observed dose of 
antituberculosis treatment after an overnight fast. Five serial blood samples were collected at 
approximately 15 minutes before the dose and 2, 3, 6 and 10 hours after the dose. Blood 
samples were processed, and plasma stored immediately at -80oC before transfer to the 
analytical laboratory at the Division of clinical pharmacology, University of Cape Town. 
Concentrations of rifampicin, isoniazid, pyrazinamide and ethambutol were determined using 
                                               
4 Reprinted from A randomised controlled trial of 3 strategies for the treatment of ART-naive HIV 
infected patients with tuberculosis - RAFA Trial – Clinical trial protocol 
43 
 
validated tandem mass spectrometry high-performance liquid chromatography (LC-MS/MS) 
methods. The concentration ranges, mean percentage accuracies during inter-day sample 
analysis and precision coefficient of variation for rifampicin, isoniazid, pyrazinamide and 
ethambutol have been previously described (Denti, Jeremiah, et al., 2015; Kwara et al., 2016). 
Desacetyl-rifampicin was validated over the range 0.0391–10 mg/L. The mean percentage 
accuracies during inter-day sample analysis at low, medium and high-quality control levels 
were 99.4%, 97.6% and 101.8% respectively. The precision coefficient of variation for 




Pharmacokinetic analyses were performed in NONMEM 7.3, using the first-order conditional 
inference with eta-epsilon interaction (FOCE-I) (Beal, Sheiner, Boeckmann, & Bauer, 2013). 
Perl-speaks-NONMEM (versions 3.7.6–4.7.0) were used to aid model development and 
evaluation (Lindbom, Pihlgren, & Jonsson, 2005). Model tracking and documentation were 
done in Pirana versions 2.8.1–2.9.6 (Keizer, Karlsson, & Hooker, 2013). Time-to-event 
modelling was implemented in Monolix Suite 2016 (Monolix version 2016R1, 2016). 
Time-to-event classification and regression trees analysis was performed in R (versions 3.0.1–
3.4.3) via RStudio interface (versions 0.97.551–1.1383). Data management, post modelling 
processing of data and graphical analysis were done in R via RStudio interface (R Core Team, 
2017; RStudio, 2014).  
 
2.3 Pharmacokinetic modelling approach 
The model development procedure generally started with a simple one-compartment 
structural model with first-order absorption and elimination, and based on scientific plausibility 
and physiological rationale, the model was made more complex by adding, for example two-
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compartment disposition, a more flexible absorption framework, saturable clearance, or more 
semimechanistic models. The statistical model included between-subject and -occasion 
variability assumed to follow log-normal distribution and residual unexplained variability which 
comprised of additive and proportional components. Allometric scaling was applied in the early 
phases of model development using either total body weight or fat-free mass. Use of priors to 
stabilise models utilising sparse data was explored. The modelling process was guided by 
change in objective function value (OFV, -2 times the log-likelihood), the standard goodness 
of fit plots (and visual predictive checks (VPCs). In cases where modelling involved parent 
drug and metabolite, a model for the parent drug was first developed and, once deemed 
sufficient, metabolite data was then included. The inclusion of patient covariates was guided 
by biological plausibility and statistical significance based on 5% level of significance in the 
forward step of covariate selection and 1% in backward elimination. Parameter uncertainty 
was assessed via the nonparametric bootstrap method. 
 
2.4 PK-PD analysis approach 
The PK-PD analysis was split into parts: analysis of time-to-stable culture conversion and 
analysis of long-term tuberculosis treatment outcomes (relapse and death). Time-to-stable 
culture conversion was defined as the time when a negative culture result was obtained and 
confirmed at the next follow-up visit. Tuberculosis diagnosis was based on smear results and 
clinical assessments. Time-to-event analysis with interval censoring methodology was applied 
to the data. The association between time-to-stable culture conversion vs drug exposure and 
patient characteristics including disease burden was assessed using a two-stage approach. 
Firstly, a time-to-event structural model was determined in Monolix. Constant, Weibull, 
Gompertz, and three-parameter surge function hazard structural models were evaluated. The 
best model was selected based on lowest AIC value, and predictive ability using visual 
predictive checks.  
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In the second stage, time-to-event CART analysis in the conditional framework was applied to 
identify the most promising covariates effects that are predictive of time-to-stable culture 
conversion and the interactions between these covariates. The analysis produces a tree like 
structure with binary splits and the root node represents the most significant predictor. 
Additional significant covariates are added as daughter nodes in order of importance using a 
predefined statistical significance criterion (5% level of significance). The permutation test is 
applied at each level to determine the most significant covariate to be included as a node. The 
procedure ensures that patients in each terminal node are as homogenious as possible.The 
terminal nodes of the final tree were used to define a single categorical covariate for further 
testing taking the best time-to-event structural model identified in Monolix as the base model. 
Two categories were combined if the model with one less parameter did not result in a worse 
fit (ΔOFV < 3.84 points). Predictors of long-term treatment outcomes were identified using 





Chapter 3: Model-based evaluation of higher doses of 
rifampicin using a semimechanistic model incorporating 
autoinduction and saturation of hepatic extraction 
 
3.1 Abstract 
Rifampicin is a key sterilizing drug in the treatment of tuberculosis (TB). It induces its own 
metabolism, but neither the onset nor the extent of autoinduction has been adequately 
described. Currently, the World Health Organization recommends a rifampicin dose of 8 to 12 
mg/kg of body weight, which is believed to be suboptimal, and higher doses may potentially 
improve treatment outcomes. However, a nonlinear increase in exposure may be observed 
because of saturation of hepatic extraction and hence this should be taken into consideration 
when a dose increase is implemented. Intensive pharmacokinetic (PK) data from 61 HIV-TB 
co-infected patients in South Africa were collected at four visits, on days 1, 8, 15, and 29, after 
initiation of treatment. Data were analysed by population nonlinear mixed-effects modelling. 
Rifampicin PK were best described by using a transit compartment absorption and a well-
stirred liver model with saturation of hepatic extraction, including a first-pass effect. 
Autoinduction was characterized by using an exponential-maturation model: hepatic clearance 
almost doubled from the baseline to steady state, with a half-life of around 4.5 days. The model 
predicts that increases in the dose of rifampicin result in more-than-linear drug exposure 
increases as measured by the 24-h area under the concentration-time curve. Simulations with 






Rifampicin is a key drug in the treatment of tuberculosis (TB), and the World Health 
Organization (WHO) currently recommends weight-adjusted doses of 8 to 12 mg/kg daily. 
Despite its being used in the treatment of TB for nearly 50 years, there is evidence that current 
rifampicin exposures may be suboptimal. Rifampicin’s efficacy is exposure dependent 
(Gumbo, Louie, Deziel, et al., 2007; Mehta et al., 2001; Steingart et al., 2011); therefore, the 
efficacy and toxicity of higher doses are under investigation. Recent reports show that larger 
doses of rifampicin are well tolerated by humans (Boeree et al., 2015) and may improve 
treatment outcomes, as well as reduce the treatment duration from the current 6 months (de 
Steenwinkel et al., 2013; Jayaram et al., 2003).  
 
Rifampicin is mainly hepatically cleared, and it undergoes extensive first-pass metabolism 
(Loos et al., 1985), whose saturation with higher doses has been reported since early 
pharmacokinetic (PK) studies (Acocella, 1978). Thus, when the rifampicin dose is increased 
above a certain level, a more-than-proportional increase in the plasma rifampicin 
concentration results. Rifampicin also induces its own metabolism via the pregnane X receptor 
(Chen & Raymond, 2006), a phenomenon known as clearance autoinduction, resulting in less 
exposure at steady state than after a single dose. 
 
Previous studies have proposed rifampicin PK models (Wilkins et al., 2008), but those trying 
to characterize clearance autoinduction have done so mostly by relying on only two PK 
sampling occasions (Smythe et al., 2012), which limited their ability to characterize the 
process. Nonlinearity in a dose-exposure relationship suggesting saturation of rifampicin 
clearance has been reported (Acocella, 1978). However, a population PK model has not jointly 
described the autoinduction and hepatic extraction (EH) of rifampicin. In this study, we 
analysed rich data from an intensive sampling scheme to develop a rifampicin PK model for 
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TB patients that accounts for both clearance autoinduction and saturation of EH. This model 
was then employed to explore changes in rifampicin exposure when doses are increased 






Study design and patient selection 
Extensive details of this study, including design, patient selection, and dose administration, 
have been reported before (McIlleron et al., 2012). Two four-drug fixed-dose combinations 
(FDCs) were administered; each tablet contained 150 mg of rifampicin, 75 mg of isoniazid, 
400 mg of pyrazinamide, and 275 mg of ethambutol. Patients received weight-adjusted doses 
for 5 days a week, from Monday to Friday, according to WHO guidelines (World Health 
Organization, 2003), except 10 patients who received medication for 7 days a week. Thus, 
patients weighing 30 to 37 kg at the start of treatment received two FDC tablets per dose, 
while those weighing 38 to 54, 55 to 70, or 70 kg received three, four, or five FDC tablets, 
respectively. Efavirenz (EFV)-based antiretroviral therapy (ART) was initiated in two-thirds of 
the patients on day 15 after the start of TB treatment. Patients were excluded if they had 
evidence of a pre-existing disease likely to affect the response to or assessment of treatment 
effects or represent contraindications to the study medication. 
 
Specimen collection and drug quantitation.  
Participants were admitted for PK blood sampling on the 1st, 8th, 15th, and 29th days of TB 
treatment after an overnight fast. Blood samples were taken immediately before dosing and 
1, 2, 4, 6, 8, and 12 h after dose administration. Additionally, a sample was collected at 
approximately 12h before the 15th dose. Details of plasma separation and storage and 
quantitation of drug concentrations were as reported before (McIlleron et al., 2012). The lower 
limit of quantitation was 0.1 mg/L. 
 
Pharmacokinetic analysis  
Population PK analysis was used to describe the concentration data in NONMEM version 7.3 
software (Beal, Sheiner, Boeckmann, & Bauer, 2013) by using the algorithm first-order 
conditional estimation with eta-epsilon interaction (FOCE-I). Perl-speaks-NONMEM, Xpose4, 
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and Pirana were used for model diagnostics and to track model development (Keizer, 
Karlsson, & Hooker, 2013). Additional diagnostic plots and post-modelling analysis were 
performed with R version 3.1.2 (R Core Team, 2017) via RStudio version 0.98.1091 (RStudio, 
2014).  
 
Several disposition models were evaluated, including one-compartment first-order elimination 
and a well-stirred liver model, with and without saturation of EH (Gordi et al., 2005) 
characterized by Michaelis-Menten parameterization. To characterize rifampicin absorption, a 
first-order model with and without lag time and a chain of transit compartments were assessed 
(Savic, Jonker, Kerbusch, et al., 2007). Different approaches were used to describe 
autoinduction of rifampicin: estimating a different clearance value at each PK sampling 
occasion, using an enzyme induction model (Smythe et al., 2012), or using an exponential 
maturation model with clearance increasing with time on treatment (Denti et al., 2010).  
 
Between-subject variability (BSV) and between-occasion variability (BOV) were assumed to 
follow a log-normal distribution. A PK profile was treated as a separate occasion: four sampling 
occasions with intensive sampling and three catering for concentrations obtained prior to 
dosing on days 8, 15, and 29. Allometric scaling was applied to all disposition parameters, 
with allometric exponents fixed to 0.75 for clearance parameters and 1 for volume parameters, 
as described by Anderson and Holford (Anderson & Holford, 2008). Total body weight (TBW) 
and fat-free mass (FFM) were evaluated on each of these parameters. All samples (including 
pre-dose after day 1) with concentrations below the limit of quantitation (BLQ) were handled 
by the M6 method (Beal, 2001). This means that they were replaced with half the lower limit 
of quantitation (LLQ), except for consecutive values in a series, for which the trailing BLQ 
values were ignored for the fit but included in the diagnostic plots. Pre-dose concentrations 
from day 1 were excluded from the fit after it was verified that they were BLQ, as expected. 
Overall, a combined additive and proportional error model was used to describe unexplained 
residual variability. The effect of covariates on PK parameters was assessed by exploring 
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proportional changes with a linear model for continuous variables and additive covariate model 
for categorical variables (Bonate, 2011). 
 
Model building was guided by change in the objective function value (OFV, assumed to be 
approximately 𝜒2 distributed), inspection of diagnostic plots including a prediction-corrected 
visual predictive check (VPC) (Bergstrand, Hooker, Wallin, et al., 2011), and physiological 
plausibility. The final model was used to simulate larger doses of rifampicin in a reference 
cohort of in silico TB patients created with demographic data of 870 TB patients in South Africa 
and West Africa (200 repetitions). With the same weight bands as described above and a 
tablet strength of 150 mg of rifampicin, daily doses of 15, 20, 25, 30, and 35 mg/kg were 
evaluated, assuming drug administration every day of the week. The model-based 24-h area 
under the concentration-time curve (AUC0–24) and maximum concentration (Cmax) were derived 
at the first dose and at steady state. The probability of target attainment (PTA) for each 
rifampicin daily dose at each specific MIC was calculated as the proportion of simulated 
patients with a steady-state AUC0–24/MIC ratio of at least 271, a cut-off value that has been 
shown to correlate well with the bactericidal activity of rifampicin against Mycobacterium 
tuberculosis (Jayaram et al., 2003). The MICs were derived from the distribution of M. 
tuberculosis MICs in South African isolates (Chigutsa et al., 2015). The selected PTA was 
plotted against the range of MICs to describe the killing effects of different doses of rifampicin. 
The cumulative fraction of response (CFR) was computed by using equation 5 for the 
reference MIC distribution and expressed as a percentage to assess the overall PTA for each 
dose (Mouton, Dudley, Cars, et al., 2005). 





The subscript i shows the MICs ranked from the lowest to the highest for the population of 
microorganisms. PTAi is the PTA for each MIC, and Fi is the fraction of the population of 
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microorganisms at each MIC. Simulations were also used to explore changes in 24-h trough 







 In total, 61 patients were recruited into the study. Their baseline characteristics are presented 
in Table 3.1, and further information can be found in the previous report (McIlleron et al., 2012). 
The median weight, FFM, and height were 55.2 kg, 42.2 kg, and 1.59 m, respectively. The 
median age of the patients was 32 years, and their ages ranged from 18 to 47 years. 
Rifampicin concentrations in 1,342 plasma samples were included in the analysis, and 140 
(10%) of these, mostly in pre-dose samples, were below the limit of quantitation. Of the 61 
patients, 41 started EFV-based ART on day 15. 
 
Table 3.1 Baseline characteristics of patients in TB-HAART (rifampicin model)  
Characteristic Value 
N 61 
No. (%) of females 33 (54%) 
No. (%) undergoing ART 41 (67%) 
No. (%) treated 5 days/wk 51 (84%) 
Median age, yr (range) 32 (18–47) 
Median wt, kg (range) 55.2 (34.4–98.7) 
Median ht, m (range) 1.59 (1.41–1.81) 
Median FFM, kg (range) 42.2 (28.0–57.6) 
Median albumin level, g/liter (range) 26 (15–43) 
Median creatinine level, µmol/liter (range) 74 (53–155) 
Median viral load, 103 copies/ml (range) 86 (0.05–13000) 
Median no. of CD4+ cells/µl of blood (range) 254 (12–500) 
 
Structural model  
Rifampicin PK were best characterized by a well-stirred liver model, with absorption through 
a chain of transit compartments. A schematic diagram of the final model is shown in Figure 
3.1. Inclusion of saturation of EH further improved the model (a 216-point drop in the OFV, 1 
degree of freedom, P < 0.001). In the final model, rifampicin clearance and bioavailability are 
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both dependent on EH. EH is influenced by the unbound fraction of rifampicin (fu), hepatic 
plasma flow rate (QH), and intrinsic clearance (CLint), which changes with time on treatment 
because of autoinduction. CLint was saturable and followed Michaelis-Menten kinetics; that is, 
the rate of elimination had a maximum saturation value (CLint,max) dependent on the Michaelis 
constant (Km). More details of the model, including all of the equations describing saturable 
elimination, are included in the Appendix. 
 
Figure 3.1 Schematic diagram of the final model for rifampicin (TB-HAART study) 
V is the volume of the observation/central compartment, and NN is number of absorption 
transit compartments. 
 
Rifampicin autoinduction was characterized by applying an exponential-maturation model to 
CLint,max so that this increased with time on treatment from a baseline value of CL0int,max to a 












The model was used to estimate the half-life of the induction process (t1⁄2ind). The typical value 
of prehepatic bioavailability (Fprehep) was fixed to a reference value of 1 and allowed to vary 
between occasions. Typical values of the volume of the liver (VH) and hepatic plasma flow 
(QH) were fixed to 1 liter and 50 liters/h, respectively, and allometric scaling was included to 
account for size differences. The fraction of unbound rifampicin (fu) was fixed to 20% (Acocella, 
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1978). Different typical values of VH, QH, and fu were explored by sensitivity analysis, and the 
model was found to be robust. 
  
Allometric scaling of all disposition parameters, including those for the well-stirred hepatic 
model (CLint, hepatic plasma flow, volume of the liver and the central compartment), was best 
characterized by using fat-free mass (FFM) compared to TBW (a 40-point decrease in the 
Akaike information criterion [AIC]) in addition to a 27-point drop in the AIC when allometric 
scaling was applied by using TBW. The median FFM of 42 kg was used as a reference. EFV 
co-administration was not found to affect rifampicin PK. 
 
Parameter estimates of the final model 
A VPC provided in Figure 3.2 shows that the simulated concentrations mirror the observed 
values well and that the model correctly captures the decrease in rifampicin exposure with 




Figure 3.2 Prediction-corrected VPC for rifampicin model (TB-HAART study) stratified by 
day after treatment initiation  Open circles are the observed concentrations. The middle 
continuous line is the 50th percentile of the observed data, and the upper and lower dashed 
lines are the 95th and 5th percentiles of the observed data, respectively. The shaded regions 
represent the 95% prediction intervals of the 5th, 50th, and 95th percentiles. 
 
The parameter estimates of the final model and their precision obtained with a 200-sample 
nonparametric bootstrap with replacement are presented in Table 3.2. The maximum CLint 
almost doubled from the first day of treatment to steady state; for a typical individual, it 
increased from 93 to 176 liters/h. The half-life of the induction process was estimated to be 
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4.5 days. The model estimated that a Km concentration (bound plus unbound) of 3.4 mg/liter 
will result in half the maximum CLint. The final model included BSV in clearance (23%) and the 
volume of the observation compartment (14%) and included BOV in clearance (22%), 
bioavailability (11%), the absorption rate constant (Ka) (81%), and the mean transit time (MTT) 
(63%). A combined additive (0.07 mg/liter) plus proportional (11%) error model was supported 





Table 3.2 Values estimated by the final model 
Parameter Estimate Bootstrap 90% CIa 
𝐶𝐿𝑖𝑛𝑡,𝑚𝑎𝑥
0  (L/h)b 93.2 83.7–108.1 
V (L)b 50.1 47.7–52.8 
Ka (/h) 1.96 1.7–2.2 
MTT (h) 0.71 0.67–0.78 
NNc  19.3 18.1–22.2 
Fd 1 FIXED  
𝐶𝐿𝑖𝑛𝑡,𝑚𝑎𝑥
𝑆𝑆  (L/h)b 176 159–210 
𝑡1
2⁄ 𝑖𝑛𝑑
 (days) 4.5 4.1–4.9 
VH (L)b 1 FIXED  
QH (L/h)b 50 FIXED  
fu 0.2 FIXED  
Km (mg/L)e 3.35 3.0–3.56 
   
Between subject variability (%)   
 CL 22.5 19.1–26.1 
 V 14.2 11.5–16.2 
Between occasion variability (%)   
 CL 21.9 18.3–25.7 
 F 11.0 9.6–13.6 
 Ka 81.2 72.8–88.4 
 MTT 62.7 57.0–75.4 
Error   
 Additive (mg/L) 0.064 0.059–0.07 
 Coefficient of variation (%) 10.8 10.0–12.8 
a CI, confidence interval. 
b This parameter has been adjusted by allometric scaling, and the values reported refer 
to a subject with an FFM of 42 kg (the median value of the cohort). 
c NN, number of absorption transit compartments. 
d F, bioavailability. 
e Total concentration (bound plus unbound). 
 
Simulations 
Model-simulated rifampicin exposures on days 1 and 29 after TB treatment initiation for our 
reference cohort of 870 TB patients are shown in Table 3.3.  
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Table 3.3 Simulated exposures at first dose and steady state by dosea 













































































a Data are medians (90% ranges) 
 
Changes in the AUC0–24 from the first day of treatment due to autoinduction for a reference 
male in the data set (median weight of 55 kg and height of 1.65 m) are presented in Figure 
3.3a for the current 10-mg/kg dose and larger doses of up to 35 mg/kg. Figure 3.3b shows the 
concentration-time PK profiles for the same male patient at full induction. As expected, a 
nonlinear increase in exposure with increasing doses is predicted. At steady state, with the 
currently recommended dose of 10 mg/kg as the reference, increases in exposure were 2.2-
fold for 15 mg/kg, 3.2-fold for 20 mg/kg, 5.3-fold for 25 mg/kg, 7.1-fold for 30 mg/kg, and 10.8-
fold for 35 mg/kg. At a dose of ≥ 25 mg/kg, the simulations predict a median trough 
concentration (Cmin) of 0.3 mg/liter, higher than the LLQ of 0.1 mg/liter in this study. The 
changes in exposure during the first days of treatment are a result of the balance between the 
effect of autoinduction and that of accumulation after multiple consecutive doses. Our model 
predicts that, for doses of > 20 mg/kg, the daily exposures from the first dose on will 
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significantly increase during the first days and then decrease to levels lower than that of the 
first day because of autoinduction. 
 
 
Figure 3.3 Change in AUC0–24 over time and simulated day 29 concentrations for doses of 
10 mg/kg to 35 mg/kg  (a) Change in the AUC0–24 from the first day of treatment to day 29 
for a typical male patient (median weight of 55 kg and height of 1.65 m) daily administered 
600 mg and larger doses of up to 2,100 mg (3.5 times larger) (b) Simulated concentration-
time profile on day 29 after TB treatment initiation for a typical male patient. 
 
Moreover, with the current dosing recommendations based on total weight, the model predicts 
that patients in lower-weight bands are exposed to lower drug levels, as shown in Figure 3.4. 
In the TB patient population used in our simulation, subjects with weights of 30 to 37 kg had, 





Figure 3.4 Distribution of exposures (AUC0–24) at steady state (day 29) based on the 
currently recommended doses  The simulated exposures are shown in box plots with the 
individual values observed in the present study superimposed in closed circles. 
 
The PTA results are shown in Figure 3.5. At the current MICs prevalent in the South African 
population of drug-sensitive TB patients (0.016 to 0.5 mg/liter), the current rifampicin dose of 
10 mg/kg alone is predicted to have a PTA of slightly above 60% for a median MIC of 0.125 
mg/liter, so larger doses of rifampicin are likely to be more effective. For M. tuberculosis strains 
with higher MICs, the currently recommended doses are predicted to be ineffective. The 
predicted CFR for a daily dose of 10 mg/kg was 65%, and increasing the dose to 15 mg/kg 
achieves a CFR of 90%. A further increase to 20 mg/kg will result in a CFR of 96%. Doses of 




Figure 3.5 Probabilities of target (steady-state AUC0–24/MIC ratio of 271) attainment over a 







A population PK model of rifampicin describing autoinduction and saturation of EH was 
developed and used to simulate larger doses of rifampicin of up to 35 mg/kg of body weight. 
Autoinduction of rifampicin clearance has been previously described on the basis of results of 
both traditional noncompartmental analysis (NCA) (Acocella, Lamarina, Nicolis, et al., 1972; 
Loos et al., 1985) and population PK (Smythe et al., 2012). To our knowledge, previous reports 
were based on two sampling occasions (first dose and steady state), while our data comprised 
four sampling occasions starting from treatment initiation and we could characterize rifampicin 
autoinduction by using an exponential-maturation model, enabling us to estimate the half-life 
of the process. The model suggests that, on average, clearance of rifampicin almost doubles 
from the first day of treatment to steady state, and the induction process takes around 2 weeks 
to reach 90% of the fully induced state. The duration of the process differs from that reported 
in other studies, possibly because of the richness of data and the dosing strategies used (daily 
versus intermittent dosing) (Acocella, Pagani, Marchetti, Baroni, & Nicolis, 1971; Smythe et 
al., 2012). Though the induction half-life estimated by our model is shorter than that reported 
by Smythe et al., the extent of the autoinduction effect on clearance is roughly the same.  
 
EH was described by using a well-stirred liver model, and its saturation was characterized by 
using Michaelis-Menten kinetics. This model confirms findings of previous studies showing 
saturation of rifampicin clearance already at doses of about ≥ 450 mg (Acocella, 1978, 1983; 
Gumbo, Louie, Deziel, et al., 2007). The proposed PK model with saturable EH could 
mechanistically explain three different phenomena seen in the present data and/or previously 
reported in other studies: nonlinearity of rifampicin exposure with dose, underexposure of 
lower-weight patients by the current weight band approach, and a correlation between faster 




Previous studies and recent clinical trials show the nonproportionality of the dose-exposure 
relationship (Mouton, Mattie, Swart, et al., 1979; Pargal & Rani, 2001). This means that the 
rifampicin exposure level for doses larger than the current recommendation is greater than 
that expected if the dose-exposure relationship were linear. Our model mechanistically 
explains this nonproportionality by using saturable EH. For example, simulations based on our 
model show that doubling of the dose is associated with more than double the exposure. This 
could be explained by saturation of the beta-esterase metabolizing enzymes and/or p-
glycoprotein after oral administration with a reduction in the first-pass effect and increased 
bioavailability. With the currently used doses, the effect of -saturation is evident only on first-
pass metabolism and not on systemic clearance. With larger doses, however, our model 
predicts that systemic clearance will also be affected by the saturation effect, resulting in, inter 
alia, nonnegligible accumulation of rifampicin between consecutive doses. Our results 
showing nonproportionality of the dose-exposure relationship are in line with previous studies 
evaluating doses of rifampicin of 15 to 20 mg/kg (Acocella, 1983; Ruslami et al., 2007) and 
more recently up to 35 mg/kg (Boeree et al., 2015). Ruslami et al. predicted a 65% larger 
AUC0 –24 for patients receiving 13 mg/kg than for those receiving 10 mg/kg (Ruslami et al., 
2007), and Boeree et al. recently showed that increasing the dose to 35 mg/kg results in a 
10-fold increase in the AUC0 –24 (Boeree et al., 2015). Simulations based on our model closely 
mirror the exposures detected by Boeree et al., as shown in Figure 3.6, which provides a 





Figure 3.6 Comparison of simulated exposure (Cmax and AUC0–24, median and 90% range) 
on day 14 after TB treatment initiation  and exposure (Cmax and AUC0–24, geometric mean 
and range) obtained from Boeree et al. (Boeree et al., 2015) 
 
 
Although our model predictions for larger rifampicin doses closely mirror the median exposure 
values observed in recent trials, the simulations for 30 and 35 mg/kg showed alarmingly large 
variability and predictions of extremely high values in some individuals (Table 3.3). These 
results could be due to the limits of the extrapolation capability of our model, since it was 
developed on the basis of data obtained with a 10-mg/kg dose. Despite this caveat, greater 
variability in exposure is to be expected when increasing the dose of a drug that exhibits 
saturation kinetics, because relatively small changes in the dose may be enough to reach the 
“tipping point” for some patients but not for others. Boeree et al. also reported increased 
variability in exposure with larger doses (Boeree et al., 2015), although not to the extent that 
our model predicted. It is interesting that in our simulations, the patients with extremely high 
exposure values were mostly women with high body weights, whom our model found to be 
relatively overexposed even on the basis of the current guidelines, as discussed below. In the 
present simulations, it was assumed that the level of autoinduction remains the same even at 
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higher rifampicin concentrations. The consistency of our predictions with the values observed 
in clinical trials supports this assumption. 
 
Before the inclusion of saturable EH, the model detected a positive effect of the total dose on 
bioavailability; that is, patients in the higher-weight bands receiving larger absolute doses had 
greater bioavailability than patients in the lower-weight bands. This suggests that doses 
intended to achieve the same dose in milligrams per kilogram of body weight across weight 
bands are not appropriate and lower-weight patients should be prescribed larger doses. This 
finding is driven by saturation of first-pass metabolism, which was more evident for patients in 
the highest weight band, the relatively increased clearance per unit of body size described by 
allometric scaling theory, and FFM being the most appropriate body size descriptor for scaling 
of clearance, which is consistent with previous evidence (Jeremiah et al., 2014; Smythe et al., 
2012). Geiseler et al. showed that daily dosing of a number of anti-TB drugs, including 
rifampicin, should be based on the ideal body weight rather than the TBW (Geiseler, Manis, & 
Maddux, 1985). This argument has implications in settings where a significant proportion of 
the population is overweight, and it could cause differences in exposure among patients 
receiving the same dose (milligrams per kilogram) in different weight bands. This was indeed 
the case in our study cohort, which contained several women with high body mass indexes 
who were found to achieve greater exposures. This is in keeping with previous NCA results 
based on the same data set (McIlleron et al., 2012), which showed that patients in the lower-
weight bands, as well as males, have lower drug exposure levels than other patients do.  
 
Similar to findings described by Jeremiah et al. (Jeremiah et al., 2014), a negative correlation 
between absorption MTT and bioavailability was observed, so that faster absorption was 
associated with increased bioavailability. Upon inclusion of the saturable EH model, this 
phenomenon could be explained mechanistically as follows: higher absorption rates achieve 
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higher rifampicin concentrations in the liver, thus saturating the clearance and reducing the 
extent of first-pass extraction, resulting in greater exposure. Rifampicin exposure levels 
greater than those achieved with the current dosing have been shown to correlate with better 
treatment outcomes (Long, Snider, & Farer, 1979; Pasipanodya et al., 2013); hence, the 
increased rifampicin exposure due to saturation is likely to be beneficial to patients. On the 
basis of the range of MICs obtained from a South African study (Chigutsa et al., 2015), our 
simulation suggests that the currently recommended dose may not be adequate for some 
patients. The PTA for the currently recommended dose was 63% for a median MIC of 0.125 
mg/liter. This result corroborates the notion that increasing rifampicin doses is likely to result 
in improved responses to treatment, which might allow shorter treatment times. On the basis 
of Monte Carlo simulations of exposure with the current weight and dosing and the reported 
MICs, a dose of 20 mg/kg is expected to achieve a CFR of >95%. 
 
The model presented here has some limitations. It was developed on the basis of data 
obtained only with a 10-mg/kg dose, so the extrapolation becomes less reliable as our 
simulations explore much larger doses such as 30 or 35 mg/kg. Though we could not establish 
a relationship between autoinduction and the administration schedule (5 versus 7 days/week), 
there is no guarantee that the extent of autoinduction will be similar for other intermittent 
dosing schedules, for example, dosing two or three times a week. Similarly, our data could not 
be used to predict whether larger doses of rifampicin will result in higher levels of 
autoinduction. Predicted PTAs should be interpreted while keeping in mind that the cut-off 
values used for PTA determination were obtained from a murine model (Jayaram et al., 2003) 
and extrapolation to humans may not be accurate for a number of factors, including differences 
in the lesions: more granuloma as well as cavity formations in humans (Capuano et al., 2003; 




In conclusion, the model developed here describes autoinduction of clearance and saturation 
of EH of rifampicin. The model was used to simulate doses larger than those currently 
recommended, and a more-than-proportional increase in exposure in relation to the dose was 
observed. Doses larger than those currently recommended are likely to be more effective 
against the M. tuberculosis strains considered in this study. Since it was not possible to 
characterize whether higher rifampicin concentrations may affect the extent of autoinduction, 
further research is necessary to address this question. Moreover, the effect of increased 
rifampicin exposure on the PK of co-administered drugs, in particular, the companion anti-TB 
and antiretroviral drugs, would need to be assessed. Alternative dosing strategies based on 
FFM need to be explored to reduce differences in exposure among TB patients, and this is 







Structural model with saturable EH 
The model structure depicted in Figure 3.1 is explained in detail below. Upon oral 
administration, rifampicin is transferred into the absorption compartment via transit 
compartments, and from there, it reaches the liver, where it is subjected to first-pass 
metabolism. It is then transferred into the central compartment, from which it recirculates to 
the liver because of blood circulation. The site of drug clearance, characterized with a well-
stirred model, is the liver. Clearance is determined by hepatic plasma flow (QH) and the EH 
ratio as follows: 
𝐶𝐿𝐻 = 𝑄𝐻 ∙ 𝐸𝐻 (3.2) 
The EH ratio is defined as follows: 
𝐸𝐻 =
𝐶𝐿𝑖𝑛𝑡 ∙ 𝑓𝑢
𝐶𝐿𝑖𝑛𝑡 ∙ 𝑓𝑢 + 𝑄𝐻
(3.3) 
where CLH is the saturable intrinsic hepatic clearance and fu is the unbound fraction of 





where CLint,max is the maximum CLint, CH is the concentration of rifampicin in the liver, and Km 
is the Michaelis constant, a parameter that governs saturable hepatic elimination and denotes 
the rifampicin concentration at which the CLint is half its maximal value. To stabilize the model 
during estimation of Km, the parameter was estimated on a log scale. CLint,max was autoinduced 





Chapter 4: Pharmacokinetics of pyrazinamide and optimal 
dosing regimens for drug-sensitive and -resistant tuberculosis 
 
4.1 Abstract 
Pyrazinamide is used in the treatment of tuberculosis (TB) because its sterilizing effect against 
tubercle bacilli allows the shortening of treatment. It is part of standard treatment for drug-
susceptible and drug-resistant TB, and it is being considered as a companion drug in novel 
regimens. The aim of this analysis was to characterize factors contributing to the variability in 
exposure and to evaluate drug exposures using alternative doses, thus providing evidence to 
support revised dosing recommendations for drug-susceptible and multidrug-resistant 
tuberculosis (MDR-TB). Pyrazinamide pharmacokinetic (PK) data from 61 HIV/TB-coinfected 
patients in South Africa were used in the analysis. The patients were administered weight-
adjusted doses of pyrazinamide, rifampicin, isoniazid, and ethambutol in fixed-dose 
combination tablets according to WHO guidelines and underwent intensive PK sampling on 
days 1, 8, 15, and 29. The data were interpreted using nonlinear mixed-effects modelling. PK 
profiles were best described using a one-compartment model with first-order elimination. 
Allometric scaling was applied to disposition parameters using fat-free mass. Clearance 
increased by 14% from the 1st day to the 29th day of treatment. More than 50% of patients with 
weight less than 55 kg achieved lower pyrazinamide exposures at steady state than the 
targeted area under the concentration-time curve from 0 to 24 h of 363 mg h/liter. Among 
patients with drug-susceptible TB, adding 400 mg to the dose for those weighing 30 to 54 kg 
improved exposure. Average pyrazinamide exposure in different weight bands among patients 
with MDR-TB could be matched by administering 1,500 mg, 1,750 mg, and 2,000 mg to 






Pyrazinamide is a prodrug converted to its active form, pyrazinoic acid, by hepatic microsomal 
deamidase (Konno, Feldmann, & McDermott, 1967) and is active against dormant and semi-
dormant Mycobacterium tuberculosis bacilli, especially in acidic environments (Mitchison, 
1985; Steele & Des Prez, 1988). It is currently part of a four-drug fixed-dose combination 
(FDC), which includes isoniazid, ethambutol, and rifampicin, an inducer of a number of 
cytochrome P450 enzymes via the pregnane X receptor (PXR) (Chen & Raymond, 2006). 
Pyrazinamide is currently being considered as a companion drug in novel tuberculosis (TB) 
treatment regimens for drug-susceptible and -resistant TB (Diacon et al., 2012; Mitchison & 
Fourie, 2010; Pasipanodya et al., 2013). 
 
Interest in the drug derives from its potent sterilizing activity, which confers the ability to 
shorten treatment duration. Pyrazinamide exposures have been correlated with favourable 
treatment outcomes in patients on standard doses (Chideya et al., 2009; Chigutsa et al., 2015; 
Gumbo et al., 2014; Heifets & Lindholm-Levy, 1992; Mitchison, 2005; Pasipanodya et al., 
2013; Zhang & Mitchison, 2003). A pyrazinamide area under the concentration-time curve 
from 0 to 24 h (AUC0–24) of at least 363 mg·h/liter has been associated with long-term TB 
treatment outcomes among patients with drug-susceptible TB and could be targeted for 
treatment optimization (Pasipanodya et al., 2013). The current recommended weight-adjusted 
daily dose of pyrazinamide for treatment of drug-susceptible TB is approximately 25 (range, 
20 to 30) mg/kg of body weight (World Health Organization, 2003), while that for treatment of 
MDR-TB is about 35 (range, 30 to 40) mg/kg (World Health Organization, 2009). Doses higher 
than those currently recommended may result in high levels of 5-hydroxypyrazinoic acid, 
which is responsible for pyrazinamide induced hepatotoxicity (Shih et al., 2013). On the other 
hand, there exist discrepancies in exposure between the weight bands; patients in the lower 





Despite interest in pyrazinamide, relatively few studies have described its pharmacokinetics 
(PK) longitudinally (Chigutsa, McIlleron, & Holford, 2010; Peloquin et al., 1998; Wilkins et al., 
2006; Zhu et al., 2002). We previously reported PK exposures of pyrazinamide in this cohort 
of HIV/TB-coinfected patients (McIlleron et al., 2012). Here, we use a population modelling 
approach to describe changes in PK parameters during the first month of treatment and 
identify other factors affecting the PK. We then used parameter estimates of the final model 
to simulate exposures associated with a range of feasible doses for treatment of drug-






This report is a model-based secondary analysis of a study described before. The original 
report includes a detailed description of the study design, including patient selection, inclusion 
and exclusion criteria, informed consent, adherence monitoring, and blood sample collection 
(McIlleron et al., 2012). Briefly, patients were administered 4-drug FDC tablets, each 
containing 150 mg of rifampicin, 75 mg of isoniazid, 400 mg of pyrazinamide, and 275 mg of 
ethambutol. Individual doses were adjusted based on body weight according to WHO 
guidelines (World Health Organization, 2003), with 51/61 patients receiving the medications 
daily from Monday to Friday and the remaining 10 every day of the week. 
 
Pharmacokinetic blood sampling was performed on the 1st, 8th, 15th, and 29th day of TB 
treatment after an overnight fast. Samples were collected immediately before the dose and at 
1, 2, 4, 6, 8, and 12 h post-dose. An additional sample was collected at approximately 12 h 
before the dose administered on the 15th day. Details of procedure and methods used for 
separation of plasma, storage of samples, and quantification of drug concentrations were as 
described in a previous report (McIlleron et al., 2012). The lower limit of quantification for the 
assay was 0.2 mg/liter.  
 
Pyrazinamide concentrations were described using nonlinear mixed-effects modelling using 
the software NONMEM 7.3 (Beal, Sheiner, Boeckmann, & Bauer, 2013) and the first-order 
conditional estimation method with eta-epsilon interaction (FOCE-I). Model diagnostics and 
documentation of model development were performed using Perl-speaks-NONMEM (PsN) 
version 3.7.6, Pirana version 2.9.2, and Xpose4 (R package) (Keizer, Karlsson, & Hooker, 
2013). Additional plots were generated using R, version 3.2.1 (R Core Team, 2017), via 





One- and two-compartment disposition models with first-order elimination and different 
absorption models, including first-order absorption with and without lag time and a more 
flexible transit compartment absorption (Savic, Jonker, Kerbusch, & Karlsson, 2007), were 
assessed. Plots of random effects of PK parameters were generated to identify trends in 
pharmacokinetic parameters with time on treatment. Three approaches to characterize the 
change in clearance over time were explored: estimating a separate value of clearance at 
each sampling day, an exponential increase in clearance from the first day to day 29 
(exponential induction model), and linear increase in clearance from day 1 to day 29. The 
exponential induction model characterizing clearance on each day was parameterized using 
clearance on the first day (CLday 1), change in clearance at day 29 (ΔCLday 29), and a half-life of 
the exponential process (t50), as in equation 4.1. In the equation, the time variable for days on 
treatment went from 0 (day 1) to 28 (day 29). 
 








The model with a linear increase in clearance was parameterized using clearance at baseline 
(day 1) and change in clearance on day 29 (ΔCLday 29), and the relationship is shown in 
equation 4.2. Similar to the exponential induction model, time on treatment was recorded from 
day 0 (day 1) to 28 (day 29). 




Allometric scaling was applied testing either total body weight (TBW) or fat-free mass (FFM) 
as a body size descriptor. The allometry exponents were either estimated or fixed to 0.75 for 
CL and 1 for V, as suggested by Anderson and Holford (Anderson & Holford, 2008). Individual 









The maximal weight height squared (WHSmax) is 42.92 kg/m2 for males and 37.99 kg/m2 for 
females. The WHS50 has values of 30.93 kg/m2 for males and 35.98 kg/m2 for females 
(Janmahasatian et al., 2005). 
 
The typical value of bioavailability was fixed to a reference value of 1. Between-subject 
variability (BSV) and between-occasion variability (BOV) in the PK parameters were explored 
assuming log-normal distribution. An error model with both additive and proportional 
components was used to describe residual unexplained variability. Model building was guided 
by a change in objective function value (ΔOFV; assumed to be approximately 𝜒2 distributed), 
inspection of diagnostic plots, including prediction-corrected visual predictive check (PcVPC) 
(Bergstrand, Hooker, Wallin, & Karlsson, 2011), and physiological plausibility. The effect of 
CD4+ count, viral load, early antiretroviral therapy (ART) initiation, alanine transaminase (ALT), 
albumin, creatinine clearance, and formulation on PK parameters was assessed by exploring 
proportional changes in parameter estimates per unit of difference from the median for 
continuous covariates or relative changes from a reference category for categorical variables 
as described by Mould and Upton (Mould & Upton, 2013). Creatinine clearance was calculated 
from serum creatinine using the Cockroft-Gault equation (Cockcroft & Gault, 1976). The 
precision of parameter estimates of the final model was evaluated using a nonparametric 
bootstrap method with replacement (n = 200). 
 
The final PK model was then used to simulate steady-state pyrazinamide concentrations 
achieved during the treatment of drug-susceptible TB and MDR-TB after administration of 
feasible doses based on WHO-defined weight bands. Simulations (1,000 repetitions) were 
performed using demographic data of 870 tuberculosis patients obtained from PK studies 
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conducted in South Africa and West Africa (Chigutsa et al., 2011; Diacon et al., 2007; McIlleron 
et al., 2012; Pepper et al., 2010; Smythe, 2016; Wilkins et al., 2008). For drug-susceptible TB, 
dosing strategies were assessed using the current weight bands and currently available FDC 
tablet sizes or additional 400-mg pyrazinamide tablets. For each dosing strategy, the 
proportion of patients achieving a target AUC0–24 of 363 mg · h/liter in each weight band was 
determined (Pasipanodya et al., 2013). In the simulations for MDR-TB, we used estimated PK 
parameters for day 1 of treatment to explore exposure associated with currently recommended 
doses: patients with between 33 and 50 kg receive 1,000 to 1,500 mg, while patients with 
weight between 51 and 70 kg and those above 70 kg receive 1,750 mg and 2,000 to 2,500 
mg, respectively (World Health Organization, 2009). Using the same weight bands and 
available single-dose tablet sizes of 400 mg, 500 mg, and 750 mg, we explored exposure 
obtained under different dosing strategies and identified the dose at which comparable 
exposure is attained in the different weight bands. Additionally, the proportion of patients 
achieving an AUC0–24 of 363 mg · h/liter was evaluated, since there is limited information on 
AUC/MIC pharmacodynamic index for MDR-TB. However, the MIC distributions for 
pyrazinamide do not seem highly variable between patients with drug-susceptible or MDR-TB. 
Zheng et al. reported MIC values ranging from 6.2 mg/liter to 400 mg/liter among MDR-TB 
patients, and among patients with drug-susceptible tuberculosis, Chigutsa et al. reported MIC 
values from 12.5 mg/liter to >100 mg/liter (Chigutsa et al., 2015; Zheng et al., 2016). 
Furthermore, using the clinical breakpoints suggested by Zheng et al. of 18.75 mg/liter and 
37.5 mg/liter, associated with 4-month culture conversion and treatment success, respectively 
(Zheng et al., 2016), and an AUC0–24 of 363 mg · h/liter, the calculated AUC/MIC values are 






Demographic characteristics. Pyrazinamide concentration data for 61 HIV/TB co-infected 
patients were available for analysis. Demographic characteristics of these patients have been 
reported previously (McIlleron et al., 2012), and a summary is provided in Table 4.1. A total of 
1,342 plasma samples were included in the analysis. One sample had a concentration below 
the lower limit of quantification and was discarded.  
 
Table 4.1 Baseline characteristics of patients in TB-HAART (pyrazinamide model) 
Characteristic or parameter Value 
Total no.  61 
Females, n (%)  33 (54) 
Receiving ART, n (%)  41 (67) 
Treatment 5 days/week, n (%)  51 (84) 
Age (yr)  32 (18–47) 
Weight (kg)  55.2 (34.4–98.7) 
Height (m)  1.59 (1.41–1.81) 
FFM (kg)  42.2 (28.0–57.6) 
Albumin (g/liter)  26 (15–43) 
ALT (U/liter)  16 (5–44) 
Creatinine (mol/liter)  74 (53–155) 
Viral load (1,000) (copies/ml)  86 (0.05–13,000) 
CD4 count (cells/liter)  254 (12–500) 




Structural model and parameter estimates 
Pyrazinamide pharmacokinetics was best described by a one-compartmental model with first-
order elimination and transit compartment absorption. Table 4.2 shows the parameter 
estimates of the final model and their 95% bootstrap confidence interval. Clearance (CL) was 
found to increase by 14% on day 29 from a typical value of 3.35 liters/h on day 1, thus, day 
29 clearance would be estimated at 3.83 liters/h (change in objective function value [ΔOFV] 
of -21 compared to a model with one estimate for clearance, 1 degree of freedom [df], and a 
P value of <0.001). This process was best described using a linear model, which was more 
parsimonious than estimating separate values of CL. The clearance estimates for day 1 and 
day 29 obtained using a linear model were similar to the ones obtained by estimating separate 
clearance values on the 4 days. The latter model estimated clearance values of 3.35 liters/h 
on day 1, 3.46 liters/h on day 8, 3.66 liters/h on day 15, and 3.82 liters/h on day 29. Using the 
arguably more biologically plausible exponential model did not significantly improve the fit and 
could not provide a robust estimate of the half-life of the induction, sometimes producing 
implausible results in the bootstrap analysis. The absorption process was best characterized 
using the transit compartment absorption, which provided significant improvement compared 
to simple first-order absorption with a delay using a lag (ΔOFV of -37, 1 df, P value of <0.001). 
On average, the time from drug ingestion to absorption is around half an hour and then is 
followed by very fast absorption. Large variability (>50%) in absorption between occasions 
was observed. The model also identified between-subject variability in clearance and 
bioavailability as well as between-occasion variability in clearance, bioavailability, and 










Inclusion of allometric scaling on CL and volume of distribution (V) using total body weight 
(TBW) improved the fit (ΔOFV of -13), but the better predictor to adjust PK for body size was 
fat-free mass (FFM), which dramatically reduced the OFV further when changed to FFM 
(ΔOFV of -37). Estimating allometry exponents did not result in a significant improvement in 
OFV and the estimated values were close to 0.75 for CL and 1 for V, hence the exponents 
were fixed to these literature values. After the inclusion of allometric scaling, the model could 
not detect any additional effect of CD4+ count, viral load, early antiretroviral therapy (ART) 
initiation, alanine transaminase (ALT), albumin, creatinine clearance, and formulation. The 
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visual predictive check plot in Figure 9 shows that our model correctly describes the observed 
concentrations and captures the change in clearance over time. 
 
Figure 4.1 Visual predictive check for pyrazinamide model (TB-HAART study) stratified by 
treatment day  Open circles are the observed concentrations. The middle continuous line is 
the 50th percentile of the observed data, and upper and lower dashed lines are the 97.5th 
and 2.5th percentiles of the observed data, respectively. The shaded regions represent the 





Monte Carlo simulations 
The median weight, height, and FFM of the 870 patients with drug-susceptible TB were 53 kg 
(range, 30 to 102 kg), 1.65 m (range, 1.35 to 1.98 m), and 40.7 kg (range, 25.3 to 71.7 kg), 
respectively, with 45% being female. Figure 4.2 shows the simulated exposures at day 29 of 
treatment achieved under dosing strategies for the treatment of drug-susceptible TB. With the 
currently recommended weight-adjusted dose, patients in the lower weight bands are exposed 
to much lower levels of pyrazinamide, with patients of <38 kg being exposed to 42% lower 
AUC0–24 than those weighing >70 kg.  
 
Figure 4.2 Box plots of simulated AUC0–24 for currently recommended doses for 
drug-susceptible TB and 3 alternative dosing strategies, stratified by weight band  (World 
Health Organization, 2003) Dots are the observed AUC0–24 on day 29 of treatment. The 
dashed line represents an AUC0–24 of 363 mg·h/liter. The dosing strategies used for the 30- 
to 37-, 38- to 54-, 55- to 70-, and >70-kg weight bands are 800 mg, 1,200 mg, 1,600 mg, 
and 2,000 mg for current doses. For alternative dosing strategy 1, patients weighing 30 to 
37 kg receive 1,200 mg, while the doses for patients in the other weight bands are 
unchanged. For alternative 2, 1,200-mg and 1,600-mg doses are administered to patients 
weighing 30 to 37 kg and 38 to 54 kg, respectively, while other patients’ dosing is 
unchanged. For alternative 3 dosing, 1,600 mg is administered to patients weighing 30 to 




The proportion of patients achieving a target AUC0–24 of 363 mg h/liter in each weight band is 
presented in Table 4.3. The model predicts that at the current dose, only around 10% of the 
patients in the 30- to 37-kg weight band and 40% in the 38- to 55-kg weight band achieve the 
target exposure. Alternative dosing approaches minimizing the difference in exposure 
between weight bands without changing the weight bands are depicted in Figure 4.2. In the 
most balanced alternative, alternative 2 (administering 1,200 mg to patients in the 30- to 37-
kg weight band and 1,600 mg to those in the 38- to 54-kg weight band; other patients’ dosing 
remained unchanged), the highest median exposure would be in the >70-kg weight band while 
the lowest will be in the 55- to 70-kg weight band, resulting in a maximum difference in 
exposure of 16%. The simulations show that overall, 73% of the patients will achieve target 
exposure with alternative 2 dosing strategies compared to 51.5% for the current dosing 
strategy.  
Table 4.3 Proportion of simulated patients with drug-susceptible TB achieving a target AUC0- 24 
of 363 mg·h/liter 
 
 
Figure 4.3a and b show simulated concentrations for two typical male patients of weights of 
34 kg and 46 kg achieved with the current dose and alternative dosing strategy 2. The two 
typical patients attain a maximum concentration of drug in serum (Cmax) of at least 35 mg/liter 
when dosing is administered per alternative strategy 2. As shown in Figure 4.2, alternative 
dosing strategies 1 and 3 do not seem to minimize differences in exposure between weight 
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bands, and some patients in the lower weight bands would achieve extremely high exposure 
when dosed using the alternative strategy 3. 
 
Figure 4.3 Predicted concentrations for typical male patients weighing 34 kg and 46 kg  (a) 
Predicted concentrations for a typical male patient weighing 34 kg, receiving 800 mg (solid 
line) and 1,200 mg (dashed line). (b) Predicted concentrations for a typical male patient 
weighing 46 kg, receiving 1,200 mg (solid line) and 1,600 mg (dashed line) 
 
Figure 4.4 shows simulated steady-state pyrazinamide AUC0–24 achieved with doses within 
the recommended range of 1,000 mg to 2,500 mg for the treatment of MDR-TB. Simulations 
were performed using estimated PK parameters for day 1 without the increase in clearance, 
which may be due to co-administration with rifampicin. Pyrazinamide exposure associated 
with the currently recommended dose is only comparable if patients in the 33- to 50-kg weight 
band are administered 1,500 mg, while patients in the 51- to 70-kg and >70-kg bands receive 
1,750-mg and 2,000-mg doses, respectively. These doses ensure that on average, at least 
90% of patients in the three weight bands achieve an AUC0–24 of at least 363 mg · h/liter. On 
the other hand, administering 1,000 mg or 1,200 mg to patients in the 33- to 50-kg weight 




Figure 4.4 Box plots of simulated AUC0–24 achieved during treatment of MDR-TB  using the 
model without the increase in clearance over time, stratified by weight band and dose 
administered. Single-dose tablets of pyrazinamide were used in the simulations, with each 
tablet containing either 400 mg, 500 mg, or 700 mg. The minimum and maximum values of 
the box plots are the 2.5th and 97.5th percentiles, and the horizontal tick mark on each box 







We described the population pharmacokinetics of pyrazinamide among HIV/TB co-infected 
patients during the first month of treatment using nonlinear mixed-effects modelling. The 
model described an increase in pyrazinamide clearance with days on treatment (from day 1 
to day 29) and identified FFM as the best predictor of the effect of body size on exposure 
compared to total body weight. Simulations were used to explore pyrazinamide exposure 
achieved with different dosing strategies for the treatment of drug-susceptible and multidrug-
resistant TB.  
 
FFM is calculated based on weight, height, and sex and was found to be superior to total body 
weight when included in the model via allometric scaling to capture the effect of body size on 
differences in CL/F and V/F (Anderson & Holford, 2008). Some previously proposed 
population PK models of pyrazinamide do not account for the effect of body size using 
allometric scaling (Wilkins et al., 2006; Zhu et al., 2002). One of these, by Wilkins et al. (Wilkins 
et al., 2006), described a linear effect of weight on both CL/F and V/F and also reported higher 
V/F in males than females (16% more). More recently, Chigutsa et al. (Chigutsa, McIlleron, & 
Holford, 2010) proposed a model incorporating allometric scaling using total body weight and 
reported larger bioavailability in women. When we accounted for body size using total body 
weight instead of FFM, the model estimated bioavailability among females to be 26% higher, 
the same effect observed by Chigutsa et al. Both results discussed above are consistent with 
ours, although the covariate effects were accounted for differently. By using allometric scaling 
to explain variability in body size, we apply a well-known concept without estimating any 
additional parameters (Anderson & Holford, 2008). We believe that this strategy, also applied 
by Denti et al. (Denti, Jeremiah, et al., 2015) and Rockwood et al. (Rockwood et al., 2016), of 
describing the differences as being due to differences in size and body composition is both 
more parsimonious and physiologically plausible. Furthermore, this strategy has also been 
reported for other drugs in the FDC (Chirehwa et al., 2016; Denti, Jeremiah, et al., 2015; 
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Geiseler, Manis, & Maddux, 1985; Rockwood et al., 2016; Smythe et al., 2012); hence, dosing 
regimens using current FDCs could be modified to take into account the variability in body size 
and composition.  
 
Clearance of pyrazinamide was found to increase from the first day to day 29. The increase 
in clearance with time on treatment has been described by Smythe and Denti et al., with a 
later report of a 16% increase among Tanzanian patients, which is close to our 14% (Denti, 
Jeremiah, et al., 2015; Smythe, 2016). Smythe reported a higher increase (30%) in clearance 
from the first day to steady state in a cohort of TB patients from West Africa. The exact 
mechanism driving this change needs further investigation, and a number of reasons might 
explain this. Rifampicin is a potent inducer of a large number of metabolic pathways via PXR 
(Chen & Raymond, 2006). Induction of microsomal deamidase and xanthine oxidase enzymes 
responsible for pyrazinamide metabolism by rifampicin might explain the observed result. 
Tuberculosis has been reported to lower drug-metabolizing capacity in animals (Batra, 
Venkitasubramanian, & Raj, 1987), hence, treatment and improvement of the disease 
symptoms may enhance drug metabolism and other body functions, consistent with the 
observed increase in pyrazinamide clearance. Our estimated value of CL/F on day 29 is 
comparable to those reported in other studies, conducted in healthy volunteers, TB patients, 
and HIV/TB-coinfected patients (Peloquin et al., 1997; Wilkins et al., 2006; Zhu et al., 2002). 
However, when predicting appropriate doses for patients with MDR-TB, we assumed a 
constant clearance over time, as the regimens used do not contain Rifampicin and the 
response to treatment is generally more gradual with the weaker second-line regimens than 
for patients with drug-susceptible TB.  
 
Parameter estimates of the final model were used to simulate pyrazinamide exposure under 
different dosing schemes so as to achieve comparable AUC0–24 values across weight bands. 
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Consistent with the previous noncompartmental analysis (NCA) of the data (McIlleron et al., 
2012), our model predicted that patients in lower weight bands attain lower drug exposures 
than those in the 55- to 70-kg weight band despite administering similar weight-adjusted 
doses. Disease severity is associated with low body mass index (Van Lettow et al., 2004). 
Lower pyrazinamide exposure among these patients is likely to be even more critical and is 
associated with poor treatment outcomes (Chideya et al., 2009; Pasipanodya et al., 2013). 
Alternative doses for the treatment of drug-susceptible TB suggested in this report are based 
on the current weight bands and available FDC tablet sizes or single pyrazinamide tablets, 
each at a strength of 400 mg. Implementation of a fixed pyrazinamide dose of 1,500 mg as 
proposed by Sahota and Della Pasqua might be challenging under the current FDC therapy. 
Moreover, while desirable in terms of simplification, it implies reducing exposures of 
pyrazinamide and other drugs among patients with weight greater than 54 kg, thereby 
increasing the risks of poor treatment outcomes (Sahota & Della Pasqua, 2012). The 
distribution of model predicted AUC0–24 suggests that adding 400 mg of pyrazinamide to the 
current FDC for patients with weights less than 55 kg (alternative dosing strategy 2) would 
achieve more uniform exposures across weight bands and increase the proportion of patients 
attaining an AUC0–24 of 363 mg·h/liter. The same dosing strategy will result in the majority of 
patients attaining a Cmax of 35 mg/liter, which was found to be associated with favourable 
treatment outcomes (Chideya et al., 2009). McIlleron et al. reported reduced exposure to drugs 
in FDC among patients who are male or with low weight (McIlleron et al., 2012), hence our 
proposed optimal dosing strategy could be transferable to other drugs of the FDC. Another 
advantage of the proposed dosing strategy is the reduction of weight bands from 4 to 3, where 
the 38- to 54-kg and 55- to 70-kg weight bands are combined. There would be a slight gain in 
the proportion of patients achieving the target AUC0–24 overall under the alternative dosing 
strategy 3 compared to alternative 2, but the risk of hepatotoxicity could be elevated for 
patients in the 30- to 37-kg weight band treated under the alternative dosing strategy 3, who 
would be administered between 42 and 53 mg/kg doses (US Public Health Service, 1959). 
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The currently recommended pyrazinamide dose of 30 to 40 mg/kg results in disparate 
exposure among patients with MDR-TB (World Health Organization, 2009). Moreover, a 
significant proportion of patients treated according to the recommended dose do not achieve 
the therapeutic AUC0–24 of 363 mg·h/liter identified for drug-susceptible TB. Assuming 
availability of 400-, 500-, and 750-mg tablet sizes, our simulations predict that prescription of 
doses at the higher end of the recommended range for low-weight patients will help minimize 
the differences in exposure between weight bands. Our proposed optimal dosing strategy of 
1,500 mg for patients in the 33- to 50-kg weight band, 1,750 mg for patients weighing up to 70 
kg, and 2,000 mg for heavier patients ensures that exposures between weight bands are 
comparable. Furthermore, the strategy guarantees that 90% of MDR-TB patients achieve 
exposures of >363 mg·h/liter. 
 
The model presented here has some limitations. A simple linear change in clearance over 
time from initiation of treatment was assumed, hence limiting our capacity to extrapolate from 
our results beyond those observed on day 29. On the other hand, since the values of CL on 
day 29 are similar to those of prior reports, one can speculate that the change in clearance 
after the first month is not as large as the one observed in the first month of treatment. Our 
simulations were based on the assumption of first-order elimination. Since pyrazinamide is 
eliminated mainly as metabolites through multiple pathways (Chigutsa, McIlleron, & Holford, 
2010; Lacroix, Tranvouez, Phan Hoang, et al., 1990), if one or more of these pathways were 
to saturate at higher doses, the model may be underpredicting exposure in lower weight 
bands. The model developed was based on PK from a single study population. However, 
demographic characteristics broadly representing an African population were used in the 
simulations to account for a key covariate effect (FFM) during simulations, hence the use of 
FFM values outside the range that was used to optimize parameter estimates of the model. 
The demographic characteristics of patients with drug-susceptible TB were assumed to be 
similar to those of MDR-TB patients in the simulations, but there could be differences between 
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the two groups of patients in terms of disease chronicity and severity that may influence 
pharmacokinetics and pharmacokinetic targets. Another limitation of the study is the 
nonavailability of MIC distribution for calculation of AUC/MIC ratio as a pharmacodynamic 
index. However, the range of MICs for drug-susceptible and MDR-TB are comparable as 
reported by Chigutsa et al. and Zheng et al., respectively (Chigutsa et al., 2015; Zheng et al., 
2016). Regardless of the therapeutic index used (AUC or AUC/MIC), the target will be affected 
by activity of concomitant drugs as well as the synergy or antagonism with pyrazinamide, 
demonstrated with rifampicin and bedaquiline (Chigutsa et al., 2015; Field, 2015). 
 
In conclusion, our data in patients on the standard rifampicin-based first-line regimen suggest 
that there is an increase in clearance of pyrazinamide during the first month of treatment. The 
currently recommended doses of pyrazinamide result in different levels of exposure among 
patients in the different weight bands. More uniform exposures with more patients attaining 
target exposures would be achieved by adding 400 mg to the dose for patients weighing 
between 30 and 54 kg. Reduced exposure to other drugs of the FDC has been reported among 
patients with low weight; hence, alternative 2 dosing strategy could be applied to all four drugs 
by adding one FDC tablet. While it is necessary to confirm our findings in patients with MDR-
TB, our analysis suggests that average pyrazinamide exposure in different weight bands could 
be made uniform by administering 1,500 mg to those with weights of at most 50 kg and 1,750 







Chapter 5: Effect of efavirenz-based antiretroviral therapy on 




To describe the pharmacokinetics of isoniazid and acetyl-isoniazid in TB/HIV co-infected 
patients, and assess the effect of efavirenz co-administration and a 50% increase in dose of 
rifampicin on pharmacokinetic parameters. 
 
Methods 
TB/HIV co-infected patients participating in the three-treatment arm RAFA randomised 
controlled trial conducted in West Africa were recruited into the pharmacokinetic sub study. 
Five serial blood samples were collected on a single visit at between four and eight weeks 
after initiation of antituberculosis treatment. Concentration-time data for isoniazid and 
acetyl-isoniazid were analysed using nonlinear mixed-effect modelling. 
 
Results 
Isoniazid concentrations from 150 patients were available for analysis, and 79 of these (53%) 
also had concentrations of acetyl-isoniazid. Isoniazid pharmacokinetics was best described 
using a two-compartment disposition model with first-order absorption and elimination using a 
semi-mechanistic model describing hepatic extraction. The model could identify two 
elimination pathways, separating formation of acetyl-isoniazid from other routes of 
metabolism. The elimination route for the formation of acetyl-isoniazid was best described 
using a mixture model with fast and slow acetylator status. In patients classified as fast 
acetylators who started efavirenz-based antiretroviral therapy at two weeks after 






Co-administration of isoniazid and efavirenz-based antiretroviral therapy results in reduced 
exposure to isoniazid. Efavirenz-based antiretroviral therapy affects the acetylation metabolic 
pathway, and the mechanism of action will require further investigation. Pharmacokinetics of 






Isoniazid is part of a four-drug Fixed-Dose Combination (FDC) for the treatment of drug-
susceptible tuberculosis (TB) which also includes rifampicin, pyrazinamide and ethambutol 
(World Health Organization, 2003). The currently recommended daily dose of isoniazid is 5 
mg/kg (4–6 mg/kg)(World Health Organization, 2010c), administered with the aim of achieving 
maximum concentrations of 3 to 6 mg/L (Alsultan & Peloquin, 2014b). The drug has excellent 
early bactericidal activity (EBA) mostly against rapidly metabolising and replicating bacilli 
(Donald et al., 1997). In an EBA study, a steady-state area under the concentration-time curve 
(AUC) of 10.52 mg·h/L achieved 90% of the maximum bactericidal activity (Donald et al., 
2007). In addition, isoniazid is also effective in preventing resistance to companion drugs in 
the FDC (Donald & Schaaf, 2011; Mitchison, 2000).  
 
The major metabolic pathways for isoniazid include acetylation via the N-acetyltransferase 2 
(NAT2) pathway to form acetyl-isoniazid, and hydrolysis to produce isonicotinic acid (Ellard, 
1976; Ellard & Gammon, 1976). Polymorphisms in NAT2 confer high interindividual variability 
in isoniazid exposure and are associated with fast, intermediate and slow phenotypes (Parkin 
et al., 1997). Exposure among fast acetylators is on average between 5-6 times lower than 
slow acetylators (Ellard & Gammon, 1976). Information on acetylator genotype is not always 
available, and mixture models are often used to classify patients into the different metabolic 
groups (Wilkins et al., 2011). Interindividual variability in isoniazid due to NAT2 polymorphisms 
may be associated with the emergence of multi-drug resistant tuberculosis, treatment failure 
or relapse and reduced bactericidal activity (Donald et al., 2004; Pasipanodya, Srivastava, & 
Gumbo, 2012). Regardless of the acetylator status, variability in isoniazid pharmacokinetics is 
also attributed to drug-drug interactions, weight, sex, health conditions, and formulation 
(Babalik et al., 2013; Bhatt et al., 2014; McIlleron et al., 2012; Wilkins et al., 2011). TB/HIV co-
infected patients receiving antituberculosis therapy and antiretroviral therapy (ART) are at risk 
of drug-drug interactions, and results of a non-compartmental analysis of a study conducted 
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in Mozambique showed a 29% reduction in isoniazid exposure when co-administered with 
efavirenz based ART (Bhatt et al., 2014).  
We have found only one publication describing the integrated population pharmacokinetics of 
isoniazid and acetyl-isoniazid. However, the study was conducted among healthy volunteers 
who may have different absorption and distribution profile compared to tuberculosis patients 
with or without HIV (Seng et al., 2015a). In this study, we describe the pharmacokinetics of 
isoniazid and acetyl-isoniazid among TB/HIV co-infected patients recruited in a trial that 
mimicked a routine clinical setting and evaluated the effect of efavirenz-based ART and a 50% 






Study design and patient selection 
The RAFA study was a three-arm randomised controlled study designed to assess the effect 
of timing of antiretroviral therapy and high dose (+50%) of rifampicin on patient survival and 
tuberculosis treatment outcomes among TB/HIV co-infected and treatment naïve patients. 
Patients in arm A started efavirenz-based ART at two weeks after initiating antituberculosis 
treatment whereas those in arm B and C started antiretroviral therapy after eight weeks of TB 
treatment. Patients in arm C received a 50% higher dose of rifampicin in the first eight weeks 
of TB treatment. Patients were included in the study if they were aged 18 or above, had a 
positive HIV test result, had a CD4+ lymphocyte count of at least 50 cells/µL, had recently 
been diagnosed with tuberculosis (with bacteriological or molecular evidence) and were ART 
naïve. Women were excluded from the study if they were pregnant, lactating, or unwilling to 
use contraception. Other criteria used for exclusion include HIV-2 infection, recreational drug 
and alcohol abuse, and laboratory values outside the normal ranges defined by the National 
Institutes of Health, excluding patients with up to grade three anemia (National Institute of 
Allegy and Infectious Diseases, 2001). 
 
Antituberculosis treatment was administered as a four-drug FDC according to WHO weight 
band-based guidelines (World Health Organization, 2010c). Each tablet contained 75 mg of 
isoniazid, 150 mg of rifampicin, 400 mg of pyrazinamide and 275 mg of ethambutol. Patients 
in arm C received additional 150 mg single dose tablet(s) of rifampicin together with the 
standard dose of FDC tablets to attain a dose of 15 mg/kg of body weight. A dose of 600 mg 
of efavirenz was administered to patients regardless of body weight. All patients received co-
trimoxazole preventive therapy at the start of TB treatment as recommended by WHO (World 





Specimen collection and drug quantification 
Between four and eight weeks after antituberculosis treatment initiation, patients were 
admitted overnight before PK sampling. Five serial blood samples were drawn pre-dose 
(approximately 15 mins before a dose), and at 2, 3, 6, and 10 hours post-dose. Blood samples 
were processed and plasma stored immediately at -80ᴼC before transfer on ice to the 
analytical laboratory (Division of Clinical Pharmacology, University of Cape Town, South 
Africa) for analysis. Isoniazid and acetyl-isoniazid were analysed with a validated liquid 
chromatography tandem mass spectrometry assay developed at the laboratory. Samples 
were processed with a protein precipitation extraction method using isoniazid-d4 and 
acetyl-isoniazid-d4 as internal standards, followed by high-performance liquid 
chromatography with MS/MS detection using an AB SCIEX API 3000 instrument. The analyte, 
metabolite, and internal standards were monitored at mass transitions of the protonated 
precursor ions m/z 138.11, m/z 180.16, m/z 142.21 and m/z 184.21 to the product ions m/z 
79.10, m/z 121.10, m/z 83.10 and m/z 83.20 for isoniazid, acetyl-isoniazid, isoniazid-d4 and 
acetyl-isoniazid-d4, respectively. The calibration curves fitted quadratic (weighted by 
1/concentration) regressions over the ranges 0.102 to 26.0 mg/L for isoniazid and 0.0501 to 
25.6 mg/L for acetyl-isoniazid. The combined accuracy (%Nom) and precision (%CV) statistics 
of the limit of quantification, low, medium, and high-quality controls (3 validation batches, 
N=18) of the analyte and metabolite were between 92.2% and 107%, and 2.9% and 10.9%, 
respectively.  
 
Pharmacokinetic data analysis 
Isoniazid and acetyl-isoniazid pharmacokinetic data were interpreted using nonlinear mixed-
effects modelling in the software NONMEM version 7.3 and the algorithm First-Order 
Conditional Estimation with eta-epsilon interaction (FOCE-I)(Beal, Sheiner, Boeckmann, & 
Bauer, 2013). Pearl-Speaks-NONMEM (PSN) version 3.7.6, Pirana version 2.9.6, and R 
(Xpose4 package) software were used to interact with NONMEM, track model development, 
and evaluate model diagnostics, respectively (Keizer, Karlsson, & Hooker, 2013). R version 
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3.2.3 was used for data manipulation, generating additional plots and post-modelling analysis 
using RStudio interface version 0.99.903 (R Core Team, 2017; RStudio, 2014). 
 
Model development was performed in a stepwise manner, starting with the structural 
pharmacokinetic model for isoniazid and then incorporating the pharmacokinetic model for 
acetyl-isoniazid. One- and two-compartment disposition models together with a liver 
compartment to capture the first-pass effect were explored to describe the pharmacokinetics 
of isoniazid (Gordi et al., 2005). Information on each patient’s acetylator genotype was not 
available, and a mixture model with two or three sub-populations was investigated to classify 
patients into different acetylator phenotypes (Frame, 2007). Allometric scaling was applied to 
all clearance and volume of distribution parameters (exponent fixed to 0.75 for clearance and 
1 for volume) for both isoniazid and acetyl-isoniazid to account for the effect of body size using 
either total body weight (TBW), fat-free mass (FFM) or body fat (Anderson & Holford, 2008). 
Both the mixture model on clearance of isoniazid and allometric scaling were included since 
the early phases of model development, as there is strong evidence supporting their effect on 
the pharmacokinetics of isoniazid (Denti, Jeremiah, et al., 2015; Parkin et al., 1997). 
Absorption of isoniazid was described using a first-order absorption model, with or without a 
delay using a lag time or a chain of transit compartments (Savic, Jonker, Kerbusch, & 
Karlsson, 2007). Bioavailability of isoniazid was fixed to a reference value of 1 and variability 
was included. Clearance of isoniazid was assumed to be either via a single metabolic pathway 
or two metabolic pathways, with one being responsible for the formation of acetyl-isoniazid. 
The pharmacokinetics of acetyl-isoniazid were described using either a one- or 
two-compartment disposition model and first-order elimination from the central compartment. 
Concentrations of isoniazid and acetyl-isoniazid were measured in mg/L, and a correction 
factor was included to adjust for differences in molecular weight at the formation of 
acetyl-isoniazid (179.18 g/mol for acetyl-isoniazid vs. 137.139 g/mol for isoniazid) (Zannikos 




A log-normal distribution was assumed for the between-subject variability (BSV) and 
between-occasion variability (BOV) of the pharmacokinetic parameters. To account for the 
uncertainty in reported dosing time for the dose administered the day before PK sampling, 
inclusion of a scaling parameter on BOV in bioavailability was investigated. Residual 
unexplained variability defined separately for isoniazid and acetyl-isoniazid comprised both 
additive and proportional components. Concentrations below the lower limit of quantification 
(LLOQ) for both isoniazid and acetyl-isoniazid were provided by the laboratory and included 
in the analysis. Undetectable concentrations of isoniazid and those below 0.01 mg/L, which 
corresponds to 10% of the LLOQ value, were censored at 10% of the LLOQ, and half the 
censoring value was imputed as suggested by Beal 2001 (Beal, 2001). A similar approach 
was applied to undetectable concentrations of acetyl-isoniazid and those below 0.005 mg/L. 
The minimum value of the additive error for both isoniazid and acetyl-isoniazid was fixed to 
20% of the respective LLOQ value. 
 
The effects of physiologically plausible covariates including early initiation of ART, high dose 
rifampicin, creatinine clearance, drug batch of FDC tablets, alanine transaminase (ALT), and 
study site on the PK parameters were investigated in the model. Covariate effects resulting in 
a significant drop in objective function value (OFV) and improvement in goodness of fit (GOF) 
plots, were retained in the model. A drop in OFV of 3.84 associated with 1 degree of freedom 
for a chi-squared distribution was considered for statistical significance. A nonparametric 
bootstrap (n=300, with replacement) was applied to evaluate the robustness of the parameter 
estimates by computing the 95% confidence intervals. Model derived individual exposures 
were extracted from the final model and presented for different strata of significant covariates 
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A total of 222 patients were recruited for the pharmacokinetic sub-study of the RAFA 
randomised controlled trial in Benin and Guinea. Plasma samples from 72 patients 
were temporarily thawed due to a freezer failure, and stability tests showed that 
isoniazid concentrations could not be reliably quantified in these samples. Thus, only 
data from the remaning 150 patients were included in the analysis. Table 5.1 shows 
the baseline characteristics of the 150 patients. The median weight, height and FFM 
were 52 kg, 1.7 m and 43.5 kg respectively. Of the 150 patients, 40 (26%) started ART 
at two weeks after initiating antituberculosis treatment, and 79 (53%) were randomised 
to high dose rifampicin. A total of 745 plasma isoniazid concentrations and 390 plasma 
acetyl-isoniazid concentrations from the 150 patients were included in the PK analysis. 
Concentration of isoniazid could not be detected in 12% of the plasma samples 
(concentrations were less than the sensitivity of the spectrometer), and 83% of these 





Table 5.1 Baseline characteristics of patients with isoniazid concentrations (RAFA study) 
Characteristic Valuea 
Total No. 150 
No. (%) of females 56 (37.3) 
No. (%) in early ART arm 40 (26.7) 
No. (%) in high dose rifampicin arm 70 (46.7) 
Weight, kg  51 (33–87) 
Height, m  1.7 (1.4–1.94) 
FFM, kg 43.3 (24.8–65.3) 
Age, years 38 (19–65) 
CD4+ cells/µL  167 (51–772) 
Viral load, copies/mL (x103) 150 (0.08–10000) 
Serum creatinine, µmol/L 89 (23–212) 
Haemoglobin level, g/dL 9.35 (5.2–15.9) 
ALT, units/L 26 (3–97) 
White blood cells, x109/L 7 (2.6–26.2) 
Platelets, x109/L 339 (124–832) 
a Unless otherwise indicated, the median (range) values are presented. 
 
Isoniazid and acetyl-isoniazid pharmacokinetics 
Figure 5.1 shows the schematic diagram of the final integrated model for isoniazid and 
acetyl-isoniazid pharmacokinetics. Isoniazid pharmacokinetics was best described 
using a two-compartment disposition model. A mixture model was incorporated in the 
base model to describe the multimodal distribution of isoniazid clearance. Our model 
could only separate fast and slow acetylator status and estimated the proportion of 
fast acetylators to be 50%. A mixture model with three sub-populations for isoniazid 
clearance was not significantly different from the one with two sub-populations. The 
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inclusion of a liver compartment to capture hepatic extraction including first-pass effect 
improved the model (ΔOFV= -9, no extra parameter was estimated). The model could 
also separate acetylation, which leads to the formation of acetyl-isoniazid, from other 
routes of elimination (OFV= -143, one additional parameter, p-value<0.001). The 
pharmacokinetics of acetyl-isoniazid followed a two-compartment disposition model 
with first-order elimination.  
 
Figure 5.1 Schematic diagram of the model describing the pharmacokinetics of isoniazid 
and acetyl-isoniazid  Fpre-H, pre-hepatic bioavailability; Ka, absorption rate constant; EH, 
hepatic extraction; EH_AC, hepatic extraction to acetyl-isoniazid via acetylation; EH_OTHER, 
hepatic extraction to via other routes of metabolism; VC, volume of central compartment for 
isoniazid; VP, volume of peripheral compartment for isoniazid; VC-AC, volume of central 
compartment for acetyl-isoniazid; VP-AC, volume of peripheral compartment for 
acetyl-isoniazid; VH, volume of liver; Q, inter-compartmental clearance for isoniazid; QAC, 
inter-compartmental clearance for acetyl-isoniazid; QH, hepatic plasma flow; CLAC, 
clearance for acetyl-isoniazid. 
 
Pre-hepatic bioavailability was fixed to a reference value of 1 for a typical individual 
and varied between the two occasions in the dataset (one occasion for pre-dose 
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samples and another for post-dose samples). The typical values for the volume of the 
liver and hepatic plasma flow were fixed to 1 L and 50 L/h respectively, and the 
unbound fraction of isoniazid was fixed to 95% (Clemmesen, Tygstrup, & Ott, 1998; 
Sturkenboom et al., 2015). Sensitivity analysis was performed on the values for liver 
plasma flow and unbound fraction to assess their effect on overall conclusion. 
Allometric scaling was applied to all clearance and volume parameters including that 
of the liver and peripheral compartments using FFM, which was superior to total body 
weight (ΔOFV= -14, no extra parameter was estimated). All typical values for 
clearance and volume parameters refer to a patient with FFM of 43 kg, the median 
value in the cohort.  
 
Table 5.2 shows the parameter estimates from the final model and the associated 
precision obtained using a 300-sample nonparametric bootstrap. The visual predictive 
check displayed in Figure 5.2 provides evidence that the model describes the 
observed data adequately. The model estimated that the average intrinsic clearance 
via acetylation was around 6-fold higher for fast compared to slow metabolisers. 
Acetylation is the major route of elimination for the fast metabolisers contributing about 
75% of the total clearance, while around a third of the clearance among slow 
metabolisers is due to acetylation. Patients classified as fast acetylators and receiving 
efavirenz-based ART at two weeks after initiation of antituberculosis treatment had 
54% higher intrinsic clearance compared to ART naïve patients for the pathway 
associated with the formation of acetyl-isoniazid (ΔOFV= -9, one additional parameter, 
p-value<0.002). The effect of efavirenz-based ART on clearance of isoniazid via 
acetylation in patients classified as slow acetylators was not supported in the model 
and clinically insignificant (p-value>0.05, 5% increase in clearance). There was no 
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effect of efavirenz-based ART on the clearance component not associated with 
acetylation. While the increased dose of rifampicin did not affect isoniazid PK, our 
model detected a 61.6% reduced bioavailability in all 28 patients who were treated 
with two of the drug batches (ΔOFV= -106, one additional parameter, p-value<0.001). 
Of these patients, 70% were in the high-dose rifampicin treatment arm whereas, 11% 
and 18% were in the early ART and standard treatment arms, respectively. The 
proportion of patients who received tablets from the two batches did not differ by 
acetylator status (20% and 18% among slow and fast acetylators respectively). 
Regardless of acetylator status and whether patients received tablets for batches with 
reduced bioavailability, the distribution of clearance due to acetylation and that of other 




Table 5.2 Parameter estimates of the final model for isoniazid and acetyl-isoniazid 
Parameter Estimate (95% CI)a Variability (BSV) 
Isoniazid   
Clearance (L/h)   
 Acetylation: Fastb,c 35.9 (30.1; 45.1) 35.6 (28.6; 41.8) 
 Acetylation: Slowb,c 6.64 (5.55; 8.39) 35.6 (28.6; 41.8) 
 Other pathwaysc 11.4 (9.11; 13.3) 34.6 (17.7; 45.4) 
Central volume (L)c 47.7 (40.8; 56.3) 18.9 (8.29; 27.7) 
Inter-compartmental clearance (L/h) c 4.8 (0.73; 11.5)  
Peripheral volume (L) c 8.14 (5.06; 247)  
Absorption constant (/h) 1.59 (1.36; 2.09) 36.7 (22.9; 54.3) 
Absorption lag (h) 0.287 (0.202; 0.59)  
Pre-hepatic bioavailabilityd 1 FIXED 16.9 (12.4; 22.8)e 
Proportion of fast acetylator (%) 50.1 (40.5; 59.0)  
Efavirenz effect on acetylation clearance 
in fast acetylors (%) 
54.1 (23.2; 97.8)  
Drug batch effect on bioavailability (%) -62.1 (-66.7; -57.0)  
Proportional error (%) 11.2 (9.55; 12.6)  
Additive error (mg/L) 0.02 FIXED  
Acetyl-isoniazid   
Clearance (L/h) c 6.77 (5.78; 7.87) 17.5 (13.9; 21.3) 
Central volume (L) c 34.4 (30.5; 40.1)  
Inter compartmental clearance (L/h) c 0.506 (0.323; 1.42)  
Peripheral volume (L) c 81.4 (19.8; 991)  
Proportional error (%) 5.25 (3.9; 6.49)  
Additive error (mg/L) 0.013 (0.01; 0.019)  
aObtained with a non-parametric bootstrap (n=300). 
bIntrinsic CL of isoniazid when given without efavirenz. 
cAll CL and volume parameters have been allometrically scaled with FFM, and the typical 
values reported here refer to the typical patient, with FFM of 43.5 kg.  
dPre-hepatic bioavailability is the fraction of the drug that is absorbed, crosses the gut wall 
unchanged, thus entering the portal vein and reaching the liver. 





Between-subject variability in clearance attributed to acetylation was slightly higher 
compared to other routes of metabolism. A large improvement in model fit (ΔOFV= -
37, one additional parameter, p-value<0.001) was observed after separating 
between-subject variability by the route of metabolism. Inclusion of the effect of the 
high-dose rifampicin arm on pharmacokinetics of isoniazid was not significant and did 
not improve the model fit.  
 
Figure 5.2 Visual predictive checks for isoniazid and acetyl-isoniazid stratified by metabolic 
status  The lines represent the 2.5th, 50th and 97.5th percentile of the observed 
concentrations (hollow circles). The shaded regions are the 95% prediction intervals for the 
2.5th, 50th and 97.5th percentiles. The sub-plot in each stratum shows the same VPC with a 
logarithmic transformation applied to the y-axis. 
 
Model derived steady-state individual estimates of AUC0–24 and Cmax were obtained 
from the final model. AUC0–24 and Cmax estimates for 28 patients who were 
administered tablets from the two batches with reduced bioavailability are not 
presented in Figure 5.3 and 5.4, hence the results in the plots shows what would 
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normally be observed if the bioavailability is not significantly reduced. Figure 5.3 shows 
the model-derived steady-state AUC0–24 for isoniazid and acetyl-isoniazid, stratified by 
acetylator status and co-administration with efavirenz. Among the patients classified 
as fast acetylators by the model, the median AUC0–24 in those who were not receiving 
ART was 56% higher than those who had started ART two weeks after antituberculosis 
treatment start. Regardless of the timing of ART initiation, slow acetylators had 3.6 
and 2.3 times higher AUC0–24 compared to fast acetylators who did and did not receive 
ART, respectively. None of the patients classified as fast acetylators achieved the 
AUC0–24 of 10.52 mg·h/L associated with early bactericidal activity, whereas more than 
75% of slow acetylators achieved this exposure level. As expected, acetyl-isoniazid 
exposure was higher among fast acetylators compared to slow acetylators. 
 
 
Figure 5.3 Boxplot of AUC0–24 for isoniazid and acetyl-isoniazid stratified by treatment arm  
(receiving efavirenz based ART vs. no ART) and NAT2 metaboliser status. The dots are 
model-derived individual exposures (steady-state AUC0–24). The dashed line represents the 
exposure (AUC0–24=10.52 mg·h/L) associated with 90% of early bactericidal activity of 
isoniazid.(Donald et al., 2007) 
 Figure 5.4 depicts the model-derived Cmax on the pharmacokinetics sampling day 
(equivalent to steady state). Regardless of treatment arm, all patients classified as fast 
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acetylators had Cmax below the range of 3–6 mg/L and more than 85% of the slow 
acetylators had Cmax below the range. 
 
Figure 5.4 Boxplot of Cmax for isoniazid stratified by treatment arm  (receiving efavirenz 
based ART vs. no ART) and NAT2 acetylator status (fast or slow). Dashed line indicates 






This study described the pharmacokinetics of isoniazid and acetyl-isoniazid in a cohort of 
TB/HIV co-infected patients. Using population pharmacokinetic modelling, we show that co-
administration of isoniazid and efavirenz results in reduced exposure to isoniazid. This effect 
has also been reported in a study among TB/HIV-infected patients in Mozambique (Bhatt et 
al., 2014), suggesting that the effect can be generalised to a wider population of TB/HIV co-
infected patients on tuberculosis treatment and efavirenz-based ART. One difference with the 
Mozambican study is that Bhatt et al. reported the effect of efavirenz on isoniazid clearance 
regardless of the metabolic pathway whereas, in our study, the effect was supported on the 
acetylation metabolic pathway. Efavirenz has also been found to increase the clearance of 
para-aminosalicylic acid, a drug that is also metabolised by NAT1 and NAT2 enzymes (de 
Kock et al., 2014). Efavirenz induces a number of enzymes in the cytochrome P450 
family(Adkins & Noble, 1998), but to the best of our knowledge, nothing has been reported on 
the effect of efavirenz on the activity of NAT2. Our results, that of Bhatt et al., and de Kock et 
al., suggest that efavirenz could modulate the activity of NAT2.  
 
The 6-fold higher intrinsic clearance via acetylation for fast compared to slow acetylators 
observed in our study is within the range previously reported (Ellard, 1984; Seng et al., 2015a). 
Slow acetylators lack functional NAT2 enzyme (Hein et al., 2000), and our results show that 
the clearance reported in other studies for slow acetylators is driven largely by metabolic 
pathways other than acetylation. Furthermore, since the NAT2 enzymes are predominantly 
hepatic, the higher exposure among slow acetylators would be a result of reduced clearance 
rather than higher pre-hepatic bioavailability. Overlapping of exposure range between slow 
and fast acetylators is not unexpected since multiple slow acetylator phenotypes may lead to 
high pharmacokinetic variability (Chen, Li, Xu, et al., 2006; Fretland, Leff, Doll, et al., 2001; 
Leff, Fretland, Doll, et al., 1999). 
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Adequacy of exposure to isoniazid is evaluated against target AUC0–24 or Cmax. The Cmax range 
of 3–6 mg/L was suggested based on concentrations observed in healthy volunteers recruited 
under controlled phase I studies (Peloquin, 2002). However, the Cmax observed in patients 
could be lower than these and a weakness of using the Cmax is that it could be affected by high 
variability in the absorption process (Devaleenal Daniel, Ramachandran, & Swaminathan, 
2017). On the other hand, steady-state AUC0–24 is a more stable exposure index with a value 
>10.52 mg·h/L being associated with 90% of the maximum early bactericidal activity of 
isoniazid (Donald et al., 2007). All patients classified as fast acetylators had AUC0–24, of less 
than 10.52 mg·h/L, and this reflects the extent of metabolism due to NAT2 activity in fast 
compared to slow acetylators and its overall effect on exposure. This results in widely varying 
exposure levels between fast and slow acetylators, thereby contributing to differences in 
treatment outcomes and toxicity. To quantify the effect of increased exposure in slow 
acetylators, Azuma et al. compared the currently recommended dose of 5 mg/kg to a NAT2 
adjusted dose (2.5 mg/kg for slow acetylators and 7.5 mg/kg for fast acetylators). The risk of 
drug-induced liver injury was 78% in the standard treatment group compared to none in the 
NAT2 adjusted dose group. Among fast acetylators, early treatment failure in the standard 
dose arm was double that of the NAT2 adjusted dose arm (Azuma et al., 2013). Reduced 
isoniazid exposure could imply an innapropriate continuation phase TB drug regimen with 
patients being almost only on monotherapy with rifampicin. This might increase the risk of 
emergence of drug resistance. Along with other factors, this could explain the increased risk 
of MDR-TB in HIV patients (Mesfin, Hailemariam, Biadgilign, et al., 2014). 
 
While genotyping is expensive in a resource-limited setting, other approaches could be used 
to classifying patients according to acetylator status. Collecting and quantifying isoniazid and 
acetyl-isoniazid concentration from a single blood sample after dose administration, combined 
with the use of mixture models in population pharmacokinetics to determine the acetylator 




The result that a 50% increase in rifampicin dose does not influence the pharmacokinetics of 
isoniazid is in line with reports by Boeree et al., who investigated the effect of higher dose of 
rifampicin of up to 35 mg/kg (3.5 fold increase) on pharmacokinetics of the other drug in the 
FDC and did not find any difference in AUC of the co-administered drugs between the standard 
dose rifampicin arm and higher dose arms (Boeree et al., 2017). Based on these results, we 
can conclude that doses higher than the current dose of rifampicin are less likely to affect 
isoniazid exposure.  
 
Our finding showing reduced bioavailability in two of the drug batches of the same formulation 
used in the study shows the need for continuous quality control checks on batch-to-batch 
variability. This result also reflects the challenges associated with conducting clinical trials in 
routine clinical settings and, most importantly, it provides essential information for monitoring 
tuberculosis treatment programmes. An analysis of the drug content in a sample of tablets 
from the two batches with reduced bioavailability could have helped to explain if the quality of 
the tablets was unsatisfactory, but there were no remaining tablets at the end of the trial to 
conduct the tests. Fortunately, the demographic characteristics of the patients who received 
tablets from the two batches were not dissimilar from the rest of the cohort, and their 
distribution was comparable across treatment arms, so this finding is not expected to have 
any significant impact on the main study question.  
 
Differences in body size and composition included in our model via allometric scaling using 
FFM also explain some variability in the pharmacokinetics of isoniazid in addition to acetylator 
status (Anderson, 2008). This combined effect of weight, height, and sex could explain the 
reported disparity in exposure among males and females (McIlleron et al., 2012), since 
females usually have a larger proportion of body fat, which does not contribute to the size of 
other body organs such as the liver (Green & Duffull, 2004). Recent population 
pharmacokinetics models for the first-line antituberculosis drugs have shown that FFM is a 
better size descriptor for scaling clearance and volume compared to total body weight (Denti, 
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Jeremiah, et al., 2015; Rockwood et al., 2016; Smythe, 2016). The feasibility of introducing 
FFM based dosing with the current FDCs for the treatment of tuberculosis in the clinic setting 
could be investigated. We postulate that the implementation of FFM based dosing could 
reduce the variability in drug exposure usually observed among tuberculosis patients, which 
will translate to favourable treatment outcomes and reduced toxicity.  
 
A limitation of our study is that no genotyping has been performed to identify the acetylator 
status of each patient but will be done in a future study using DNA samples from some 
patients. Without genetic information, it is difficult to separate homozygous fast and 
heterozygous fast acetylator status (Hickman & Sim, 1991). However, the proportion of fast 
acetylators (50%) in our model is not different from the ones that have been reported for 
African populations.  and more closely to the 47% reported by Smythe (Ellard, 1984; Roy, 
Majumder, & Roy, 2008; Smythe, 2016). 
 
In conclusion, we developed a population pharmacokinetic model for isoniazid and 
acetyl-isoniazid in a population of TB/HIV co-infected patients. The model could separate 
clearance due to acetylation and other routes of metabolism and showed reduced exposure 
to isoniazid among fast acetylators receiving efavirenz-based ART. A 50% increase in dose 
of rifampicin did not influence the pharmacokinetics of isoniazid and acetyl-isoniazid.  
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Chapter 6: Pharmacokinetics of rifampicin, pyrazinamide, and 
ethambutol in patients recruited in the RAFA study 
6.1 Introduction 
Rifampicin is metabolised to desacetylrifampicin by liver esterase. It is also excreted in bile 
unchanged or as desacetylrifampicin (Acocella, 1983). The results in chapter three and other 
studies show that increase in dose of rifampicin yields a more than proportional increase in 
exposure due to saturation of transporters involved in the extraction of rifampicin in the liver 
(Boeree et al., 2015; Chirehwa et al., 2016; Svensson, Aarnoutse, et al., 2017). The 
transporters responsible for the excretion of rifampicin are also involved in the excretion of 
desacetylrifampicin hence the concentrations of both substrates drive the saturation of the 
transporters (Acocella, 1983; Denti et al., 2017). The pharmacokinetics of rifampicin has been 
described in tuberculosis patients receiving higher than the currently recommended 10 mg/kg 
dose of rifampicin (Boeree et al., 2015), but the TB/HIV infected patients recruited in that study 
had a CD4+ count of greater than 350 cells/µL. It is important to describe the pharmacokinetics 
of rifampicin in TB/HIV infected patients including those low CD4+ count. 
Pyrazinamide is included as part of the treatment for drug-sensitive and -resistance 
tuberculosis and is also being evaluated in some novel tuberculosis treatment regimens. It is 
active against dormant and semi-dormant M. tuberculosis bacilli in acidic environment 
(Mitchison, 1985). The currently recommended daily dose of pyrazinamide for the treatment 
of drug-susceptible tuberculosis is 25 (range: 20–30) mg/kg of body weight (World Health 
Organization, 2010b).  
 
Ethambutol is a broad antimycobacterial agent which shows concentration dependent 
microbial killing and protect against rifampicin resistance in patients with known resistance to 
isoniazid (Srivastava et al., 2010). A 15 mg/kg daily dose of ethambutol is currently 
recommended together with rifampicin, isoniazid and pyrazinamide. The objective of the study 
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was to describe the pharmacokinetics of (1) rifampicin and desacetylrifampicin, (2) 
pyrazinamide, and (3) ethambutol. We also sought to determine the effect of a 50% increased 
dose of rifampicin on the pharmacokinetics of pyrazinamide and ethambutol.  The effect of 
early introduction of efavirenz-based ART on the pharmacokinetics of rifampicin, pyrazinamide 




The details of the study design including patient recruitment and quantification of drug 
concentrations for the RAFA clinical trial is described in chapter 2. Concentration time data 
were described using nonlinear mixed-effects modelling and  the software NONMEM 7.3 
(Beal, Sheiner, Boeckmann, & Bauer, 2013) using the first-order conditional estimation 
method with eta-epsilon interaction (FOCE-I).  Model diagnostics and documentation of model 
development were performed using Perl-speaks-NONMEM (PsN) version 3.6, Pirana version 
2.9.0, and Xpose4 (R package) (Keizer, Karlsson, & Hooker, 2013). Additional plots were 
generated using R version 3.4.0 (R Core Team, 2017) via RStudio version 0.98.1091 
(RStudio, 2014).The model building procedure was generally the same for rifampicin, 
pyrazinamide, and ethambutol. We started with a one-compartment model with first-order 
linear absorption and elimination. Between-subject variability was tested on all parameters of 
the model, while between-occasion variability was included on the bioavailability parameter to 
describe the difference in the bioavailability on the pharmacokinetic sampling day and dose 
administered the previous day. The model was further improved by inclusion of a delay in 
absorption by using a lag time or a chain of transit compartments. Allometric scaling based on 
total body weight or fat-free mass was included in the initial phase of model building using 
known allometric exponents of 0.75 for clearance and 1 for volume parameters (Anderson & 
Holford, 2008). Two-compartment disposition models were also evaluated to verify ether that 
the chosen one compartment model was sufficient to describe the pharmacokinetics of the 
drug or that a two-compartment was better than a one-compartment model.  
 
For the joint model describing the pharmacokinetics of rifampicin and desacetylrifampicin, we 
first developed a model for rifampicin as described above and included the semi-mechanistic 
component describing saturation of hepatic extraction, as described in chapter 4. 
Concentration-time data for desacetylrifampicin were included in the model for rifampicin after 
the rifampicin model was deemed sufficient. We evaluated one- and two-compartment 
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disposition models including a liver compartment to describe the pharmacokinetics of 
desacetylrifampicin. A semi-mechanistic component to capture saturation of 
desacetylrifampicin elimination was also assessed. Since both rifampicin and 
desacetylrifampicin compete for the same transporters for excretion, an attempt was made to 
describe this process in a semi-mechanistic way. The difference in molecular weight of 
rifampicin and desacetylrifampicin was adjusted for in all models describing the 
pharmacokinetics of rifampicin and desacetylrifampicin jointly.   
 
A physiologically plausible covariate was included and retained in the model if upon its 
inclusion, it resulted in a reduction in OFV of at least 3.84 points, corresponding to 5% level of 
significance for a chi-squared test. Model fit was evaluated by using a change in OFV and 




6.3.1 Pharmacokinetics of rifampicin and desacetyl-rifampicin 
The RAFA study recruited 222 patients for the PK sub-study. Plasma samples of 19 patients 
were affected by a temporary change in temperature of the storage freezer and were deemed 
unreliable, hence rifampicin concentrations were not determined. After these exclusions, 
plasma samples of 203 patients were available for pharmacokinetics analysis. Desacetyl-
rifampicin concentrations were quantified in plasma samples from 132 patients due to limited 
budget. Table 1 shows the baseline characteristics of the 203 patients included in the 
pharmacokinetic analysis. The distributions of the baseline characteristics closely mirror those 




Table 6.1 Baseline characteristics of patients with rifampicin concentrations (RAFA study) 
Characteristic Value 
Total No. 203 
No. (%) of females 80 (39.4) 
No. (%) in early ART arm 55 (27.1) 
No. (%) in high dose rifampicin arm 87 (42.3) 
Weight, kg  51 (33–87) 
Height, m  1.7 (1.4–1.94) 
FFM, kg 42.9 (24.8–65.3) 
Age, years 37 (19–69) 
CD4+ cells/µL  170 (51–772) 
Viral load, copies/mL (x103) 150 (0.08–10000) 
Serum creatinine, µmol/L 89 (23–212) 
Haemoglobin level, g/dL 9.3 (5.2–15.9) 
ALT, units/L 31 (3–97) 
White blood cells, x109/L 7 (1.8–26.2) 
Platelets, x109/L 337 (119–832) 
 
 
A total of 1008 and 653 concentrations were available for analysis for rifampicin and 
desacetyl-rifampicin respectively. Values below the limit of quantification were released by the 
laboratory and available for analysis. However, rifampicin and desacetyl-rifampicin 
concentrations were not detected by the mass spectrometer in 59 and 92 plasma samples, 
respectively. Most of these were pre-dose samples, 92% and 96% for rifampicin and 
desacetyl-rifampicin, respectively. For these, we imputed a value equal to half of the lower 
limit of detection (defined as 10% of the LLOQ) as suggested by Keizer et al., (Keizer et al., 
2015).  
 
Figure 6.1 shows the schematic diagram of the model for rifampicin and desacetyl-rifampicin. 
Pharmacokinetics of rifampicin were best described by a one-compartment disposition model 
linked to the liver compartment modelled with the well-stirred assumption (Gordi et al., 2005) 
and a chain of transit compartment to capture the delay in absorption. The model could 
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estimate two clearance pathways from the liver compartment; one for the formation of 
desacetyl-rifampicin and another for excretion and other pathways. Desacetyl-rifampicin was 
described by a one-compartment disposition model attached to the liver compartment that is 
connected to the liver compartment of rifampicin. Elimination of desacetyl-rifampicin was via 
the hepatic route.  
 
Figure 6.1 Schematic diagram of the semi-mechanistic model of rifampicin and desacetyl 
rifampicin in TB/HIV co-infected patients  MTT, mean transit time; NN, number of transit 
compartments; Fpre-hepatic, pre-hepatic bioavailability; Ka, absorption rate constant; VH, 
volume of liver; QH, hepatic plasma flow; VC, volume of central compartment for rifampicin; 
VCD, volume of central compartment for desacetyl-rifampicin; CLint_OTHER, intrinsic 
clearance of rifampicin to other metabolites; CLint_DES_F, intrinsic clearance of rifampicin to 
desacetyl-rifampicin; CLint_DES_, intrinsic clearance of desacetyl-rifampicin. 
 
 
Table 6.2 shows the parameter estimates of the final model and the associated 95% 
confidence interval obtained from the SIR procedure with five iterations, as suggested in 
Dosne et al. (Dosne, Bergstrand, & Karlsson, 2017). The SIR procedure was used due to long 
model run times, and the nonparametric bootstrap method would have taken very long to 
complete. The absorption model with a chain of transit compartments was superior to a lag 
time and resulted in 126 points lower AIC value. The inclusion of allometric scaling using total 
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body weight improved the model fit (ΔAIC = -21), and a further improvement of 3 points in AIC 
was observed when FFM was used as size descriptor for allometric scaling. The model with 
hepatic extraction and saturation was superior to a simple one-compartment disposition model 
(ΔOFV = -32 points, 1 df, P value<0.0001). The typical values for the liver volume of 
distribution, hepatic plasma flow, and unbound fraction of rifampicin were fixed to 1 L, 50 L/h, 
and 0.2 respectively. Allometric scaling was also applied to the liver volume of distribution and 
hepatic plasma flow using fat-free mass. Sensitivity analysis was performed on the typical 
values of parameters for the well-stirred model, and the main conclusions were not affected. 
All typical values for clearance and volume parameters refer to a patient with FFM of 43 kg, 
the median value in the cohort. Upon inclusion of desacetyl-rifampicin data into the model, we 
discovered that the disappearance of rifampicin could be ascribed to two separate metabolic 
pathways: the first one non-saturable and responsible for the synthesis of desacetyl-
rifampicin, and the second one not associated with desacetyl-rifampicin formation and 
displaying saturation. The elimination of desacetyl-rifampicin was also found to be saturable 
with a Michaelis-Menten constant that is lower than that of rifampicin (1.62 mg/L vs 2.32 mg/L). 
The intrinsic clearance of rifampicin not associated with the formation of desacetyl-rifampicin 
(excretion intrinsic clearance) was found to be correlated with the intrinsic clearance of 
desacetyl-rifampicin (55%). Since concentrations of rifampicin and desacetyl-rifampicin was 
measured in the same plasma sample, a component of the residual unexplained variability is 
common between the two measurements hence a correlation (78%) between the RUV was 
included in and supported by the model. The volume of distribution of the central compartment 
for desacetyl-rifampicin was defined to be the same as the volume of distribution of the central 
compartment for rifampicin to avoid overparameterisation. Two of the drug batches of the 
same formulation used in the study were found to have 62.5% reduced bioavailability. Finally, 
the variability in bioavailability was found to be 59% higher on the day before the 
pharmacokinetics sampling day. This parameter was included in the model to account for the 
uncertainty in the reported time of dose on the day before the PK sampling day. 
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Table 6.2 Parameter estimates of the final model for rifampicin and desacetyl-rifampicin 
(RAFA study) 
Parameter Estimate  
(SIR 95% CIa) 
BSV / BOV+ (%) 
(SIR 95% CIa) 
Rifampicin   
CLint,max,deac (L/h)b 36.5 (34; 38.9) 19.8 (16.3; 23.6) 
CLint,max,other (L/h)b 150 (120; 181) 64.3 (57.3; 72.5) 
V (L)b 52.2 (49.5; 54.8)  
Ka (/h) 1.27 (1.04; 1.57) 67.3 (53.3; 77.1) 
MTT (h) 0.515 (0.345; 0.682) 74.4 (52.6; 104) 
NNc  3.76 (1.94; 7.09)  
Fd 1 FIXED 23.5 (20.3; 26.9) + 
Km (mg/L)e 2.32 (1.69; 3.32)  
Covariates   
Batch on bioavailability (%) -62.5 (-68.3; -55.2)  
Scaling factor for variability in 
bioavailability for unobserved doses (-fold)f 
1.59 (1.09; 2.28)  
Error   
Additive (mg/L)g 0.0234 FIXED  
Proportional (%) 13.5 (12.4; 14.7)  
   
Desacetyl-rifampicin   
CLint,max,des (L/h)b 423 (390; 467) 27.7 (23.3; 31.5) 
Km,des (mg/L)e 1.62 (1.27; 2.03)  
Error   
Additive (mg/L)g 0.00782 FIXED  
Proportional (%) 19.2 (17.5; 21.5)  
   
Correlations   
BSV CLint,max,other and BSV CLint,max,des (%) 55 (37.3; 72.7)  
Error component parent/metabolite (%) 78.2 (73.6; 82.2)  
 
a SIR 95% CI, Sampling Importance Resampling 95% confidence interval. 
b This parameter has been adjusted by allometric scaling, and the values reported refer to a 
subject with an FFM of 43 kg (the median value of the cohort). 
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c NN, number of absorption transit compartments. 
d F, bioavailability. 
e Total concentration (bound plus unbound). 
f The scaling factor modulate the magnitude of the between-occasion variability in pre-hepatic 
bioavailability for the unobserved doses. 
g These parameters were fixed to 10% of the LLOQ  
h The scaling factor modulates the magnitude of the between-subject variability in volume of 
distribution of desacetyl-rifampicin. A single parameter was estimated for the BSV in volume 
of distribution and BSV in clearance due to high correlation. 
 
 
Figure 6.2 shows that the model adequately described the pharmacokinetics of rifampicin and 
desacetyl-rifampicin. The model was deemed acceptable for the purposes of the analysis as 
the main objective was to describe rifampicin concentrations and extract individual exposures 
for input into the PK/PD modelling described in chapter 7. 
 
Figure 6.2 Prediction-corrected visual predictive check for a model describing the 





6.3.2 Pharmacokinetics of pyrazinamide 
Pharmacokinetic modelling of pyrazinamide included 1103 plasma concentrations from 222 
patients. Concentrations of pyrazinamide could not be detected in 11 plasma samples, and 
we imputed a value of half the lower limit of detection of the assay (defined as 10% of the 
LLOQ). The baseline characteristics of the 222 patients are in Table 6.3.  
 
Table 6.3 Baseline characteristics of patients recruited in the pharmacokinetic sub-study and 
had pyrazinamide concentrations measured (RAFA study) 
Characteristic Value 
Total No. 222 
No. (%) of females 87 (39.2) 
No. (%) in early ART arm 62 (27.9) 
No. (%) in high dose rifampicin arm 97 (43.7) 
Weight, kg  51 (33–87) 
Height, m  1.7 (1.4–1.94) 
FFM, kg 43.3 (24.8–65.3) 
Age, years 37 (19–69) 
CD4+ cells/µL  171.5 (51–880) 
Viral load, copies/mL (x103) 150 (0.08–10000) 
Serum creatinine, µmol/L 89 (11–212) 
Haemoglobin level, g/dL 9.2 (5.2–15.9) 
ALT, units/L 31.5 (3–97) 
White blood cells, x109/L 6.75 (1.8–26.2) 
Platelets, x109/L 334 (103–832) 
 
Pyrazinamide pharmacokinetics were best described by a one-compartment disposition model 
with first-order elimination and a transit compartment absorption model. The final parameter 
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estimates are presented in Table 6.4 and a prediction-corrected visual predictive check is 
shown in Figure 6.3. The model included two transits (NN=1) with no separate estimate of Ka 
value since it was more parsimonious and had comparable OFV to the model with separate 
estimate of Ka. The model was parameterised in such a way that Ka can be calculated from 







Table 6.4 Parameter estimates of the final model for pyrazinamide (RAFA study) 
Parameter Estimate (95% CI)a BSV/ BOV+ (%) (95% CI) 
CL (L/h) 3.7 (3.45; 3.97) 27.2 (23; 31.2) 
V (L) 35.1 (32.8; 36.4)  
MTT (h) 0.342 (0.00342; 0.428) 66.6 (49; 428) 
NN 1 FIXED  
Bioavailability 1 FIXED 10 (0.571; 14.6)/ 
12 (3.35; 16.4)+ 
Covariates   
Batch effect on bioavailability (%) -19.5 (-24.9; -14.5)  
Guinea site effect on clearance (%) -15.1 (-21.9; -7.46)  
Error   
Additive 0.892 (0.501; 1.29)  
Proportional (%) 10.9 (9.55; 12.1)  
aCI, confidence interval 
 
Fat-free mass was the best size descriptor for allometric scaling of clearance and volume of 
distribution, and improved the model fit by 145.5 points in AIC (22.5 point better than using 
total body weight). Patients receiving tablets from the same two drug batches that were found 
to have low rifampicin and isoniazid bioavailability also had reduced pyrazinamide 
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bioavailability (-20%) (ΔOFV of 64.5 points, 1 df, p-value<0.001). In patients recruited in the 
Guinea site, clearance was reduced by 13% compared to those from Benin (ΔOFV of 10 
points, 1 df, p-value=0.002). The model did not detect any effect of high dose (+50%) of 




Figure 6.3 Prediction-corrected visual predictive check for a model describing the 
pharmacokinetics of pyrazinamide  The left panel is the VPC in the normal scale and right 





6.3.3 Pharmacokinetics of ethambutol 
All 222 patients had concentrations of ethambutol measured and their baseline characteristics 
are presented in Table 6.3. Plasma concentrations were below the nominal limit of 
quantification in 16 of the 1103 samples, but the analytical laboratory released the values 
detected, and were included in the model. Ethambutol pharmacokinetics was best described 
by a two-compartment disposition model with first-order elimination, and absorption via a chain 
of transit compartments. The two-compartment model significantly improved the model fit 
compared to a one-compartment model (ΔOFV= -822, 2 df, p-value<0.001). The parameter 
estimates of the final model are presented in Table 6.5, and the prediction-corrected visual 
predictive check is shown in Figure 6.4.  
Table 6.5 Parameter estimates of the final model for ethambutol (RAFA study) 
Parameter Estimate (95% CI)a BSV / BOV+ (%) (95% CI) 
Non-renal clearance (L/h) 40.6 (32.7; 49.7) 15.4 (10.8; 19.8) 
Glomerular filtration (L/h/ 75 mL/min CrCL) 12.9 (3.69; 21.8) 
Vcentral (L/h) 225 (196; 245)  
Ka (h-1) 1.56 (1.17; 2.08) 84.7 (69.1; 97.5) 
MTT (h) 1.25 (1.08; 1.4) 24.5 (14.1; 42.7) 
NN 15.7 (3.42; 49.7)  
F 1 FIXED 21.7 (14.5; 27) /  
17.5 (2.72; 23.9)+ 
Vperipheral (L/h) 415 (376; 462)  
Q (L/h) 47.2 (43.3; 52.2)  
Covariates   
Batch effect on bioavailability (%) -17.8 (-29.8; -3.43)  
Guinea site effect on clearance (%) -13.7 (-18.8; -8.67)  
Error   
Additive (mg/L) 0.0224 (0.0062; 
0.0396) 
 
Proportional (%) 13.8 (11.8; 15.7)  
aCI: Confidence interval;  
Allometric scaling was applied to all clearance and volume parameters including that of the 
peripheral compartment using fat-free mass (40 points drop in AIC). Using total body weight 
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for allometric scaling did not result in a worse fit, but fat-free mass was used to maintain 
consistency with pharmacokinetic models for the co-administered drugs of the FDC. 
Clearance of ethambutol was separated between glomerular and extra glomerular pathways, 
and this was associated with a 12 points improvement in OFV (1 df, P value< 0.001) compared 
to using one clearance pathway. Parameter estimates of clearance (extra glomerular) and 
volume of distribution in Table 6.5 are reported for an individual with a fat-free mass of 43 kg. 
The glomerular filtration pathway was scaled by creatinine clearance, which was computed 
based on the Cockcroft and Gault formula. This route of elimination for an individual with a 
reference creatinine clearance of 75 mL/min was estimated to be 12.9 L/h. The model also 
estimated a 13% reduced clearance (both pathways) of ethambutol in patients recruited from 
Guinea (ΔOFV= -20.7, 1 df, p-value<0.001). Similar to other drugs in the FDC, patients who 
received tablets the two drug batches described before had lower estimated bioavailability (-
18%) (ΔOFV= -10.8, 1 df, p-value=0.001). The inclusion of the effect of drug batch improved 
the model by 9 OFV points (1 df, P value= 0.003). There was no evidence of the influence of 







Figure 6.4 Prediction-corrected visual predictive check for a model describing the 
pharmacokinetics of ethambutol.  The left panel is the VPC in the normal scale and right 




6.3.4 Model-based steady-state individual exposure to rifampicin, pyrazinamide, and 
ethambutol 
The parameter estimates of the final models for rifampicin, pyrazinamide, and ethambutol 
presented in sections 6.1.1 to 6.1.3 were used to derive steady-state individual estimates of 
AUC0–24 and Cmax. These individual values are affected by covariates and are based on EBEs 
which are known to be influenced by shrinkage. The estimates for shrinkage in the models 
were below 40%. The AUC0–24 was obtained by integrating the concentration in the central 
compartment over a 24-hour period post-dose, and the Cmax was obtained by following 
individual profile during numerical computation over time and identifying the maximum 
concentration in the central compartment. These exposures were stratified by the treatment 
arm and a reference line indicating the target exposure found in the literature for the different 
drugs (Alsultan & Peloquin, 2014a). The effect of arm was tested in the model and was not 
found to be significant hence any differences visible in the plots are either not significant or 
are ascribable to other factors already included in the models. 
 
Figure 6.5 shows the steady-state AUC0–24 and Cmax for rifampicin for the 203 patients who 
had rifampicin concentrations. As a consequence of the higher dose, patients who received 
15 mg/kg rifampicin have slightly higher AUC0–24 and Cmax. The median AUC0–24 in the high 
dose RIF arm was 73% higher than that of the standard 10 mg/kg dose which includes the 
early ART and delayed ART treatment arms (45.2 vs 26.1 mg·h/L). Overall, only 24% of the 
patients achieved the target rifampicin Cmax of 8 mg/L and most (73%) of these were in the 
high-dose rifampicin arm. In this cohort of TB/HIV patients, there is large variability in 




Figure 6.5 Steady-state AUC024 (left) and Cmax (right) for rifampicin stratified by the 
treatment arm. The horizontal line Cmax = 8 mg/L represents the suggested threshold for peak 
concentration of rifampicin. The hollow circles represent the exposure for patients who 
received tablets from the two drug batches found to have reduced bioavailability. 
 
Steady-state pyrazinamide AUC0–24 and Cmax for the 222 patients recruited in the 
pharmacokinetic sub-study are shown in Figure 6.6. In most patients, the Cmax lies within the 
target range of 20 – 50 mg/L except in two patients who had very low Cmax. The plots also 
suggest that in patients who received a 50% higher dose of rifampicin, both AUC0–24 and Cmax 
are slightly reduced, although the effect was not significant when tested in the model. 
However, only 55% of the patients achieved an AUC0–24 of at least 363 mg·h/L, which was 
previously found to be associated with long-term favourable treatment outcomes 
(Pasipanodya et al., 2013). These results were not dissimilar when comparing the Cmax to a 




Figure 6.6 Steady-state AUC0–24 (left) and Cmax (right) for pyrazinamide stratified by the 
treatment arm. The dotted line in the left panel is the AUC0–24 of 363 mg·h/L and the one in 
the right panel is a Cmax of 35 mg/L. The dashed lines in the right panel show the target Cmax 
range for pyrazinamide. The hollow circles represent the exposure for patients who received 
tablets from the two drug batches found to have reduced bioavailability. 
 
Figure 6.7 shows the steady-state individual exposures to ethambutol for 222 patients in the 
cohort. Patients recruited into the high dose rifampicin arm had marginally reduced ethambutol 
exposure, but this was not statistically significant when tested in the model. Ethambutol Cmax 
was below the target range in 26% of the patients overall, and this was more pronounced in 





Figure 6.7 Steady-state AUC0–24 (left) and Cmax (right) for ethambutol stratified by the 
treatment arm  The dashed lines in the right panel show the target range of Cmax for 
ethambutol. The hollow circles represent the exposure for patients who received tablets from 






Population pharmacokinetics of rifampicin, desacetyl-rifampicin, pyrazinamide, and 
ethambutol were described in TB/HIV co-infected patients recruited in the pharmacokinetic 
sub-study of the RAFA randomised clinical trial. Model-based steady-state individual 
exposures were derived for rifampicin, pyrazinamide, and ethambutol and compared with 
target exposure based on PK-PD studies and “normal” concentrations observed after standard 
doses (Alsultan & Peloquin, 2014b). 
 
The elimination of rifampicin was found to be saturable, due to the saturation of the pathway 
that is not linked to the formation of desacetyl-rifampicin. The total intrinsic clearance of 186.5 
L/h reported here is close to the value of 176 L/h reported in chapter 3 (Chirehwa et al., 2016). 
The results are in keeping with previous reports describing rifampicin elimination as mainly 
due to two processes: deacetylation and biliary excretion, and with the latter hypothesised to 
be saturating. (Acocella, 1978; Acocella, Pagani, Marchetti, Baroni, & Nicolis, 1971). A 
semimechanistic model describing the liver as a separate compartment explained the data 
significantly better than a traditional model with elimination from the central compartment 
(where the concentrations are observed). 
 
The Km for desacetyl-rifampicin was lower than for rifampicin. This phenomenon was reported 
by Acocella, who observed that the rate of transfer into bile of desacetyl-rifampicin was three 
times higher than that of rifampicin (Acocella, 1983). Denti et al. also reported a higher affinity 
for the metabolite than for the parent (Denti et al., 2017). It is quite likely that rifampicin and 
desacetyl-rifampicin compete for the same transporters for excretion, and it we attempted to 
capture this by implementing saturation with competing substrates as described by Cornish-
Bowden (Cornish-Bowden, 2015). However, this more complex model was not supported by 
our data, as the estimation was unstable and provided unrealistic values of Km for both 
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rifampicin and desacetyl-rifampicin. The excretion intrinsic clearance of rifampicin was 
positively correlated (55%) with excretion clearance of desacetyl-rifampicin, and this shows 
that both rifampicin and desacetyl rifampicin are transferred into bile, but the strength of the 
correlation suggests different transfer rates. 
 
The model describing the pharmacokinetics of pyrazinamide in TB/HIV co-infected patients 
presented here mirrors previous reports in TB infected and TB/HIV co-infected patients from 
Africa (Denti, Jeremiah, et al., 2015; Smythe, 2016). However, the value clearance of 3.7 L/h 
detected here are much lower than those reported in a cohort of South African patients by 
Rockwood et al. (Rockwood et al., 2016) and another study with patients from South Africa, 
Uganda, and United States (Alsultan et al., 2017) where the clearance were 4.17 and 5.06, 
respectively. Further investigation suggests that this could be a bioavailability difference 
because the clearance is around 10% of the volume of distribution in all the three models. 
Chigutsa et al. described the elimination of pyrazinamide as a parallel first- and mixed-order 
process (Chigutsa, McIlleron, & Holford, 2010), but in our analysis simple first-order 
elimination fit the data suitably. Smythe reported lower concentration of pyrazinamide in the 
Benin site of their study and the effect was reportedly due to differences in bioavailability 
(Smythe, 2016). In our study, only a difference in clearance of pyrazinamide was observed 
between the two sites (Benin vs Guinea), but the difference in concentrations between the 
sites is in the same direction, in that Guinea patients have higher exposure than those from 
Benin. It could be speculated that there could be differences in expression of enzymes 
responsible for the metabolism of pyrazinamide in the two populations. 
 
Pharmacokinetics of ethambutol has been previous reported to show a biphasic 
disappearance, which was also confirmed in this study. Population pharmacokinetics of 
ethambutol in African adult population has been reported in studies conducted in Benin, 
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Guinea, Senegal, South Africa and Tanzania (Denti, Jeremiah, et al., 2015; Jönsson et al., 
2011; Smythe, 2016). The disposition parameters are closely in line with the parameters 
reported before among TB/HIV co-infected patients. In our model, we separated glomerular 
filtration from extra glomerular filtration clearance, since a significant proportion of ethambutol 
is eliminated renally. The effect of age on exposure to ethambutol reported by Denti et al. and 
McIlleron et al. in patients recruited from Tanzania and South Africa, respectively (Denti, 
Jeremiah, et al., 2015; McIlleron et al., 2006) is compatible with the effect of creatinine 
clearance on the glomerular filtration component of clearance in our model. However, this 
effect plays a significant role only if the age range of the study participants is wide and includes 
a significant proportion of older participants who are known to have reduced renal function.  
 
The effect of body size on the disposition parameters was included via allometric scaling in all 
the three models. The World Health Organisation currently recommends weight-adjusted daily 
doses of antituberculosis drugs for the treatment of drug-susceptible tuberculosis (World 
Health Organization, 2010c). Despite patients being dosed based on their weight, disparities 
in exposure have been reported: reduced exposure to all drugs of the FDC in patients with 
lower weight who are males (McIlleron et al., 2012), higher exposure to pyrazinamide in female 
patients (Chigutsa, McIlleron, & Holford, 2010; Wilkins et al., 2006), and faster clearance of 
rifampicin in males (Sloan et al., 2017). For the three drugs reported in this chapter, the effect 
of body size was best described using fat-free mass as opposed to total body weight except 
for the pharmacokinetic model for ethambutol where model diagnostics were comparable 
when either fat-free mass or total body weight was used. Developing and evaluating dosing 
guidelines based on fat-free mass could help reduce the disparities in exposure currently 




The variability in rifampicin exposure was found to be higher and more noticeable in patients 
who received the increased dose of rifampicin. With an increased dose of rifampicin, enzymes 
present in the gut wall and transporters such as P-glycoprotein may become saturated, and 
the level of saturation could differ in different patients (Prakash, Velpandian, Pande, et al., 
2003). Exposure to rifampicin achieved in patients recruited in the study is consistent with 
those reported in several studies despite one treatment arm receiving a 50% higher dose. The 
proportion of patients who did not attain a target Cmax of 8 mg/L was 67%, and comparable to 
the OFLOTUB study (70%) also conducted in West Africa but also including a South African 
site (Smythe, 2016). Studies conducted in South Africa show that between 61–75% of patients 
receiving rifampicin fail to achieve a Cmax of 8 mg/L (McIlleron et al., 2006, 2012; Rockwood 
et al., 2016). The proportion was higher in studies conducted in Botswana (78% and 
84%)(Chideya et al., 2009; Tappero et al., 2005), Kenya (90%) (Choudhri et al., 1997) and 
Burkina Faso (100% at 10 weeks)(Saleri et al., 2012). The median Cmax of rifampicin in patients 
from Malawi was much lower than the target (4.8 mg/L; range (1.4–10.9 mg/L))(Sloan et al., 
2017). Encouraging results were reported in patients from Uganda where the lowest proportion 
of patients not achieving the target was 54% (Wiltshire et al., 2014). That our results show 
most of the patients who did not achieve the target Cmax were in the treatment arms that 
received the standard 10 mg/kg dose is not surprising. However, increasing the dose by 50% 
might have been too conservative considering that recent studies have explored doses of up 
to 40 mg/kg (Boeree et al., 2015; Svensson, Aarnoutse, et al., 2017). Jeremiah et al. showed 
that in TB/HIV co-infected patients, nutritional supplementation improves the rifampicin 
exposure by around 14% and more research needs to be conducted to confirm the result and 
its implications for dosing (Jeremiah et al., 2014).  
 
Virtually all patients achieved a pyrazinamide Cmax of 20 mg/L. However, only slightly more 
than half of the patients achieved a target Cmax of 35 mg/L that was found to be associated 
with improved tuberculosis treatment outcomes (Chideya et al., 2009). Variability in exposure 
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to pyrazinamide was not as large as that observed for rifampicin. This result has been 
previously reported and could be partly due to efficient absorption of pyrazinamide compared 
to rifampicin (Denti, Jeremiah, et al., 2015; Tappero et al., 2005).The target of 35 mg/L 
identified by Chideya et al. was derived by dichotomising the Cmax prior to analysis based on 
the median dose of 35 mg/kg. Pasipanodya et al. applied CART methodology and reported 
that a target Cmax of at least 58.3 mg/L was associated with 2-month culture conversion 
(Pasipanodya et al., 2013). Less than 5% of the participants in the present study achieved the 
threshold. The Cmax used by Pasipanodya et al. was derived from a cohort of TB patients with 
a TB/HIV co-infection rate of only 10% hence we could speculate that low Cmax in the current 
research work might be due to malabsorption since all the patients were TB/HIV coinfected. 
Results of MARS analysis showed that pyrazinamide interacted synergistically with rifampicin 
where in patients with rifampicin Cmax of at least 8.2 mg/L, having an AUC0–24/MIC ratio of 
pyrazinamide > 11.3 was associated with enhanced sterilizing activity. Pasipanodya et al. 
reported that AUC0–24 is associated with long-term tuberculosis treatment outcomes: 
favourable outcomes were observed in patients with AUC0–24 of at least 363 mg·h/L. Only 55% 
of patients in our cohort achieved the target, and this could also be linked to lower drug 
exposure reported in TB/HIV co-infected patients. The small decrease in pyrazinamide 
exposure in patients who received an increased dose of rifampicin highlights the need to 
assess the effect of rifampicin exposure on co-administered drugs in studies evaluating high 
doses of rifampicin. Early introduction of ART does not seem to affect exposure to 
pyrazinamide.  
 
Ethambutol Cmax was below the target of 2 mg/L in 26% of the patients in the cohort. A similar 
proportion was reported among patients from Tanzania (Denti, Jeremiah, et al., 2015). Our 
proportion and the one reported by Denti et al. was lower than the one reported in two studies 
conducted in Botswana (41% and 87%) (Chideya et al., 2009; Tappero et al., 2005). In a 
cohort from South Africa, McIlleron et al. reported a low proportion (12%) of patients who did 
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not attain the targeted 2 mg/L Cmax of ethambutol (McIlleron et al., 2012). Chigutsa et al. 
reported that the target therapeutic index (Cmax/MIC > 0.46) associated with treatment 
outcomes for ethambutol, but our study did not measure MICs, and this association was only 
significant in patients with rifampicin AUC0–24 < 35.4 mg·h/L (Chigutsa et al., 2015). Both Cmax 
and AUC0–24 of ethambutol were marginally reduced in patients who received 15 mg/kg of 
rifampicin, but the effect of treatment arm was not significant hence the observed pattern could 
be a result of effects already in the model, and this should be investigated further with higher 
than 15 mg/kg doses of rifampicin. The effect of exposure to ethambutol has not received 
much attention until recently where ethambutol was found to accumulate in diseased tissues 
and penetrates into lesions (Zimmerman et al., 2017). 
 
The result showing reduced bioavailability in all four drugs used in the RAFA study shows the 
need to monitor the quality of FDC products including batch to batch variability. The reason 
for the reduced bioavailability is unclear, but we speculate that both the quality of products 
and variation in storage conditions such as temperature changes could have influenced the 
bioavailability (Hutchings, Monie, Spragg, et al., 1983). Regular dissolution testing suggested 
by Ashokraj et al. could be implemented as part of tuberculosis treatment programmes 
(Ashokraj, Agrawal, & Panchagnula, 2008). 
 
A limitation of this study is that the MICs of the isolates were not quantified which would have 
enabled further assessment of drug exposure against therapeutic indices (e.g. AUC0–24/MIC) 
found to be associated with treatment outcomes. In addition, the target Cmax values used in 
this study are average concentrations derived from studies conducted in volunteers and 
tuberculosis patients hence are higher than what would be observed in TB/HIV co-infected 
patients. Exposure reported in this thesis was measured on a single day therefore does not 




In conclusion, we described the pharmacokinetics of rifampicin, desacetyl-rifampicin, 
pyrazinamide, and ethambutol in TB/HIV co-infected patients from Benin and Guinea. 
Exposure to the three drugs was generally consistent with what has been reported before, and 





6.3 Appendix  
  
Figure 6.8 Goodness of fit plots for the model describing pharmacokinetics of rifampicin 
(left) and desacetyl-rifampicin (right) 
 
 
Figure 6.9 Goodness of fit plots for the model describing pharmacokinetics of pyrazinamide (left) 





Chapter 7: Correlates of tuberculosis treatment outcomes in a 
cohort of TB/HIV co-infected patients 
7.1 Introduction 
The long duration of therapy remains a challenge for the successful treatment of tuberculosis 
(TB). Response to tuberculosis treatment is monitored by the use of sputum cultures. Time-
to-sputum culture conversion is an important measure of treatment response and is defined 
as the time in days from the start of treatment to the first negative sputum culture result which 
is confirmed at a follow-up visit after at least one week (Gillespie et al., 2014; Wallis & Johnson, 
2009). Time-to-culture conversion has been reported to be delayed in patients who have 
cavitation at baseline (Domínguez-Castellano et al., 2003) and male patients (Hesseling et al., 
2010). Similarly, high bacillary load at baseline delays culture conversion (Caetano Mota, 
Carvalho, Valente, Braga, & Duarte, 2012). Hesseling et al. showed that baseline time to 
detection in liquid media is associated with month 2 culture conversion and relapse (Hesseling 
et al., 2010). Month 2 culture result is a widely used measure of treatment bacteriologic 
response to therapy. Using CART methodology, peak concentrations of pyrazinamide, 
rifampicin and, isoniazid were found to be predictive of month 2 culture results in two separate 
studies conducted in South Africa and West Africa (Pasipanodya et al., 2013; Smythe, 2016). 
The same authors also showed that the area under the concentration-time curve for 
pyrazinamide, rifampicin and isoniazid is related to long-term treatment outcomes. In patients 
with CD4+ count less than 100 cells/µL, the proportion of relapse was reportedly higher than 
those with CD4+ of at least 100 cells/µL (Pulido et al., 1997). Poor long-term treatment 
outcome which include death and relapse is also more likely to be observed in patients with 
low BMI (Hanrahan et al., 2010). The purpose of the PK-PD analysis was to determine factors 
including drug exposure that are correlated with time-to-sputum culture conversion and long-




Data used for the analysis presented in this chapter were collected in the RAFA clinical trial 
and the study design has been described in chapter 2 this report. The analysis approach for 
the PK-PD analysis is reported in section 2.4. In summary, the “best” hazard model describing 
the time-to-sputum culture conversion was determined using Monolix Suite R2016 based on 
the AIC values for the Weibull, Gompertz and three-parameter surge function time-to-event 
models. CART methodology was applied in the conditional inference framework to identify 
drug exposure, disease burden and patient characteristics predictive of time-to-sputum culture 
conversion (Fu & Simonoff, 2017). Patients were classified into different categories based to 
the terminal nodes of the derived regression tree and the difference in hazards of culture 
conversion between the groups was assessed in the time-to-event model. Binary CART 
methodology was used to determine drivers of long-term treatment outcome using ctree 
package (Hothorn, Hornik, & Zeileis, 2006) in R software version 3.4.0 (R Core Team, 2017). 




In this chapter, we sought to evaluate the effect of drug exposure, patients’ characteristics, 
and disease burden on time-to-stable culture conversion (section 7.1.1) and the effect of these 
factors on relapse and death (section 7.1.2). For the PK-PD analysis, only the data from 
patients with exposure to all four drugs were considered, i.e. 150 subjects. Figure 7.1 shows 
histograms of drug exposure in these patients, while the patient characteristics before 
tuberculosis treatment initiation are presented in table 5.1.  
 
 
Figure 7.1 Steady-state AUC0–24 and Cmax for rifampicin, isoniazid, pyrazinamide and 
ethambutol used for the PK-PD analysis 
 
7.3.1 Time-to-stable culture conversion 
Three of the 150 patients had a negative culture result at the start of treatment and were 
excluded only for the time-to-event analysis, which describes the time-to-stable culture 
conversion and sought to identify factors modifying this measure of treatment response. The 
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Gompertz hazard model had the lowest AIC (9 points lower than the three-parameter surge 
function model). The predictive ability of the Gompertz and three parameter surge function 
were similar. The Gompertz hazard model was selected for inclusion of covariates. Figure 7.2 
is the VPC for the Gompertz hazard model without the effects of covariates and suggests 
adequate fit to the data. 
 
 
Figure 7.2 Visual predictive check of the time-to-stable culture conversion. The shaded area 
is the 95% prediction interval of the time-to-stable culture conversion profile, and the line is 
the empirical time-to-stable culture conversion. 
 
Figure 7.3 shows the final time-to-event classification and regression tree with the selected 
covariates. The procedure identified X-ray grading as the most important covariate associated 
with time-to-stable culture conversion (P value= 0.004): patients with a normal, minor, and 
advanced X-ray grade were separated from those that had a very advanced X-ray grade. 
Among patients with very advanced X-ray reading, there was an association between HIV 
stage before tuberculosis diagnosis and time-to-stable culture conversion: patients who were 
in HIV stage 2 had faster time-to-stable culture conversion compared to those in stage 3 or 4 
(P value= 0.048). Amongst the patients in HIV stage 3 or 4, those who initiated ART at two 
weeks had a faster time-to stable culture conversion compared to those who delayed ART 
regardless of the dose of rifampicin received (10 mg/kg or 15 mg/kg) (P value= 0.043). No 
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significant association between drug exposure as measured by AUC0–24 or Cmax with time-to-
stable culture conversion was observed.  
 
Figure 7.3 Variables predictive of time-to-stable culture conversion X-ray grading: 1, normal 
X-ray; 2, minor X-ray; 3, advanced X-ray; 4, very advanced X-ray. HIV stage is the WHO 
clinical staging of HIV at tuberculosis diagnosis. Treatment arm: 1, patients started ART at 
two weeks after tuberculosis treatment initiation; 2, patients started ART at two months after 
tuberculosis treatment initiation; 3, patient received increased dose of rifampicin (+50%) 
and started ART at two months after tuberculosis treatment initiation. SCC: stable culture 
conversion. 
 
The four terminal nodes shown in Figure 7.3 were included in the time-to-event model in 
Monolix as a single categorical variable: each terminal node as a category of the new variable. 
The effect of the new variable representing the terminal nodes was evaluated on the scale 
parameter of the Gompertz model. The new variable was then simplified consistently with the 






Table 7.1 Parameter estimates of the base and final model for time-to-stable culture 
conversion 
Parameter Estimate RSE (%) 
Base model   
 Scale 0.0094 28 
 Shape 0.0574 29 
   
Final model   
 Scale [nodes 1-3]a 0.0153 17 
 Scale [node 4]b 0.00529 27 
 Shape 0.0512 16 
aNodes 1-3: node 1, patients with normal, minor, or advanced X-ray grade; node 2, patients 
with very advanced X-ray grade and in HIV stage 2 before tuberculosis infection; node 3, 
patients with very advanced X-ray grade, in HIV stage 3 or 4 before tuberculosis infection who 
started ART two weeks after initiation of tuberculosis treatment. 
bNode 4, patients with very advanced X-ray grade and in HIV stage 3 or 4 before tuberculosis 
diagnosis who started ART eight weeks after initiation of tuberculosis treatment. 
 
There were no significant differences between time-to-stable culture conversion of the first 
three nodes, so these were merged into one. Comparing the scale parameter of the first three 
nodes to the last node, time-to-stable culture conversion for the last node was significantly 
higher (P value< 0.001). The median time-to-stable culture conversion in for nodes 1–3 and 
node 7 was estimated to be 23 and 37 days respectively. Figure 7.4 shows a stratified VPC of 




Figure 7.4 Visual predictive check of the time-to-stable culture stratified by patient 
characteristics. The left panel is a combined VPC for patients classified in nodes 1, 2 and 




7.3.2 Long-term treatment outcome 
Long-term treatment outcome was defined as either relapse or death over 24 months of follow-
up after tuberculosis treatment initiation. Of the 150 patients who had all tuberculosis drugs 
exposure data, 20 patients either had a relapse (13/20) or died (7/20). Patient characteristics 
of the 150 patients stratified by long-term outcome were comparable between the two groups, 





Table 7.2 Characteristics of patients with drug concentration for all four drugs stratified by 
long-term treatment outcome 
Characteristic Valuea 
 Favourable outcome Poor outcome 
Total No. 130 20 
No. (%) of females 50 (38%) 6 (30%) 
No. (%) in early ART arm 32 (25%) 8 (40%) 
No. (%) in high dose rifampicin arm 61 (47%) 9 (45%) 
Weight, kg  51 (33–87) 54 (42–73) 
Height, m  1.7 (1.4–1.9) 1.7 (1.6–1.9) 
FFM, kg 43.3 (24.7–65.3) 44.0 (30.2–58.1) 
Age, years 38 (19–64) 36 (23–65) 
CD4+ cells/µl  163.5 (51–772) 209 (51–512) 
Viral load, copies/ml (x103) 150 (0.08–10000) 150 (4–500) 
Serum creatinine, µmol/liter 89 (23–212) 89 (62–177) 
Haemoglobin level, g/dl 9.4 (5.2–15.9) 9.0 (6.7–12.4) 
ALT, units/liter 26 (5–71) 28 (3–97) 
White blood cells, x109/L 7 (2.6–26.2) 6.9 (3.7–13.8) 
Platelets, x109/L 343 (124–832) 327 (129–555) 
Rifampicin AUC0–24 29.4 (6.58–99.9) 35.4 (9.1–88) 
Rifampicin Cmax 5.43 (1.4–13.5) 5.26 (1.85–11.8) 
Isoniazid AUC0–24 7.66 (0.899–35.4) 6.85 (1.73–21.7) 
Isoniazid Cmax 1.8 (0.31–4.4) 1.56 (0.47–3.37) 
Pyrazinamide AUC0–24 343 (27.2–942) 410 (251–856) 
Pyrazinamide Cmax 36.1 (15.1–68) 37.7 (26.5–54) 
Ethambutol AUC0–24 16.5 (2.18–45.6) 16.5 (11.6–33.3) 
Ethambutol Cmax 2.44 (0.29–4.59) 2.41 (1.04–4.47) 
a Median, minimum, and maximum value presented unless specified 
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Associations between tuberculosis treatment outcome vs. drug exposure, disease burden, 
and patient characteristics were assessed via CART in the conditional inference framework. 
CART identified the presence of cavities, the degree of patient’s physical activity, and CD4+ 
count as drivers of long-term treatment outcomes (Figure 7.5). Patients with lung cavitation 
were more likely to either relapse or die (25% vs. 13%, P value= 0.045). In patients who did 
not have lung cavitation, CART identified the degree of physical activity as predictive of the 
outcome. Patients were classified as not active if they were confined to bed before tuberculosis 
treatment initiation, otherwise they were categorised as active, regardless of TB symptoms. In 
patients who were confined to bed, 24% had poor outcome compared to 6% among those 
who were active (P value= 0.021). Patient’s CD4+ count was dichotomised as either below or 
above 100 cells/µL based on preliminary results of the main RAFA study, which will be 
discussed in the next section. The CD4+ count was associated with treatment outcome in 
patients who did not present with lung cavitation and were active. A higher proportion of poor 
treatment outcome was observed in patients who had lower CD4+ count (17% vs. 2%, P 
value= 0.006). Drug exposure was not found to be predictive of long-term tuberculosis 
treatment outcome. 
 




Table 7.3 provides the measure of association and the diagnostic accuracy measures for the 
identified predictors of poor long-term treatment outcome. The ability of the decision rules 
identified by the CART to correctly classify patients with poor long-term treatment outcome 
was low as measured by the sensitivity.  
 
Table 7.3 Associations between derived cut-offs of predictors and poor long-term treatment 
outcome 
Predictor OR (95% CI) Sensitivity % (95% CI) Specificity % (95% CI) 
Cavities (N=150)    
 No 1   
 Yes 2.8 (1.0–7.6) 25 (11–45) 89 (83–94) 
Active (N=122)    
 Yes 1   
 No 5.4 (1.8–16.4) 24 (11–42) 94 (87–98) 
CD4+ count (N=89)    
 ≥ 100 cells/ µl 1   
 < 100 cells/ µl 12.8 (2.1–80) 17 (5–37) 99 (92–100) 
Overall classification (N=150) 
 Favourable 1   






The PK-PD analysis aimed to assess whether drug exposure, patient characteristics, and 
disease burden are associated with time-to-stable culture conversion and long-term poor 
treatment outcomes. We combined classical time-to-event modelling techniques, and time-to-
event classification and regression trees to identify the factors and their interactions that 
contribute to time-to-stable culture conversion. Sputum culture results were determined bi-
weekly in the first eight weeks of treatment and monthly thereafter, hence we applied interval 
censoring to handle the long gaps between observation of events.  
 
Several factors could affect time-to-stable culture conversion, such as treatment, baseline 
bacterial load, the presence of cavitation, and baseline demographic characteristics (Güler, 
Ünsal, Dursun, AydIn, & Capan, 2006; Hesseling et al., 2010; Visser et al., 2012). We found 
disease-associated patient characteristics and treatment strategy as the main drivers of time-
to-stable culture conversion. The X-ray grading reflects the extent of chest abnormality after 
tuberculosis infection (Ralph et al., 2010). Patients with X-ray graded as advanced converted 
later than other patients. However, if these patients were in early-stage of HIV infection at time 
of tuberculosis diagnosis, the time-to-stable culture conversion was shorter. The last splitting 
variable of our regression tree shows the benefits of early initiation of ART in critically ill 
patients: those with very advanced X-ray abnormality and who were in the late-stage of HIV 
infection but started ART at two weeks after tuberculosis treatment initiation converted earlier 
than those who started ART at eight weeks after the start of tuberculosis treatment. Starting 
ART at two weeks has been shown to be associated with reduced mortality in TB/HIV co-
infected (Abdool Karim et al., 2010; Shastri, Naik, Shet, et al., 2013), and our results show 




The effects of drug exposure as measured by AUC0–24 or Cmax on time-to-stable culture 
conversion could not be detected in our study. Svensson et al. reported the significant effect 
of an increased dose of rifampicin on reducing the time-to-stable culture conversion 
(Svensson, Svensson, et al., 2017), but their study observed a larger range of doses: 10 to 30 
mg/kg compared to 10 to 15 mg/kg of body weight in our study. Pharmacokinetic sampling is 
usually performed on a single day during treatment, and with the variability associated with 
Cmax (Endrenyi & Yan, 1993) the value may not be a true reflection of the overall Cmax during 
treatment. Thus, if the variability between occasions is large then the relationship between 
exposure and treatment outcomes will not be accurately captured on a single occasion. In the 
absence of serial sputum culture results, which were available both in our study and that by 
Svensson et al., 2-months culture result is usually used as a marker of treatment success. At 
two months, Pasipanodya et al. identified peak concentrations of pyrazinamide, rifampicin, 
and isoniazid as drivers for culture conversion (Pasipanodya et al., 2013). In a cohort from 
South Africa and West Africa, the peak concentration of rifampicin was associated with 2-
months culture conversion (Smythe, 2016). Pasipanodya et al. and Smythe applied CART 
without permutation tests to identify the drivers of culture conversion. However, the method 
used in these two latter reports favours continuous variables that have many splits points and 
rarely identify ordinal or nominal variables. The effect of drug exposure on the time-to-stable 
culture conversion in the present study was further explored by classifying the Cmax and AUC0–
24 into either quartiles, binary (above or below median) or using cut-off values based on 
population data in literature but PK-PD relationships could not be established (Alsultan & 
Peloquin, 2014a; Chideya et al., 2009; Chigutsa et al., 2015; Pasipanodya et al., 2013).  
 
Long-term treatment outcome was defined as relapse or death within 24 months after 
tuberculosis treatment initiation. We identified disease severity as primary drivers of long-term 
treatment outcome in the cohort of TB/HIV infected patients. This is different from some 
previous studies that identified drug exposures as primary drivers of long-term treatment 
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outcome (Pasipanodya et al., 2013; Smythe, 2016; Swaminathan et al., 2016). The 
association between cavitation and poor long-term treatment outcome could be a result of: (1) 
incomplete kill and then re-activation of previously dormant bacteria in cavities (Flynn & Chan, 
2001), and (2) reduced distribution of drugs in cavities (Dartois, 2014). Our study recruited 
TB/HIV co-infected patients, and the level of physical activity identified in our analysis could 
be representing hidden disease severity of co-morbidities since all patients were in at least 
WHO stage 2 of HIV infection before tuberculosis diagnosis. Similarly, patients with CD4+ 
count <100 cells/µL had poor long-term outcomes even if not presenting with cavities and 
physically active. 
 
This study has several limitations. By measuring drug exposure on a single day of treatment, 
an assumption is that variability in exposure between different days over the duration of 
treatment is relatively low, but the assumption may be considered weak for Cmax values. 
Multiple data imputation methods could have been used to impute exposure of patients with 
missing drug concentrations, especially for isoniazid that was the drug with most missing 
values, but this could result in less accurate exposure values due to the non-availability of 
acetylator status for isoniazid. The process would involve computing exposure assuming that 
the patient is a fast/ slow acetylator then adjust the exposure by the probability of a patient 
being a fast/slow acetylator. The exact date of culture conversion could not be accurately 
determined due to the long time period between follow-up visits, but time-to-event analysis 
with interval censoring applied in this thesis handles the problem well. Patients who relapsed 
and those who died could have different baseline characteristics, hence combining these due 
to small numbers could potentially mask some effects since death could be less likely related 
to drug exposure. The binary long-term outcome does not contain information on the time at 
which the event occurred, so we could not separate early and late treatment outcomes. Data 
on MICs of isolates were not available and this limited the analysis to PK-PD indices that are 
not adjusted for the level of resilience of the bacterial strain in each patient. 
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Chapter 8: Conclusions 
Successful treatment of TB/HIV co-infected patients remains a challenge, and calls for 
research geared towards optimising the drugs in the currently recommended regimens. 
Limited information is available on the determinants of pharmacokinetic variability and the 
effects of variability on tuberculosis treatment outcomes. Strategies that are currently under 
investigation to improve the treatment of drug-susceptible tuberculosis include increasing the 
dose of rifamycins, aggressive management of HIV infection by early introduction of 
antiretroviral therapy, and repurposing of old anti-tuberculosis drugs. It is therefore pivotal to 
investigate the potential effect of these treatment changes on the pharmacokinetics of the 
currently recommended drugs as well as improve our understanding of the pharmacokinetics 
of antituberculosis drugs in TB/HIV co-infected patients in an African setting. Equally important 
is the need to identify and profile the drivers of successful tuberculosis treatment.  
 
The research presented here contributes to the body of knowledge by describing the 
pharmacokinetics of first-line antituberculosis drugs in two cohorts of TB/HIV co-infected 
patients from South Africa and West Africa using nonlinear mixed-effects modelling 
techniques. While developing and refining the models, we chose to use a semi-mechanistic 
approach based on physiological plausibility and made possible by the availability of 
intensively-sampled pharmacokinetic data. Secondly, we sought to establish whether TB/HIV 
patients in the cohorts attain drug exposures with known associations with tuberculosis 
treatment success. HIV co-infection is expected to increase the variability in drug exposure 
due to possible drug-drug interactions between ART and TB medications and the previously 
reported effect of HIV infection on pharmacokinetics of tuberculosis drugs. Hence, another 
aim was to determine the drivers, including drug exposure, of successful treatment outcomes 
(time-to-stable culture conversion, and death or relapse). The main findings and their practical 
implications, together with limitations and suggestions for further research are discussed in 
the next sections. 
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8.1 Pharmacokinetics of rifampicin and desacetyl-rifampicin: increased dose, 
autoinduction and saturable pharmacokinetics 
Increasing evidence points towards the possible benefits of increasing rifampicin dose within 
the 1st line regimen (Aarnoutse et al., 2017; Boeree et al., 2015, 2017; Diacon et al., 2007). 
There has been further research on the pharmacokinetics of rifampicin since the publication 
of the manuscript on autoinduction of rifampicin and its saturable pharmacokinetics (chapter 
3). It is reassuring that the recent publication by Svensson et al. confirms our results on the 
duration of autoinduction and saturable pharmacokinetics. In our study, autoinduction of 
rifampicin was estimated to be complete in three weeks, which is 50% longer than the two 
weeks previously reported in early pharmacokinetic studies of rifampicin (Acocella, 1978) but 
in line with the most recent results (Svensson, Aarnoutse, et al., 2017). The longer duration of 
autoinduction implies exposures reported in pharmacokinetic studies at two weeks after 
initiation of daily rifampicin intake are relatively overestimated and would need to be adjusted 
to reflect the average exposure at the fully induced state. Overestimation of steady-state 
exposure becomes a challenge at a time when evaluation of doses higher than the currently 
recommended 10 mg/kg are ongoing and considering that the level of induction may increase 
with the larger administered dose (Svensson, Aarnoutse, et al., 2017). The two models for 
rifampicin presented in chapter 3 and chapter 6 described the nonlinearity of the dose-
exposure relationship due to the saturable pharmacokinetics of rifampicin. The inclusion of 
desacetyl-rifampicin data into the model for rifampicin helped separate deacetylation from 
other routes of metabolism, and the later shows saturable pharmacokinetics. Furthermore, the 
model presented in chapter 6 included the saturable pharmacokinetics of desacetyl-rifampicin 
and demonstrated that saturation occurs at lower concentrations than for rifampicin. Monte 
Carlo simulations of increased doses of up to 3.5 times higher mirrored the exposures reported 
in a clinical trial evaluating exposures achieved with increased doses of rifampicin. We also 
showed using simulations that a rifampicin dose of at least 25 mg/kg will be sufficient to reach 
an AUC0–24/MIC ratio of 271 mg·h/L reportedly correlated with bactericidal activity of rifampicin 
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(Jayaram et al., 2003). A recent clinical trial showed no improvement in bacteriological 
response with a 20 mg/kg dose compared to the currently recommended 10 mg/kg (Aarnoutse 
et al., 2017) hence our simulations could have played a significant role in informing the doses 
for the clinical trial. 
 
Our findings also showed that current weight band-adjusted dosing resulted in exposure 
disparities among patients in different weight bands: patients with lower weight have reduced 
exposure, a result also reported in a non-compartmental analysis of the TB-HAART study 
(McIlleron et al., 2012). The difference in exposure is by and large driven by the saturable 
pharmacokinetics of rifampicin, and hence exposure to rifampicin in linked to the absolute 
dose of rifampicin rather than weight-adjusted dose. Additionally, the difference in exposure 
is also worsened by the result that fat-free mass was preferable to total body weight as the 
size descriptor for allometric scaling, and the relationship between weight and clearance is 
nonlinear. This difference becomes important in a population of tuberculosis patients with a 
wide range of body mass index or fat-free mass. Most importantly, low weight patients tend to 
be the ones with worse health status and may have lost weight because of tuberculosis, so it 
is even more crucial for them to achieve suitable drug concentrations. 
 
The exponential model used to describe the autoinduction of rifampicin has a limitation that it 
cannot be used to simulate exposures associated with non-daily treatment. However, the rich 
data collected on days 1, 8, 15 and 29 was vital in describing the autoinduction process and 
was sufficient for estimation of the duration of autoinduction within the period when 
pharmacokinetic sampling was conducted. For the data used in the analysis reported in this 
thesis, the semimechanistic autoinduction model with an enzyme compartment did not 
perform significantly better than the one reported in chapter 3. The TB-HAART study 
implemented a 10 mg/kg dose hence we could not assess the effect of increased dose on 
extent and duration of autoinduction. This effect later evaluated by Svensson et al., but their 
study was did not have pharmacokinetic samples collected beyond two weeks after 
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tuberculosis treatment initiation (Svensson, Aarnoutse, et al., 2017). SNPs such as SLCO1B1 
rs4149032 have been suggested to be associated with the pharmacokinetics of rifampicin, but 
the effect needs to be reassessed in different patient populations. Data on genetic 
polymorphisms were not available at the time of this analysis but will be usefull to incorporate 
it in future projects linked to the RAFA study. This data might help explain the large between 





8.2 Pharmacokinetics of pyrazinamide and optimal doses for drug-susceptible 
and -resistant tuberculosis 
 
The population pharmacokinetics of pyrazinamide was described in a cohort of TB/HIV co-
infected patients from South Africa during the first month of tuberculosis treatment and a 
cohort of TB/HIV infected patients from West Africa between four and eight weeks after 
tuberculosis treatment initiation. The models for pyrazinamide presented in chapter 4 and 6 
also supported the use of fat-free mass as the best body size descriptor for allometric scaling 
compared to total body weight. The result supports the hypothesis that hepatic function does 
not increase linearly with total body weight and that the contribution of fat mass to metabolic 
rate is minimal (Anderson & Holford, 2008). As reported for rifampicin, the implementation of 
a constant mg/kg dose based on total body weight in the study resulted in reduced exposure 
to pyrazinamide in lower-weight patients. Without modifying the boundaries of the currently 
used weight bands, we explored the doses of pyrazinamide required to achieve comparable 
exposure across the weight bands currently used for the treatment of drug-susceptible 
tuberculosis. Adding one tablet with 400 mg pyrazinamide to patients weighing 30-54 kg would 
ensure similar exposure across weight bands and 73% of the patients will achieve a target 
AUC0–24 of 363 mg·h/L reportedly associated with successful treatment outcomes. The 
strategy proposed here reduces the weight bands from four to three: 30–37 kg, 38–70 kg and 
>70 kg. Monte Carlo simulations using population pharmacokinetic models for co-
administered drugs of the FDC suggest that adding a single FDC tablet to the currently 
recommended dose among patients with a weight between 30 and 54 kg is sufficient to 
balance the exposure (Court et al., 2018; McIlleron & Roscigno, 2017). Simulations also 
showed reduced pyrazinamide exposure in MDR-TB patients with lower weight. Exposure to 
pyrazinamide among MDR-TB patients in different weight bands could be balanced by using 
a dosing strategy of 1 500 mg for patients in the 30- to -50 kg weight band, and 1 750 mg and 
2 000 mg for patients weight between 51–70 kg and >70 kg respectively. Another result of the 
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study is that clearance of pyrazinamide increased by 14% from the first day of tuberculosis 
treatment to day 29 which is consistent with other studies (Denti, Jeremiah, et al., 2015; 
Smythe, 2016). However, this change was considered too small to warrant a dose modification 
after the start of treatment.  
The simulations used demographic data of patients with drug-susceptible tuberculosis from 
South Africa and West Africa, hence providing a wide distribution of patient characteristics. 
However, these patients might be different from MDR-TB patients with regards to the influence 
of disease severity on the pharmacokinetics of antituberculosis drugs. Another limitation was 
the non-availability of MICs for pyrazinamide to compute MIC adjusted PK-PD indices that 





8.3 The effect of increased dose of rifampicin and efavirenz-based ART on 
pharmacokinetics of co-administered drugs 
A 50% increased dose of rifampicin did not significantly influence the pharmacokinetics of co-
administered drugs, consistent with results from a Tanzanian cohort where AUC0–24 and Cmax 
were comparable regardless of the dose of up to 20 mg/kg (Aarnoutse et al., 2017). Our 
increase in the dose of rifampicin was modest hence the effect of rifampicin doses of at least 
20 mg/kg on pharmacokinetics of concomitant drugs should be evaluated. Collaborative work 
done by this author, but not included in this thesis, showed that moxifloxacin clearance was 
reduced by 29% when administered alone compared to when co-administered with rifampicin 
(Naidoo et al., 2017). The reduction in exposure to isoniazid, when co-administered with 
efavirenz-based ART reported in this thesis, has also been reported in a study conducted in 
Mozambique (Bhatt et al., 2014). In this study, the effect is noticeable in patients who are of 
fast acetylator status who already achieve lower exposures than slow acetylators. 
 
A limitation of the RAFA study was that the acetylator status for isoniazid elimination had not 
been determined at the time of this analysis, hence we had to resort to using mixture modelling 
to separate fast and slow acetylators. Mixture models have been used before for the same 
purpose, and in our analysis we included the mixture model from the early phases of model 
development. The proportion of “fast” (which included fast and intermediate) acetylators of 
aroung 50%  based on the mixture model is line with the values reported before in West African 
countries (Patin et al., 2006; Sabbagh et al., 2008; Smythe, 2016). The precision of the 
estimates based on the nonparametric bootstrap gives us some level of assurance for stability 
of models with large covariate effects. There is also need to assess if the site effects reported 
for pyrazinamide and ethambutol in chapter 6 are not a result of genetic differences between 





8.4 Drivers of time-to-stable culture conversion and long-term tuberculosis 
treatment outcomes 
To the best of our knowledge, this is the first study applying regression trees and statistical 
significance testing simultaneously (conditional inference framework) to identify the nonlinear 
relationship between tuberculosis treatment outcomes, drug exposure and clinical 
characteristics. Time-to-stable culture conversion was associated with chest X-ray grade, 
WHO HIV stage prior to tuberculosis diagnosis and early (2 weeks) vs delayed (2 months) 
initiation of ART. Long-term treatment outcome was correlated with the presence of cavities, 
patient’s level of physical activity and CD4+ cell (<100 vs ≥100 cells/µL). In the parent TB-
HAART study, low BMI was significantly associated with poor treatment outcome (Mfinanga 
et al., 2014), but the association could not be established in our CART analysis of the RAFA 
study. The main RAFA study reported reduced mortality in patients who received a 50% higher 
dose of rifampicin and had low CD4+ count (<100 cells/µL) (Merle et al., 2016), but this was 
not significant in the subset of patients recruited for the pharmacokinetic sub-study. There was 
no association between drug exposure and tuberculosis treatment outcomes in this study. 
 
In terms of limitation, the dichotomous long-term treatment outcome (death or relapse) 
recorded does not distinguish between early and late treatment outcome, and the timing of 
occurrence of the outcome was not available and could not be taken into account. The 
regression tree method used in this study and other regression tree methods applied to 
pharmacokinetic data assume no uncertainty in the estimates of drug exposure, which is not 
true, especially due to between occasion variability. There is need to develop or adapt 





8.5 Implications of findings on tuberculosis treatment and research 
Rifampicin doses of at least 25 mg/kg have the potential to improve overall tuberculosis 
treatment outcomes and this would need to be evaluated in larger and longer (~6 months) 
follow-up studies. The result on the duration of autoinduction suggests that studies assessing 
rifampicin doses should be stretched at least beyond three weeks, when the steady-state is 
expected to be achieved. There is need to explore the use of fat-free mass-adjusted dosing, 
since cumulative evidence shows its superiority over total body weight in driving exposure via 
allometric scaling for all first-line antituberculosis drugs. On the other hand, an immediate 
solution would be to add a single tablet of the FDC to patients weighing below 55 kg. Reduced 
exposure to isoniazid in patients receiving efavirenz-based ART calls for an assessment of 
this influence on the development of resistance to companion drugs. Strategies need to be 
put in place for regular monitoring of drug content in tablets distributed within national 
tuberculosis programmes to reduce the effect of between batch variability, formulation, and 
storage conditions on drug exposure. The decision trees identified in our analysis could be 
used towards the implementation of stratified medicine in tuberculosis treatment, since it could 
reliably identify patients expected to achieve favourable treatment outcomes. This means that 
more aggressive treatment strategies could be implemented in a subset of patients who are 
likely to fail treatment, while the chances of toxicity could be reduced by shortening treatment 





8.6 Overall summary 
This thesis described the pharmacokinetics of first-line antituberculosis drugs in TB/HIV co-
infected patients using nonlinear mixed-effects modelling techniques. For rifampicin, the 
backbone of the treatment regimen, the autoinduction process and saturable 
pharmacokinetics were characterised and quantified. Furthermore, the thesis shows that not 
all pathways of rifampicin elimination are saturable, and that desacetyl-rifampicin exhibits 
saturable pharmacokinetics. The dose-exposure nonlinearity was established as a result of 
the saturable pharmacokinetics. Higher doses of rifampicin of at least 25 mg/kg are likely to 
improve overall treatment success. Based on the result presented in this thesis, developing 
treatment guidelines based on the use of allometric scaling with fat-free mass to account for 
nonlinear relationships between weight and clearance could guarantee similar exposure to 
antituberculosis drugs in patients of different body size and composition. The thesis also 
confirmed the result that exposure to isoniazid is reduced with concomitant intake of efavirenz-
based ART, and what is novel is that this effect of efavirenz-based ART is significant in patients 
of fast NAT2 acetylator status. The baseline characteristics identified using classification and 
regression trees could be used to profile patients with high or low risk of treatment failure for 
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